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Abstract
In order to investigate the contribution that the HTLV-I (Human T-cell Leukaemia Virus 
Type I) tax oncogene contributes to the transformed phenotype we generated transgenic 
mice that expressed the HTLV-I tax transgene under the regulatory influence of the CD3- 
e promoter-enhancer elements. These mice developed a variety of different types of 
pathology, the most pertinent of which were tumours (overall incidence 28/57 (49%)). 
The principal tumours were mesenchymal tumours which developed at sites of wounding 
(ear and tail tips) (overall incidence 18/31 (58%); average latency 202.5 days), and 
salivary and mammary adenomas (overall incidence 10/26 (38%); average latency 399 
days). Immunocytochemical analysis of these tumours revealed that subpopulations of 
tumour cells expressed high levels of Tax protein as well as Myc, Fos, Jun and p53 
proteins. Analysis of these tumours using the TUNEL (Terminal dUTP Nick End 
Labelling) technique revealed a similar pattern of apoptosis. Dual immunofluorescent 
localisation of Tax expressing cells with cells undergoing apoptosis revealed a 
remarkable degree of coincidence between these processes indicating that Tax expression 
and apoptosis are intimately linked in vivo. When CD3-tax transgenic mice were bred 
onto a p53 null or hemizygous background the resultant tumours which emerged at ear 
and tail tips were identical to the original cohort of tumours indicating a lack of co­
operation between tax and p53 (average latency for mesenchymal tumours emerging on a 
p53 wild type background: 277d (9.2months) and 128d (4.3 months) cf p53+/‘ 
background: 233d (7.8 months) and 156d (5.2 months)).
A Tax expression system was also developed in vitro using a pBabe retroviral vector 
which transcribed a Tax-MER (Tax-modified oestrogen receptor) fusion product. This 
fusion protein was dependent upon functional activity by induction with 4-hydroxy 
tamoxifen. The results of these experiments using a CREB/ATF responsive reporter gene 
indicated that this system produced a functional fusion protein that was well regulated by 
4-hydroxy tamoxifen. Functional mutants of Tax were made (Ml, M47 and C23S) based
In*
on published data (Smith and Greene, 1990; Semmes and Jeang, 1992) which were 
designed to segregate the functional domains of Tax. Analysis of these mutants indicated
that M47 least efficiently induced apoptosis in vitro. In our hands this protein also least 
efficiently transactivated the CREB/ATF pathway (although transactivation of the NFkB 
pathway was difficult to determine in this assay system). These results may indicate the 
general importance of the CREB/ATF pathway for apoptotic induction. Similarly these 
results, together with the transgenic mouse experiments, may also indicate that low levels 
of Tax expression does not induce apoptosis.
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Chapter 1
Overview of HTLV-I and mechanisms of viral transformation
i
Overview of HTLV-I and mechanisms of viral transformation
1.1 Introduction
“In 1775, Percival Pott, a London physician, described the alarmingly high rate of scrotal 
cancer in men who worked as chimney sweeps during childhood. In the mid-nineteenth 
century, pitchblende miners in eastern Germany were observed to die at extremely high 
rates from lung cancer. By the latter part of the century, snuff and cigar smoking were 
thought by some medical practitioners to be closely linked to the development of oral 
cancers.” It was these and other early observations that helped to develop the concept that 
cancers arose from exogenous sources and so dispel the widely held dogma that cancer was 
a breakdown of the body’s internal machinery uninfluenced by the outside world (Varmus 
and Weinberg, 1993).
While most scientific studies focused upon chemical and physical agents as the possible 
causes of human cancer, a fundamental paradigm shift occurred in 1911 when Peyton Rous 
showed that a cell free filterable agent derived from a chicken cancer (Rous sarcoma virus) 
could transmit a chicken sarcoma. Although the work was not recognised at the time, it 
went some way to substantiate the infectious theory of human malignancy. By 1965, a 
polyoma virus and Simian Virus 40 (SV40) had been found to induce tumours when 
injected into rodents, one year before Rous and his coworkers were awarded a much- 
deserved Nobel Prize.
It is now clear that a number of viruses act as inciting factors or cofactors in human cancer, 
namely: Epstein-Barr Virus (EBV), Hepatitis B (HBV) and Hepatitis C Viruses (HCV), 
Human Papilloma Viruses (HPV), and Human T-cell Leukaemia Virus Type I (HTLV-I). 
The recent cloning of a y-herpesvirus from Karposi’s sarcoma (Chang et al, 1994) has 
added another potential oncogenic virus to the list.
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Table 1.1: Human oncogenic viruses
Virus Family
HBV Hepadnaviridae
HCV Flaviviridae
HTLV-I Retroviridae
EBV Herpesviridae
HP V-16,18 Papovaviridae
(31,33,35,39,
45,51,52,56,
58,59,61)
Table 1.1 summarising the most important human oncoviruses and the types of malignancy 
they induce
It was not until the discovery in 1976 of a growth factor for mature T-cells, interleukin-2 
(IL-2) (Morgan et al, 1976) that the necessary tools were available for the growth of T- 
lymphocytes in vitro. This led to the discovery in the early 1980’s by two independent 
laboratories of type C retrovirus particles isolated from patients retrospectively diagnosed 
with Adult T-cell Leukaemia (ATL). The first isolate was derived from an American 
patient suffering from cutaneous T-cell Lymphoma (Poiesz et al, 1980; Poiesz et al, 1981; 
Popovic et al, 1983) and the second from a Japanese patient suffering from ATL (Yoshida 
et al, 1982). These isolates were very soon recognised to be identical, or very nearly so, 
and were designated Human T-cell Leukaemia Virus (Wong-Staal et al, 1983).
Malignancy
Hepatocellular carcinoma 
Hepatocellular carcinoma 
Adult T-cell Leukaemia 
Burkitt’s lymphoma
Undifferentiated nasopharyngeal carcinoma
Hodgkin’s disease
B-lymphomas in immunosuppressed
individuals
Cervical cancer
3
Soon-after, two new sub-types were discovered. Both of these viruses were isolated from 
atypical malignancies, the first designated HTLV-II-Mo from a patient suffering from 
atypical hairy cell leukaemia (Kalyanaraman et al, 1982). The second, designated HTLV-II- 
NRA (Rosenblatt et al, 1986), was isolated from a patient suffering from two malignancies: 
a B-cell malignancy that did not contain HTLV-II, consistent with atypical hairy cell 
leukaemia, and a CD8+ lymphoproliferative syndrome with oligoclonally integrated HTLV- 
II (Rosenblatt et al, 1988).
Meanwhile, an Italian isolate, HTLV-V was derived from a continuous cell line originating 
from the peripheral lymphocytes of a patient suffering from a CD4+ Tac' (EL2Ra chain) 
cutaneous T-cell lymphoma/leukaemia and subsequently identified in seven other patients 
from Italy with the same disease (Manzari et al, 1987).
1.2 Phylogeny and classification
The complete nucleotide sequence of HTLV-I was provided by Seiki and co-workers in 
1983 and was found to have a genomic organisation substantially different to the simple 
retroviruses. HTLV-I can be grouped based on nucleotide sequence homology with Simian 
T-lymphotropic virus (STLV) (90-95% homology) and Bovine Leukaemia Virus (BLV) 
(Ina and Gojobori, 1990). These viruses form part of a group known as the complex 
retroviruses, which are characterised by their greater genomic complexity making them 
distinct from the simple retroviruses typified by Feline Leukaemia Virus (FeLV), Avian 
Leukosis Virus (ALV), and Murine Leukaemia Virus (MuLV).
It is now clear that there are at least five major molecular subtypes of HTLV-I, namely the 
widespread cosmopolitan subtype, the Japanese, West African, Central African, and 
Melanesian subtypes (Vidal et al, 1994). These isolates show only low genetic variability 
which is linked to geographical location rather than pathogenicity (Malik et al, 1988; 
Komurian et al, 1991; Miura et al, 1994; Renjifo et al, 1995; Mahieux et al, 1995). The 
geographical restriction and the relatedness of HTLV subtypes to their STLV counterparts,
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recently illustrated by the close sequence identity between a new HTLV-I subtype D and 
chimpanzee STLV-I (>98% nucleotide sequence identity) (Mahieux et al, 1997) reinforces 
the hypothesis of interspecies transmission between humans and monkeys.
The complete nucleotide sequence of an infectious clone of HTLV-II was reported in 1985, 
and shown to have approximately 60% sequence homology with HTLV-I (Shimotohno et 
al, 1985). There are now known to be at least three major molecular subtypes of HTLV-II 
which again show only minor sequence variations from the prototypic subtype H TLV -IImo. 
These have been designated HTLV-IIb (Dube et al, 1993) and HTLV-IIc (Eiraku et al, 
1996).
1.3 Transmission and Epidemiology of HTLV
Transmission of HTLV occurs by transfer of infected lymphocytes during breast feeding, 
blood transfusion, sexual intercourse, and intravenous drug abuse. Transmission through 
the non-cellular fraction of blood apparently does not occur (Yamamoto et al, 1982). 
Mother-to-child transmission of the virus poses the most serious public health concern since 
horizontal transmission between spouses only very rarely leads to ATL (Sanada et al, 1989). 
Vertical transmission of HTLV-I through breast milk has been well documented (Hino et al, 
1989, Ichimaru et al, 1991) and the importance of this mode of transmission was 
underscored by an intervention study carried out in Nagasaki which showed that refraining 
from breast feeding by carrier mothers reduced the incidence of maternal transmission of 
HTLV-I by at least 80% (Hino et al, 1994).
Blood products contaminated with HTLV appear to be a very efficient mode of 
transmission (Osame et al, 1990; Manns et al, 1992). Blood transfusion has been associated 
with the very rapid development of TSP/HAM, often within a few months from initial date 
of transfusion (Gout et al 1990). In these cases it is likely that the sudden exposure to a 
high viral challenge coupled with usually some degree of immunosuppression represent
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important factors contributing to the development of TSP/HAM (Nowak and Bangham, 
1996).
Other modes of vertical transmission have not yet been clearly demonstrated. Intrauterine 
transmission of HTLV-I does occur when a human T-cell line (MT-2) producing HTLV-I is 
injected into pregnant rats (Hori et al, 1995). However, transplacental infection by HTLV-I 
in humans has not been demonstrated and at least one report suggests that the placental 
trophoblast may represent a barrier to infection protecting the foetal compartment from 
exposure to the virus (Liu et al, 1996).
Sexual transmission of HTLV-I poses a higher risk for male-to-female transmission 
(Murphey et al, 1989) and interestingly may be a risk factor for the development of 
TSP/HAM. In a retrospective study carried out in Jamaica two risk factors were identified 
as contributors to the development of TSP/HAM but not ATL: early initial age of sexual 
intercourse and high sexual promiscuity (Kramer et al, 1995).
In common with other oncogenic viruses, only a subset of infected individuals develop 
disease with more than 95% of HTLV-I infected individuals leading an unremarkable 
lifelong infection. In these individuals a symptomless balance ensues between host immune 
surveillance and uncontrolled viral proliferation. It appears that viral load in carriers attains 
a certain level in a relatively short period of time after infection and then shows little or no 
change afterwards (Shinzato et al, 1993). It is thought that it is the breakdown of this 
virus-host relationship which marks the turning point leading to disease. This manifests as 
either a chronic inflammatory immune response typified by TSP/HAM, or as a malignant 
out-growth of a T-cell clone (ATL).
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1.4 HTLV-I Associated Diseases
The cumulative life-time risk of ATL for those individuals infected before the age of 20 
years is estimated to be 4.0% for males and 4.2% for females (Murphy et al, 1989b). ATL 
normally occurs in the latter decades of life (average age: 58 years (Japan), 43 years 
(Caribbean and Africa) [Yamaguchi and Takatsuki, 1993]) which mirrors the disease 
incidence of many multi-step, time-dependent models of tumour development, such as the 
prototypic adenomatous polyposis coli (familial colon cancer). In this disease, just as in 
ATL, it is thought that several rare genetic events combine before the emergence of the 
malignant phenotype. Indeed, the multistep nature of ATL was modelled by Okamoto et al, 
(1990) who suggested that nearly 5 independent somatic mutations were required before 
the onset of malignancy.
HTLV-I is now considered to be the aetiological agent of both Adult T-cell Leukaemia 
(Hinuma et al, 1981; Yoshida et al, 1982) and Tropical Spastic Paraparesis (TSP)ZHTLV-I 
associated Myelopathy (HAM) (Jacobson et al, 1988, Reddy et al, 1988). However HTLV- 
I has been linked less substantially with a number of chronic inflammatory conditions 
summarised in Table 1.2.
The central question of whether ATL or TSP/HAM is associated with a specific strain of 
HTLV-I has not been conclusively answered (Gessain et al, 1995 and references therein). 
To date no HTLV isolate has been consistently associated with pathogenicity - it appears 
that the low genetic variability of HTLV-I depends more upon the geographic origin of the 
patients than the diagnosis of the infected individuals (Schirabe et al, 1990; Komurian et al, 
1991; Schulz et al, 1991).
On the other hand HTLV-II has no clear association with any form of disease or 
lymphoproliferative disorder (Hjelle et al, 1991) despite its early isolation from atypical 
hairy cell leukaemia and other rare forms of leukaemia (Rosenblatt et al, 1987; Lion et al, 
1988; Loughran et al, 1992; Loughran et al, 1994). Recently HTLV-II has been isolated
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from HTLV-I negative chronic neurodegenerative conditions (Hjelle et al, 1992; Jacobson 
et al, 1993) although its causal role remains uncertain.
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Table 1.2: Clinical outcome of HTLV-I infection
• Asymptomatic Carrier state:
This is the usual outcome after infection
• Neoplastic disease:
Adult T-cell Leukaemia
Cutaneous T-cell Lymphoma/Leukaemia
(Sezary syndrome/ mycosis fungoides) Hall et al, 1991
Pancake et al, 1995
• Chronic Inflammatory diseases:
TSP/HAM (discussed later) 
HTLV-1 associated arthropathy
HTLV-1 associated uveitis
HTLV-1 associated alveolitis/pneumonitis
HTLV-1 associated polymyositis 
Infective dermatitis in Jamaican children
Nishioka et al, 1989,
Sato et al, 1991,
Kitajima et al, 1991 
Mochizuli et al 1992a, 1992b 
Yamaguchi et al, 1992, 
and Taguchi et al, 1993 
Sugimoto et al, 1993,
Mita et al, 1993 
Wiley et al, 1989 
LaGrenade et al, 1990
• HTLV-I induced immunosuppression
HTLV-I is associated with a number of opportunistic diseases due partly to the 
immunodeficiency induced by HTLV-I infection:
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HTLV-I associated lymphadenitis Ohishima et al, 1992
chronic renal failure Lee et al, 1987
strongyloidiasis Nakada et al, 1987
monoclonal gammopathy Matsuzaki et al, 1985
cancer of other organs Strickler et al, 1995
Table 1.2 summarising the various clinical outcomes following HTLV-I infection.
1.5 Adult T-cell Leukaemia
ATL was first described as a distinct clinical entity in 1977 by Takatsuki and co-workers 
(Uchiyama et al, 1977) as a malignancy endemic to Southern Japan. Since that time HTLV- 
I (and consequently ATL) has been found to be endemic to a number of regions throughout 
the world including the Caribbean basin, north-eastern S. America, Central America and 
equatorial Africa. Many of the ATL patients studied in the USA, the UK, France and the 
Netherlands originated from the Caribbean area (Yamaguchi and Takatsuki, 1993).
Phenotypically, ATL usually presents as a CD3+, CD4+, CD8‘, CD25+ (Tac antigen/IL2-R<x) 
malignancy of mature T-cells, although occasionally, CD47 CD8+, CD4+/ CD8+, and CD4* 
/CD8‘ isolates occur (Kamihira et al, 1992).
ATL can be classified into four sub-types according to clinical symptoms and course of 
disease: smouldering, chronic, lymphoma and acute (Takatsuki et al, 1985, Kawano et 
al, 1985; Yamaguchi and Takatsuki et al, 1993) with acute being the prototypic form. 
Clinically the disease often evolves through a number of intermediate steps before 
progressing to fulminant end-stage ATL. Infection usually gives rise to a symptomless 
carrier state characterised usually by the presence of antibodies to HTLV-I but with only a 
low viral burden, polyclonally integrated, and undetectable by conventional Southern 
blotting techniques. This condition may then progress to an intermediate state (Yamaguchi
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et al, 1988) distinguished by polyclonal integration but with a higher proviral burden before 
developing into smouldering ATL. Smouldering ATL typically presents with a monoclonal 
or oligoclonal proviral integration which is readily detected by conventional molecular 
techniques.
Acute ATL is characterised by a highly malignant T-cell leukaemia/lymphoma which is 
usually unresponsive, or poorly responsive to aggressive combination chemotherapy. Mean 
survival time for typical ATL (CD4+ phenotype) is 10.2 months, with an even poorer 
prognosis for the rarer atypical presentations, ranging between 4.9 and 7.8 months 
(Kamihira et al, 1992).
The more indolent pre-leukaemic or smouldering form of ATL and the chronic form of 
ATL represent less severe phenotypes which often progress to full-blown full ATL (often 
termed crisis ATL) after a protracted latency period. In both conditions abnormal 
circulating leukaemic cells within the peripheral circulation can be detected. These cells 
resemble Sezary cells having indented or lobulated nuclei (so-called flower cells) (Takatsuki 
et al, 1985; Kawano et al, 1985).
Lymphoma-type ATL represents a cutaneous manifestation of ATL with few circulating 
abnormal leukaemic cells within the peripheral circulation. Speculation as to whether this 
sub-type of ATL belongs to a wider spectrum of disease has recently come under scrutiny. 
Several viruses have been implicated in the pathogenesis of cutaneous T-cell lymphomas 
(Chan et al, 1993; Zucker Franklin 1992) of which Sezary syndrome (SS) and Mycosis 
Fungoides (MF) are particularly strongly implicated, specifically with HTLV (Wantzin et al, 
1986; Detmar et al, 1991; Zucker-Franklin et al, 1991). It has long been suspected that MF 
and SS are caused by HTLV since deleted HTLV-I provirus can be detected by polymerase 
chain amplification (PCR) from blood and cutaneous lesions of patients with MF/SS (Hall et 
al, 1991; Pancake et al, 1995), and MF/SS cells are readily immortalised in vitro to yield 
HTLV like particles on electron microscopy (Zucker-Franklin et al, 1991). However few 
patients exhibit HTLV-I/II antibodies, and detection by S. hybridisation or per has not been
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met with success by all authors (Capesius et al, 1991; Lisby et al, 1992; Fujihara et al, 1997; 
Wood et al, 1997). This raises the intriguing possibility that large deletions in structural 
regions of the HTLV genome or a closely related variant virus could limit replication and 
subsequent detection by either the immune system or standard molecular techniques. 
Preferential retention of the transforming pX region including tax and loss of gag, pol and 
env genes, has been noted, hand-in-hand with limited sero-prevalence to the Tax protein 
(Pancake et al, 1995).
1.6 Tropical Spastic Paraparesis/HTLV-I Associated Myelopathy
TSP is a chronic inflammatory condition of the central nervous system (CNS) resulting over 
a protracted period of time in a demyelinating myelopathy. Approximately one out of 2,000 
individuals infected with HTLV-I go on to develop TSP/HAM (Osame et al, 1990). 
Clinically patients present with a progressive spasticity and weakness, particularly of the 
lower limbs, which usually results in paralysis of the legs and urinary dysfunction. Sensory 
loses are not a prominent feature of the disease.
Histologically the initial pathology within the CNS is characterised by diffuse inflammation 
in both the white and grey matter of the spinal cord. No particular cell type appears to be 
the focus of an (auto)-immune response. Inflammatory infiltrates are initially dominated by 
CD4+/CD45RO+ (memory) T-cells (Iwasaki et al, 1992). The balance between immune 
clearance of infected CD4+/CD45RO+ cells by CTL induced apoptosis and enhanced T-cell 
survival due to elevated bcl-2 expression may reflect important determinants of disease 
pathogenesis (Umehara et al, 1994). More advanced lesions are composed of a 
predominantly CD8+ CTL infiltrate (Akizuki et al, 1987, Moore et al, 1989) superimposed 
upon a mixed picture of demyelination/remyelination and axonal loss with secondary tract 
degeneratioa
The aetiopathogenesis of TSP/HAM is still very poorly understood. Empirically TSP/HAM 
could develop due to one of four principal mechanisms namely poor immune responsiveness
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by the host to HTLV-I infection, infection with a neurotropic strain of HTLV-I, 
autoimmune destruction of a cross-reactive antigen within the CNS or immune destruction 
of HTLV-I infected CNS cells.
Several lines of evidence supports poor immune responsiveness resulting in ‘bystander 
damage’ to the CNS. Neurotropic strains of HTLV-I have not been identified (Yoshida et 
al, 1987) despite Renjifo and colleges reporting a candidate mutant virus. These authors 
demonstrated that infection with an HTLV-I isolate carrying a tax mutation at nucleotide 
7959 exhibited enhanced transactivation of the HTLV-I U3 promoter and conferred an 
increased risk of developing TSP/HAM (Renjifo et al, 1995). However Gessain et al (1995 
and references therein) remarked that the same mutation is found in the consensus tax 
sequence of the Cosmopolitan strain of HTLV-I which infects many healthy seropositive 
individuals as well as patients with ATL.
The pathology of TSP/HAM does not support autoimmune mediated destruction of the 
spinal cord since the CTL response is characterised by a diffuse inflammation without 
targeting a specific cell type. Immune mediated destruction of the CNS would pre-suppose 
infection of the CNS by HTLV-I - this has not been conclusively demonstrated or linked 
with CNS pathology. Kira et al (1991 and 1992) suggested that constituent cells within the 
CNS might harbour the HTLV-I genome since they were able to clone pX region sequences 
from whole thoracic cord or cerebral tissue, samples derived from TSP/HAM patients. 
However this method was unable to differentiate between invading lymphocytes and 
resident CNS cells. Nevertheless, expression of viral proteins within the CNS of transgenic 
mice which have the viral LTR cloned from a HTLV-I provirus isolated from a case of 
TSP/HAM has been demonstrated (Gonzalez-Dunia et al, 1992). Moreover an in situ 
hybridisation study demonstrated the presence of tax expression within isolated and 
infrequent resident CNS cells, but was unable to spatially correlate the presence of proviral 
RNA with infiltration of lymphocytes (Lehky et al, 1995).
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Recently a coherent framework has been developed by Bangham and colleges which 
postulates that bystander damage by CTL cells to susceptible tissues results in HTLV-I 
associated inflammatory disease (reviewed by Daenke and Bangham, 1994). They propose 
that the main determinant of disease is the chronically activated CTL response to the 
HTLV-I Tax protein. Since the virus spreads mainly by cell to cell syncytium formation and 
cell division it is likely that there is very little cell free virus. Consequently the humoral 
immune response is not considered to be a critical determinant contributing to disease 
pathogenesis.
It is now clear that both healthy seropositives as well as patients with TSP mount vigorous 
anti-HTLV-1-specific cytotoxic T-lymphocyte responses (Parker et al, 1992; Daenke et al, 
1996) and humoral immune responses (Shinzato et al, 1993). The immunodominant anti­
viral CTL response is directed against the viral Tax protein (Jacobson et al, 1990, Parker et 
al 1992; Pique et al, 1996). Sequencing of several HTLV-I quasispecies has revealed that 
the intraisolate sequence variability is much greater than the variability between isolates. 
Furthermore, the naturally occurring nucleotide sequence variation within the tax open 
reading frame appears to be more variable within healthy carriers than within either TSP 
patients or ATL patients (Niewiesk et al, 1994). This suggests that healthy seropositives 
mount a stronger anti-Tax immune response driving tax sequence variability, and the 
production of ‘escape’ sequences that evade immune recognition (Phillips et al, 1991). 
Naturally occurring amino-acid substitutions in Tax both abolish recognition by CTL of the 
appropriate Tax peptide, and moderately or severely reduce the ability of Tax to 
transactivate various promoters (HTLV-I LTR, c-fos promoter, LL2-Ra chain promoter) 
(Niewiesk et al, 1995). Thus a vigorous anti-Tax CTL response drives the generation of 
Tax-escape mutants, but at the functional cost of impaired Tax activity. An elegant 
mathematical model proposed by Nowak and Bangham (1996) suggests that because the 
ratio of non-synonymous (coding) to synonymous (non-coding) codon changes (Nei and 
Gojobori, 1986) is significantly higher in healthy HTLV-I carriers (Niewiesk et al, 1996) 
these patients generate a higher selection pressure for immunologically driven amino-acid 
change in Tax. Since both healthy seropositives and TSP/HAM patients have an equally
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vigorous CTL response, the resolution of the paradox lies in the fact that TSP/HAM 
patients have between 10-100-fold higher proviral load within PBMC (Yoshida et al, 1989; 
Gessain et al, 1990; Kira et al, 1991). Consequently, low CTL responders have a higher 
proviral burden resulting in higher antibody titres (Shinzato et al, 1993) and widespread 
activation of T-cells. Extravasation of T-cells. leads to a focus of inflammation, the site of 
inflammation possibly determined by adhesion molecules displayed by proliferating 
lymphocytes (reviewed by Butcher and Picker 1996). Foci of chronically active 
inflammation would manifest symptoms particularly in sensitive tissues such as the spinal 
cord, which has little or no powers of regeneration. Hence genetic factors such as HLA 
haplotype (Usuku et al, 1988 and 1990) and the effectiveness of immune response genes 
which determine the efficiency of peptide processing and presentation may be the crucial 
factors in the development of these diseases.
1.7 Genomic Organisation of HTLV-I
The HTLV-I genome is organised into essentially two regions (Figure 1.1). A 3 ’ region 
which is homologous to the simple retroviruses containing gag, pol, and env flanked by long 
terminal repeats (LTR) plus an additional 3’ region (termed as the pX, x, or x-lor region) 
unique to the complex retroviruses. This region is now known to be alternatively spliced to 
increase the genetic diversity of what would otherwise be a relatively limited genomic 
repertoire. This region contains (at least) four overlapping open reading frames (orf) 
generating six extra proteins. The first of these to be discovered were Tax, Rex, and a C- 
terminally truncated Rex homologue, p21rex (Miwa et al, 1984; Kiyokawa et al, 1984; 
Kiyokawa et al, 1985). RT-pcr (reverse transcriptase-polymerase chain reaction) further 
revealed the presence of another three messenger RNA species which code for putative 
proteins, pl2:, pl3n and p30n (Ciminale et al, 1992; Bememan et al, 1992; Koralnik et al, 
1992).
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Figure 1.1: Schematic diagram illustrating the genomic organisation of HTLV-I
Complex retroviruses such as HTLV, BLV and HIV are composed of a 5’ simple region 
analogous to the simple retroviridae such as MuLV or FeLV containing the late structural 
genes gag, pol and env and a more complex 3’ region. This region contains multiple 
overlapping orfs, which are alternatively spliced to generate a number of extra proteins. 
These proteins (shown in the box above) represent the principal genes transcribed in the 
early phase of infection by HTLV-I before the switch to the unspliced/singly spliced 
messages mediated by p27rex. [Compiled from Franchini [1995].)
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1.7.1 Long Terminal Repeats
The long terminal repeats (Figure 1.2) located at the flanking 5’ and 3’ ends of the viral 
genome are non-coding cz's-acting elements which serve to regulate viral transcription, 
latency, and genomic replication. They consist of three highly conserved regions designated 
U3 region (353bp), the R region (221bp), and the U5 region (120bp) (Seiki et al, 1983; 
Josephs et al, 1984). The 5’ U3 region contains several important regulatory elements, 
which modulate viral gene expression. The first of these regions to be characterised were 
designated the Tax-responsive elements 1 (TRE 1) and 2 (TRE 2) and the Ets responsive 
region 1 (ERR 1) and 2 (ERR 2) (Bosselut et al, 1990 and 1991).
The viral LTR also contains other over-lapping cz's-acting sequences which allow the 
interaction of a variety of host transcription factors. Factors such as YB-1 (Kasanchi et al,
1994), Myb, (Bosselut et al, 1992; Dasgupta et al, 1992) Etsl/Sp-1, (Gitlin et al, 1991; 
Gegonne et al, 1993), Elf-1 (Clark et al, 1993) and AP-1, the Fos-Jun heterodimer, (Jeang 
et al, 1991; Fujii et al, 1995) can transactivate the viral LTR in the absence of Tax. This 
raises the intriguing possibility that host factors play key roles in the initiation of viral 
transcription following infection, and maintenance of basal viral transcription during latency. 
The switch from latency to active viral gene expression may fall under the control, at least 
in part, of the cAMP Responsive Element Binding (CREB) transcription factor (Brauweiler 
et al, 1995). The CREB factor forms a heterodimer with phosphorylated Activating 
Transcription Factor 2 (ATF-2) (Xu et al, 1996) which when it binds to the R region 
suppresses Tax expression from cell lines derived from LTR-Tax/LTR-PGal double 
transgenic mouse fibroblast tumours (Xu et al, 1994). Re-activation of HTLV-I may be 
signalled by phosphorylation of CREB and recruitment of the co-activator CREB binding 
protein (CBP) (Kwok et al, 1996).
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Figure 1.2: Schematic diagram illustrating the c/s-acting sequences located within the 
HTLV-I LTR
The viral LTR contain multiple cz's-acting sequences which are organised into a number of 
functional regions -  the Tax Responsive Elements (TRE) 1 and 2 and the Ets Responsive 
Region (ERR) 1 and 2. These elements together with binding sites for other host 
transcription factors constitute the viral promoter-enhancer regions. The viral promoter- 
enhancer is crucial for viral life cycle controlling responsiveness to the viral transcriptional 
regulator tax, as well as other host factors, which may modulate viral gene expression and 
latency. [Compiled from Goren et al, 1995; Semmes and Jeang, 1992; 1995; Gitlin et al, 
1991; Tsuchiya et al, 1994.]
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1.7.2 The TRE-I Region
The TRE-1 region consists of three imperfectly repeated 21 bp elements which are highly 
conserved between HTLV-I and HTLV-II (Sodroski et al, 1984). They act as viral 
enhancers conferring Tax responsiveness in a position and orientation-independent manner 
(Felber et al, 1985; Shimotohno et al, 1986; and Paskalis et al, 1986). Each repeat element 
contains three domains designated 5’ to 3’ as A, B, and C. Domain B contains a 
<TGACGT> motif that is homologous to the cAMP-responsive element (CRE) consensus 
sequence and is crucial for tax transactivation (Montagne et al, 1990). Tax transactivates 
viral gene expression through these repetitive elements by stimulating complex formation 
between several members of the CREB/ATF family of transcription factors (Xu et al, 1990; 
Montagne et al, 1990; Yoshimura et al, 1990; Jeang et al, 1991; Zhao and Giam, 1992; 
Suzuki et al, 1993a). These proteins form a family of transcription factors that contain a 
homologous basic region-leucine zipper (bZIP) DNA binding domain (reviewed by Watson 
et al, 1992). bZIP domains are composed of a leucine repeated every seven residues 
arranged upon a coiled-coil which forms a hydrophobic interface for dimerisation (the 
leucine zipper) and a basic region which forms two arms to specifically contact DNA. Tax 
homodimers (Tie et al, 1996; Jin et al, 1997) stimulate binding of bZIP proteins by 
enhancing their dimerisation which in turn facilitates their specific binding to DNA (Wagner 
and Green, 1993). Apparently Tax recognises the basic region of bZIP proteins (rather than 
the coiled-coil region) and in so doing alters the affinity of the transcription factor for its 
cognate sequence (Perini et al, 1995; Baranger et al, 1995). The Tax2-bZIP2 -DNA 
interaction results in a stable ternary complex which specifically enhances transcription from 
CRE motifs, especially those with 5’ G-rich and/or 3’ C-rich flanking regions. CREB, 
ATF-1, and possibly CREM appear to be the most important bZIP family members which 
interact with Tax (Zhao and Giam, 1992; Suzuki et al, 1993a). In a Saccharomyces 
cerevisiae reporter system where p-gal was fused downstream from two HTLV-I 21bp 
repeats and a minimal yeast cytochrome cl oxidase promoter, Tax in conjunction with 
either CREB or ATF-1 could stimulate expression of p-galactosidase in the absence of any 
other mammalian proteins (Shnyreva and Munder, 1996).
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1.7.3 The TRE-2 region
A second Tax responsive region, designated TRE-2 (Marriott et al, 1989) is located 
between the two proximal TRE-1 elements. This region binds a number of nuclear factors 
[Sp-1, Nuclear Factor-1, Myb] (Nyborg et al, 1990; Bosselut et al, 1992; Dasgupta et al, 
1992) including the product of the c-Ets-1 and c-Ets-2 proto-oncogene, Ets-1 and Ets-2 
(Bosselut et al, 1990; Gitlin et al, 1991).
1.7.4 The ERR-1 and ERR-2
Two distinct Ets Responsive Regions have been defined, ERR-1 which is located within 
TRE-2 and ERR-2 which is located upstream from the most proximal TRE-1 (Gitlin et al,
1991). These regions bind Ets as well as the product of the c-myb proto-oncogene, Myb 
(Bosselut et al, 1992). Ets-1 is preferentially expressed in lymphoid tissue and can trans- 
activate the LTR in the absence of Tax. In the presence of Tax it co-operates to enhance 
transactivation above the combined individual effects (Gitlin et al, 1993).
1.8 Functions of the 3’ pX region genes
1.8.1 The major HTLV-I regulatory genes: tax, rex and p21rex
Tax, rex, and p21rex represent the major RNA species both in HTLV-I infected cells and ex 
vivo samples. Tax and Rex are derived from a bicistronic mRNA molecule by the 
alternative use of AUG initiation codons located from within the second exon. The doubly 
spliced pX mRNA can support the synthesis of either a 27kDa (Rex) or a 40kDa (Tax) 
phosphoprotein.
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1.8.2 Tax
The HTLV-I Tax protein is a 353 amino-acid phosphoprotein distributed predominantly 
within the nuclear compartment of infected cells (Goh et al, 1985; Beimling and Moelling, 
1989). Tax acts as a transcriptional activator of its long terminal repeats (Cann et al, 1985; 
Felber et al, 1985) as well as modulating host gene transcription by usurping at least three 
different classes of transcription factors: CREB/ATF family, NF-kB family and the p67SRF 
(serum response factor) (Suzuki et al, 1993a; 1993b). However Tax does not bind DNA 
directly but rather acts indirectly by forming multi-protein complexes with these 
transcription factors (Fujisawa et al, 1991) which in turn bind DNA in a sequence specific 
fashion.
The amino-terminal residues of Tax (amino-acids 22-53) contain two overlapping zinc- 
fmger motifs (Semmes and Jeang, 1992) which act as a novel nuclear localisation domain 
(Gitlin et al, 1991) [Figure 1.3]. Indeed, mutants which were unable to localise to the 
nucleus were unable to transactivate heterologous CREB/ATF or NF-kB promoters (Smith 
and Greene, 1990; Gitlin et al, 1991; Smith and Greene, 1992).
Mutational analysis of the Tax protein has allowed the functional segregation of the 
CREB/ATF and NK-kB transcription factor pathways of gene activation employed by Tax 
(Smith and Greene, 1990; Semmes and Jeang, 1992). Surprisingly, discrete functional 
domains have not been easily defined since point mutations throughout the Tax protein can 
affect one or other of these pathways with approximately 95% of these mutations being 
completely redundant (Semmes and Jeang, 1992). Interestingly, the carboxyl terminal 22 
amino-acids (331-353) were completely dispensable for Tax transactivation (Smith and 
Greene, 1990). Mutation of a region of amino-acids located between 315-325 abrogated 
CREB-mediated Tax transactivation whereas three changes in amino-acids at serine 113, 
160, and 258 were found to specifically affect NF-kB function (Semmes and Jeang, 1992).
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Figure 1.3: Schematic diagram illustrating the various functional domains of HTLV-I 
Tax
The three figures illustrated from top to bottom represent:
1) (Top) The structural domains o f the Tax protein: The 5’ terminus contains the Nuclear 
Localisation Domain whereas the 3’ terminus contains the acidic region which can be 
deleted without changes in the transcriptional activity o f Tax. Acidic regions which 
define the activation domains o f a large number o f transcription factors have historically 
been associated with interaction with the basal transcriptional machinery being critical 
for transcriptional activity (Hope et al, 1988). Four cysteine residues ( C l53, C l74, 
C212 and C261) have been suggested to mediate multimerisation.
2) (Central) The transcriptionally functional domains o f Tax: Tsuchiya et al (1994) noted 
that Tax contained two independent domains (ADI and AD2), which were largely
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overlapping and inseparable. Semmes and Jeang (1995) however noted that an 
activation specific region could be defined as a discrete domain (amino acids 289-332) 
sufficient to confer a transcriptional activation function.
3) (Bottom) Mutational analysis of Tax: point mutations introduced into Tax generally 
have little effect on the transcriptional properties of Tax (Semmes and Jeang, 1992). 
However other authors have found that substitution of two amino acids drastically 
reduces the function of Tax causing conformational changes incompatible with nuclear 
localisation or transcriptional activity. The generation of these mutants has allowed the 
functional segregation of the NF-kB and CREB/ATF pathways which have each been 
found to be necessary for transformation of rodent fibroblasts.
[Compiled from Goren et al, 1995; Semmes and Jeang 1992 and 1995; Gitlin et al, 1991;
and Tsuchiya et al, 1994.]
23
Recently, the Tax protein has been dissected using Tax-Gal4 chimeric proteins to reveal 
two modular domains encompassing amino-acids 2-255 and 227-337 both of which are 
required for a functional activation domain (Tsuchiya et al, 1994). Furthermore, using a 
similar assay, Semmes and Jeang (1995) showed that amino-acids 289-322 alone were 
sufficient to confer transactivation function when fused to a Gal4 DNA binding domain, and 
may represent a minimal activation domain contacting a transcription factor. Supporting 
this notion, Tax mutants with alterations within the amino-terminal portion of Tax were 
unable to interact with CREB suggesting that the carboxyl end of Tax is involved in 
communication with the basal transcriptional machinery (Adya and Giam, 1995; Goren et al,
1995). Evidence that Tax does indeed contact a host transcription factor mediating Tax 
transcriptional activity was quickly provided by Clemens et al (1996). They demonstrated 
that Tax interacts with the TFIIA transcription factor, a member of the basal transcriptional 
machinery, which forms part of the pre-initiation complex necessary for RNA polymerase 
II-directed transcription. Other members of the pre-initiation complex may also interact 
with Tax including TATA Binding protein (TBP) and TFIID (Caron et al, 1993; Duvall et 
al, 1995).
A substantial body of evidence now supports the role that Tax may be effecting 
transcriptional activation by acting as a bridging transcription factor. In brief, 
transcriptional activators facilitate interactions between upstream enhancer-promoter 
complexes and the basal transcriptional machinery resulting in enhanced transcription rates. 
They exhibit activation domain-dependent interactions with specific members of the basal 
transcriptional machinery and may function .by increasing the number of pre-initiation 
complexes. Prominent examples of this type of transcription factor include the Adenoviral 
protein El A, and Herpes Simplex VP 16 (reviewed by Nevins et al, 1993 [El A]; Hayward 
et al, 1993 [VP 16]) the latter of which specifically interacts with TFIIA in an activation 
domain-dependent manner (Ozer et al, 1994).
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1.8.3 Trans-regulation of viral gene expression by Rex (p27rex)
The HTLV-I Rex protein is responsible for the trans-regulation of viral gene expression, 
positively controlling pol, env and gag protein expression, and inhibiting expression of 
protein pX genes (Hidaka et al, 1988). A highly basic amino terminal sequence, the 
nucleolar targeting sequence targets the Rex protein to the nucleolus (Siomi et al, 1988). 
Lack of this sequence abolishes the accumulation of unspliced pX mRNA species within the 
cytoplasm (Nosaka et al, 1989). This regulation of viral gene expression requires a cis- 
acting rex responsive element (RxRE) which consists of 255 nucleotides located within the 
3’U3/5’R region of the 3’LTR (Toyoshima et al, 1990). A critical stem-loop region located 
within the RxRE is sufficient to mediate high affinity binding (Bogred et al, 1992; Grone et 
al, 1994) possibly through direct DNA-protein contacts between the RxRE and the Rex 
arginine-rich RNA binding domain (Baskerville, 1995). A recent report suggests that p27rex 
may promote the accumulation of unspliced mRNA within the cytoplasm of infected cells by 
increasing both the stability and nucleocytoplasmic transport of unspliced mRNA 
transcripts, as well as decreasing the rate of splicing by directing unspliced mRNA to the 
cytoplasm via a nuclear compartment which avoids intron excision and degradation (Grone 
et al, 1996). Interestingly, this effect is not limited to viral mRNA, since p27rex also 
stabilises the human IL-2Ra chain mRNA (Kanamori et al, 1990).
Two RxRE have been identified in HTLV-II, one in the 5’ LTR (R/U5 region), the other in 
the 3’ LTR (R/U3 region) (reviewed by Gitlin et al, 1993). In this virus it is the active 
phosphorylated form of Rex (p26rex) which binds to the 5’ RxRE (Green et al, 1992) and 
critically this RxRE requires an intact splice-donor site (Black et al, 1991b). Moreover, the 
HTLV-II 5’ RxRE has been shown to contain cis-acting repressive elements (Black et al, 
1991a) which bind host cell factors known to be involved in RNA splicing (Black et al, 
1994; and 1995). HTLV-II Rex interacts with these elements to inhibit pre-mRNA splicing 
(Bakker et al, 1996) and so promote unspliced mRNA accumulation within the cytoplasm. 
Since all viral HTLV mRNAs contain the RxRE it is highly probable that the different
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regulation of spliced versus unspliced mRNA must rely on other cis-acting elements within 
the viral genome, as well as host factors (Black et al, 1994 and 1995).
1.8.4 Viral mRNA polyadenylation
A second function of the RxRE is to mediate a novel form of mRNA polyadenylation. The 
3’ RxRE region forms a stable secondary stem loop structure (Toyoshima et al, 1990) 
which serves to spatially juxtapose the widely separated AAUAAA poly(A) signal with the 
poly(A) site (Ahmed et al, 1991). It is the close approximation of these two sites which 
facilitates efficient 3 ’ processing and polyadenylation.
1.8.5 p21reI
p21rex is a 21kd phosphoprotein of unknown function. It has been isolated constitutively 
from both cultured HTLV-I infected cells and ex-vivo samples supporting its role as a 
biologically relevant protein (Kiyokawa et al, 1985, Berneman et al, 1992; Orita et al, 
1992). The protein lacks the p27rex N-terminal 78 amino-acids which contain the nucleolar 
targeting sequence therefore restricting its distribution to the cellular cytoplasm. p21rex may 
serve to potentiate the biological effects of p27rex by modulating the nucleocytoplasmic 
shuttling of p27rex and thus repress its nuclear export (Kubota et al, 1996).
1.8.6 The minor mRNA species: P121, pl3n, and p30n
The minor RNA species represented by pl2r, pl3n, and p30n have not yet been well 
characterised, and indeed, direct protein expression of any of these proteins has not been 
shown. RT-pcr reveals that these rare mRNA species are only detected in a minority of ex 
vivo samples (Koralnik et al, 1992, Berneman et al, 1992). None of these proteins are 
required for p27rex, tax, or env expression (Roithmann et al, 1994). Furthermore, the gene 
encoding pl3n, and p30n is frequently mutated within leukaemic cells, leading to premature
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termination codons, suggesting it is not required either for outgrowth of leukaemic clones 
in vivo (Chou et al, 1995) or for in vitro replication (Berneman et al, 1992b).
1.8.7 pl3n and p30n
pl3n, and p30n are derived by alternatively splicing an ORF II mRNA which generates two 
potential proteins of 131cDa (pl3n) and 30kDa (p30n). Transient transfection of pl3n and 
p30n epitope tagged proteins into rodent fibroblast cell lines revealed that they localise to 
the nucleus and nucleolus respectively (Koralnik et al, 1993). The nucleolar localisation 
region (NLR) of p30n has been mapped to a region between amino acids 71 and 98 
(Ciminale et al, 1997) and can functionally replace that of p27rex mediating activation of 
RxRE containing mRNAs (Ciminale et al, 1997).
1.8.8 pl2*
pl2J is a highly hydrophobic 12kDa protein which contains two potential transmembrane 
domains separated by a proline rich turn. Scattered throughout pl2! are highly conserved 
LLFL motifs (the significance of which are unknown) and four putative SH3 (PXXP) 
binding motifs (Franchini et al, 1993). Attention has focused upon the pl2* protein due to 
its known homology to the bovine papilloma virus type I (BPV-I) transforming oncoprotein 
E5. Both proteins are very hydrophobic, contain a critical glutamine residue located within 
the middle of a potential transmembrane region, bind growth-factor receptors as well as the 
16kDa subunit of the vacuolar FT-ATPase [via the proline rich turn of pl2T and molecular 
determinants located between the second and third transmembrane region of 16K (Koralnik 
etal, 1995)] and localise to similar sub-cellular compartments (perinuclear endomembranes 
[pl2r]; golgi apparatus and endoplasmic reticulum membrane [E5]) (Franchini et al, 1993). 
Tie functional extent of this homology was revealed by experiments in which E5 and pl2J 
ercoding cDNA were cotransfected into rodent fibroblast cell lines. Although pl2! alone 
cculd not induce focus formation it could significantly potentiate the transforming ability of
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E5 (Franchini et al, 1993). The mechanism of this co-operation however remains unclear 
although it does not directly correlate with pl2* binding the 16kDa subunit (Koralnik et al,
1995) - the presumed cellular target of both pl2! and E5 within the rodent fibroblast system.
The extent of the functional homology between pl2r and E5 is remarkable - pl2x also binds 
(and down regulates) a growth factor receptor, in this case the immature forms of the 
interleukin 2 receptor (IL2-R) P and yc chains in the pre-golgi compartment (Mulloy et al,
1996). These binding results have been somewhat substantiated in an in vitro 
transcription/translation system in which pl2* was found to bind the IL2R P chain but not 
the yc (Da Costa personal communication). The IL2R is a pivotal component of the 
immune response. It is composed of at least three chains designated a, P, and y (for a 
recent review see Theze et al, 1996). The y chain is now denoted as the common y chain 
(yc) since it is also a functional component of the IL-4, IL-7, IL-9, and IL-15 receptors. 
The P chain also forms a functional component of the IL15 receptor (Giri et al, 1994). 
Inheritance of a defective yc chain gene gives rise to X-linked severe combined 
immunodeficiency in humans (Noguchi et al,1 1993). The importance of the interaction 
between pl2r and the DL2-R are not fully understood although they may contribute to the 
mild immunosuppression observed in HTLV-I infected patients (Broder 1986; Yamaguchi 
and Takatsuki, 1993). Furthermore, the pl2J protein binds the IL2-RP chain at its acidic 
region and may therefore interfere with the normal functioning of the lymphocyte specific 
protein tyrosine kinase (p56lck). This tyrosine kinase also binds the acidic region of the IL2 
receptor P chain and serves to couple recognition of IL2 binding at the cell surface to the 
downstream signal transduction network (Hatakeyama et al, 1991). Therefore pl2* may 
contribute to the switch from IL2 dependent to IL2 independent cell growth observed in 
HTLV-I transformed T cell lines (discussed later).
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1.9 Phenotype of cells infected with HTLV-I
Primary cultures of T-cells from HTLV-I infected individuals, or HTLV-I infection of 
primary T-cells, most often leads to the outgrowth of an activated IL-2 dependent 
(immortalised) cell line (Popovic et al, 1983) which upon co-culture with PBMC or cord 
blood eventually leads to the generation of an IL-2 independent (transformed) T-cell line. 
Typically HTLV-I infected cultures are at first.immortalised and express high levels of IL2- 
Ra chain, (Franchini et al, 1984; Chlichlia et al, 1995) egr-1, and c-fos (Akagi et al, 1995) 
but clonal selection occurs with time and generally T-cells become ligand independent and 
do not express IL2 mRNA (Arya et al, 1984; Tendler et al, 1990). In common with HTLV 
transformed cell lines, leukaemic cells from ATL patients express neither IL2 nor EL4 (Mori 
et al, 1994) although they continuously express IL2-Ra chain. The transition from EL2 
dependent to IL2 independent growth correlates with the acquisition of a constitutively 
activated Jak-STAT pathway (Migone et al, 1995) as well as elevated levels of lyn (B cell 
specific kinase) and decreased expression of CD3 and p56lck (Akagi et al, 1995). The Jak- 
STAT pathway is an important signal transduction pathway which networks signals 
received at the cell surface after binding of the IL2R ligand with the activation of cellular 
transcription factors in the nucleus (reviewed by Ihle et al, 1995). In brief, ligand induced 
association of the IL2R P and yc chains brings the Janus kinases, Jak 1 and Jak 3 together 
which in turn phosphorylate signalling proteins recruited to the receptor complex. The 
primary substrates of Jak 1 and Jak 3 appear to be the signal transducers and activators of 
transcription (ST AT 3 and ST AT 5). Phosphorylation of these proteins induces 
dimerisation, nuclear translocation and transcriptional activity which is associated with the 
functional rather than mitogenic responses to cytokines. The factors however which govern 
the transition from IL2 dependent to IL2 independent growth are largely unknown but may 
represent contributions from other HTLV-I pX gene products since tax immortalised T- 
cells cannot be fully transformed even after 3 years in culture (Akagi et al, 1995). Thus a 
weight of evidence confirms that the minimal effect of Tax is to act as a mitogen to induce 
initially a ligand (IL2) dependent autocrine or paracrine proliferative response (Marriott et 
al, 1991) which in HTLV infected lymphocytes becomes ligand independent (transformed).
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1.10 Mechanisms of Transformation by HTLV-I
Two paradigms of retroviral oncogenesis have been developed over the past 20 years or so. 
The acutely transforming retroviruses discovered by Rous and co-workers in 1911 represent 
one class of transforming agents. Stehelin et al (1976) demonstrated that these viruses had 
transduced a host proto-oncogene - in the case of the Rous sarcoma virus this was the c-src 
proto-oncogene. Capture of the c-src gene resulted in highly elevated levels of the Src 
protein. Additionally, the error prone mechanism of reverse transcription resulted in 
mutation of the c-src gene such that the v-src gene resulted in a much more oncogenic 
protein (Varmus and Weinberg, 1993). This mechanism of transformation has since been 
widely accepted and represents an important mode of leukaemogenesis by the feline 
leukaemia virus (FeLV) in which it is estimated that one third of naturally occurring T-cell 
lymphomas in cats contain an FeLV transduced c-myc gene (Neil et al, 1984).
The second paradigm of retroviral transformation is illustrated by the chronically 
transforming class of retroviruses. This mechanism of oncogenesis probably represents the 
more common mode of tumour induction within the naturally infected host. In this 
scenario, proto-oncogene subversion is achieved by promoter-enhancer insertional 
mutagenesis (reviewed by Kung et al, 1991). In brief, neoplasia arises from promotion or 
enhancement of proto-oncogene expression by nearby integration of the viral LTR 
promoter-enhancer cis-acting sequences. In this case retroviral infection causes 
derangement of normal host control of proto-oncogene expression. As before this initiates 
the cell and spontaneous secondary collaborating lesions serve to progress the cell to the 
fully transformed phenotype. Examples of this type are provided by the Avian Leukosis 
Virus (ALV) in which 80% of B-cell tumours induced by experimental infection were due 
to integration close to the c-myc gene (Hayward et al, 1981). These mechanisms of 
oncogenesis has since provided useful tools to identify hitherto unknown oncogenes 
through retroviral transduction or insertional mutagenesis (reviewed by Jones and Katy,
1996).
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The discovery of the first human retrovirus in the early 1980s was therefore seen as an 
important step towards elucidating the underlying principals governing human oncogenesis. 
Contrary to expected opinion at the time HTLV does not transform through either of the 
aforementioned retroviral mechanisms since it does not contain a transduced cellular proto- 
oncogene and integration within the genome is essentially random with the site varying from 
patient to patient (Seiki et al, 1984). Furthermore, infection with HTLV-I leads to the 
development of ATL in only a small proportion of individuals after a prolonged latency 
typically of the order of several decades. Clearly transformation represents the accretion of 
multiple genetic aberrations combined possibly with epigenetic factors such as 
immunosuppression or mitogenic stimuli (e.g. Strongyloidiasis infection [Nakada et al, 
1987]).
However deregulation of host proto-oncogenes is still thought to be a central and perhaps 
critical mechanism through which HTLV-I transforms cells. Relevant to this hypothesis is 
the observation by a number of authors that Tax selectively up-regulates expression of 
various genes involved in T-cell growth and activation [e.g. c-myc, c-fos, c-jun, IL2, IL2- 
Ra, GM-CSF (see Table 1.3)]. Stabilisation of IL2-Ra chain mRNA by Rex (Kanamori et 
al, 1990) and binding of the IL2-RP and yc chains by pl2* (Mulloy et al, 1996) demonstrates 
that HTLV-I has targeted this cytokine network as a possible mechanism to induce at least 
an initial phase of autocrine polyclonal T-cell proliferation necessary for efficient viral 
integration and replication. Paracrine mechanisms have also been suggested since Tax is 
present in the supernatant of HTLV-I infected cells which can induce proliferation when 
internalised by human PBMC (Lindholm et al, 1990 and 1992; Marriott et al, 1991 and
1992). Transrepression of host genes involved in the maintenance of genomic integrity 
probably also contributes to transformation - Tax has been shown to repress the DNA 
repair enzyme P-polymerase (Jeang et al, 1989) as well as the anti-oncogene 
Neurofibromatosis Type I (Feigenbaum et al, 1996) (see Table 1.3).
1.11 Tax transactivation of host genes
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1.11.1 CREB/ATF
Tax has been shown to act as a promiscuous transactivator of cellular genes and appears to 
achieve this effect by interacting with two classes of transcription factors (NF-kB and 
p67SRF) in addition to the CREB/ATF family (described previously). Indeed, host genes 
containing CRE elements are largely unresponsive to Tax (Yin et al, 1995). It now appears 
likely that Tax forms a quaternary complex which specifically enhances the binding of 
CREB to both the viral and consensus cellular CRE by recruiting the transcriptional co­
activator CREB binding protein (CBP). The differential activation of viral versus cellular 
CRE elements critically depended upon the phosphorylation status of CREB (Kwok et al,
1996). Tax may bypass the need for phosphorylated CREB to stimulate the viral LTR 
under basal conditions but activate cellular CRE-containing genes under conditions that lead 
to CREB phosphorylation.
1.11.2 NF-kB
The N F -kB  family of transcription factors (NF-kB 1 (p50), NF-kB2 (p52), RelA (p65), c- 
Rel, and RelB) are a family of dimer forming proteins that bind to the consensus sequence 
<GGGANNYYCC> (reviewed by Hiscott et al, 1995). A conserved amino-terminal Rel 
homology domain acts as an interface allowing dimerisation and interaction with another 
family of inhibitory molecules known as IkB. IkB retains these proteins as inactive complex 
within the cytoplasm. The IkB proteins (IkBoi, LcBp, IxBy, bcl-3, p i00, and p i05 
[pl05=NF-KB p50 precursor]) are characterised by a carboxyl terminal domain containing 
five to seven repeats of an ankrin motif. The ankrin motif specifically binds and masks the 
nuclear localisation signal located within the Rel homology domain. Signals for cellular 
proliferation and differentiation activate N F -kB  responsive genes through rapid 
phosphorylation, ubiquitination and proteasome mediated degradation of I-kB. This allows 
transcriptionally active N F -kB  homo- and heterodimers to dissociate and translocate to the 
nucleus (Baeuerle and Baltimore, 1988; Ghosh and Baltimore, 1990).
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Tax has been shown to interact with several members of the N F -kB  family including p50 
(Suzuki et al 1993) p52 (Murakami et al, 1995; Lanoix et al, 1994; Beraud et al 1994), p65 
(Suzuki et al, 1994) and c-Rel (Suzuki et al 1994) as well as members of the I-kB  family 
(IkBoc Suzuki et al, 1995) IxBy (Hirai et al, 1994) p i05 (Hirai et al, 1992) and p i00 
(Murakami et al, 1995; Lanoix et al, 1994; Beraud et al 1994) probably through their Rel 
homology domain (reviewed by Beraud and Greene, 1996) rather than their conserved 
ankrin motif (Hirai et al, 1994). However Beraud and Green (1996) point out that not all 
these interactions may be specific suggesting that Tax interacts specifically with only p i00, 
p52 and p65. The general modus operandi purports that Tax binds various members of the 
IkB family within the cytoplasm and targets them for proteasomal degradation. Tax has 
been shown to induce rapid phosphorylation of IkBoc (Sun et al, 1994; Lacoste et al, 1995) 
and IkBP (Good and Sun, 1996). Proteasomal mediated degradation of IkBoc has been 
reported (Maggirwar et al, 1995) which may. Qccur through promotion of protein kinase C 
membrane translocation thereby triggering the PKC cascade (Lindholm et al, 1996). 
Phosphorylation by Tax may also account for Tax targeted activation of p i05 (the 
precursor of N F -kB  p50) via partially processing the p i05 inhibitor to yield the active p50 
subunit (reviewed by Palombella et al, 1994). However differential effects of Tax on the 
p i00 and p i05 molecules have been achieved (Munoz et al, 1995; Murakami et al, 1995) 
with Watanabe et al (1994) suggesting that Tax only inhibits the p i05 IkB molecule and not 
the p i00 molecule.
Tax may also act to induce the constitutive nuclear expression of various biologically active 
members of the NF-kB/Rel family of enhancer-binding proteins (Arima et al, 1991; Li et al,
1993) through transcriptional upregulation. Binding of Tax to the p50 precursor pl05 
(Hirai et al, 1992) and p50 (Suzuki et al, 1993b) may serve to indirectly associate Tax with 
NF-kB responsive promoters and thereby transcriptionally activate these genes.
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1.11.3 The serum response factor, p67SRF
HTLV-I infected cells constitutively express a high proportion of immediate-early serum 
responsive genes as a result of enhanced transcription [AP-1: Fos, Fra-1, Jun, JunB, and 
JunD, and egr-1, egr-2] (Fujii et al, 1991; 1992; Kelly et al, 1992). Several of these 
immediate-early response genes [<c-fos, egr-1, egr-2\ are transactivated via a common 
mechanism whereby Tax complexes with and activates the p67SRF resulting in 
transactivation of its cognate recognition sequence [the CArG box] (Fujii et al, 1992; 1995; 
Suzuki et al, 1993). Tax binds the serum response factor, p67SRF at its C-terminal domain 
(Suzuki et al, 1993b; Fujii et al, 1995) which in turn not only acts as an intermediary 
tethering Tax to the CArG box but supplies an essential component to the transcriptional 
activation machinery (Fujii et al, 1994).
Table 1.3: Literature survey demonstrating the wide array of cellular genes whose 
expression is modulated by Tax/HTLV-I expression
Activation
Gene Tax responsive promoter reference 
/enhancer element
Act-2 cytokine 
Egr-1 and Egr-2 
c-fos
Fra-1
human (3/s globin genes
p6 7 SRF though CArG box 
p67SRF through CArG box 
direct repeat element 
cAMP response element 
v-sis conditioned medium element
Fujii et al, 1991 
pentanucleotide CTGAC Fox et al, 1989 
element
Napolitano et al, 1991 
Fujii et al, 1991,1992 
Fujii etal ,  1988, 1991, 1992 
Alexandre and Verrier, 1991 
Nagata et al, 1989
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gp34
human GM-CSF 
human G-CSF 
murine GM-CSF
HIV-l™
HCMVI-E enhancer 
IL2
IL2-Receptor a  chain
IL-3
IL-4
EL -6
c-jun
junD
Krox 20/Krox 24
MHC class 1 
murine/human c-myc 
Nerve growth factor
CREB/ATF and NF-kB 
NF-kB
GC rich stretch and 
lymphokine element 1 
NF-kB
18 and 19-bp repetitve 
sequence motif 
NF-kB
NF-kB
GC-rich region
N F -kB
Miura et al, 1991 
Himes et al, 1993 
Himes et al, 1993 
Miyatake et al, 1988
Siekevitz et al, 1987 
Zimmermann et al, 1991 
Moch et al, 1992 
Lai and Rudolph, 1991 
Maruyama et al, 1987 
Hoyos et al, 1989 
Inoue et al, 1986 
Leung and Nabel, 1988; 
Ruben et al, 1988 
Hoyos et al, 1989 
Nishida et al, 1991 
Marriott et al, 1992 
Miyatake et al, 1988 
Arai et al, 1989 
Muraoka et al, 1993 
Yamashita et al, 1994 
Hooper et al, 1991 
Fujii et al, 1991 
Fujii et al, 1991
Serum response element and Alexandre et al, 1991 
cAMP responsive element
Sawada et al, 1990 
NF-kB Duyao et al, 1992a, 1992b
AGGGTGTGACGA (92% Green et al, 1991
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homology with 21 bp repeat)
p56Iyn
PTHrP
proenkephalin gene 
c-sis
TIMP-1( or erythroid 
-potentiating activity) 
murine TGF-P 
murine TNF a  (cachetin)
P2 promoter via Ets-1/ 
Ets-I binding site 
partly through cAMP- 
responsive elements
AP-1
NF-kB2
murine TNF-p (lymphotoxin) NF-kB
Transferrin receptor
vimentin NF-kB
zinc-finger gene
Yamanashi et al ,1989 
Watanabe et al, 1990 
Dittmer et al, 1993 
Joshi and Dave, 1992
Pantazis et al, 1987 
Ratner et al, 1989 
Uchijima et al, 1994
Kim et al, 1991 
Albrecht et al, 1992 
Lai and Rudolph, 1991 
Tschachler et al,1993 
Vidal et al, 1988 
Lilienbaum et al, 1990 
Salvetti et al, 1993 
Wright et al, 1990
Repressed
p-polymerase
CD3 (T-cell recepetor)
p56kk E-box
Neurofibromatosis type 1 gene
Jeang et al, 1989 
De Waal Malefyt, 1990 
Lemasson, 1997 
Feigenbaum et al, 1996
Table 1.3 summarising the various domains which Tax up/down regulates to modulate gene 
transcription.
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1.12 Oncogenicity of Tax
Several lines of evidence have now established that Tax is indeed an oncogene. Screening 
of tumours has shown that each tumour cell contains one or a few copies of the HTLV-I 
provirus monoclonally integrated into the host genome (Franchini et al, 1984). PCR 
analysis of proviral genomes demonstrate that a high proportion (56%) of patients carry 
deleted viral genomes, and that the pX region of the HTLV-I genome encoding the 
regulatory proteins Tax and Rex are preferentially retained (Korber et al, 1991; Tamiya et 
al, 1996). In situ hybridisation (Setoyama et al 1994), reverse transcriptase (RT)-pcr 
(Ciminale et al, 1992, Bememan et al, 1992, Koralnik et al, 1992) and the persistence of 
anti-Tax antibodies supports the notion that Tax expression occurs constitutively in PBMC 
of ATL patients but at very low levels.
Tax immortalises primary human CD4+ cord blood lymphocytes in the context of a Herpes 
saimiri vector to yield T-cell lines with the same phenotype (CD4+, CD5+, HLA class I+, 
IL2-Ra+) as lymphocytes transformed by co-culture with HTLV-I (Grassman et al, 1989 
and 1992). Tax transforms rodent fibroblast in vitro in NIH 3T3, Rat 1 and Rat 2 cells 
(Tanaka et al, 1990) which requires constitutive expression of Tax to maintain the 
transformed phenotype (Yamaoka et al, 1992). Tax also co-operates with the ras oncogene 
to transform early passage rat embryo cells (Pozzatti et al, 1990). A single amino acid 
substitution (58Pro~>Ser) results in loss of Ras co-operative focus formation but does not 
affect other tax functions such as growth in soft agar, focus formation in Rat-1 cells, 
immortalisation of REF and transcriptional activation through the CREB/ATF or NF-kB 
pathways (Matsumoto et al, 1994).
1.13 Oncogenicity of Tax in transgenic mice
The expression of Tax in transgenic mice lends further support to the notion that Tax is a 
bone fide oncogene. HTLV-I Tax transgenic mice develop a number of interesting 
pathologies including several different types of tumours (as shown in Table 1.4). The cause
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of the variance in phenotypic expression is unknown but it may be partly explained by the 
use of different promoter/enhancer elements and the different level of transgene expression. 
The most common and consistent phenotype is the development of mesenchymal tumours 
(Nerenberg et al, 1987) which have also been reported as neurofibromas (Hinrichs et al, 
1987). These tumours occur in conjunction with adrenal medullary tumours and iris 
proliferation (Green et al, 1992) consistent with human neurofibromatosis, although the 
analysis of neurofibromas from Japan and the United States did not associate HTLV-I 
infection with neurofibromatosis (Nerenberg et al, 1991). Other phenotypes include 
inflammatory polyarthritis which resembles Rheumatoid arthritis (Iwakura et al, 1991; 
Yamamoto et al, 1993), an exocrinopathy resembling Sjogrens syndrome (Green et al, 
1989), thymic atrophy (Furata et al, 1989), oxidative muscle degeneration (Nerenberg et al, 
1989) and large granular lymphocytic (LGL) leukaemia (Grossman et al, 1995). 
Interestingly, leukaemic cells derived from these tumours could not be propagated in vitro, 
and did not display typical T-cell surface antigens (CD4, CD8, TCRot/p or TCRy/5). Other 
attempts to transform thymocytes have proven unsuccessful. A Thy-1 based vector which 
expressed high levels of Tax in the thymus of transgenic mice was unable to transform this 
compartment (Nerneberg et al, 1991) but instead produced mesenchymal tumours 
infrequently, and after a long latency.
LTRHtlv-i c-/wyc/IgGpromoter-/ax bigenic mice develop a mixed phenotype: 30% of tumours 
are CD4+ CD8' T-cell lymphomas, and the remaining 70% are brain tumours derived from a 
neuronal lineage that resemble neuroblastomas (Benvenisty et al, 1992). Monogenic LTR 
^ ^ I  c-myc mice develop CD4+ CD8+ T-cell lymphomas at a lower frequency whereas 
IgGpromoter- to  mice develop no pathology. This raises the interesting possibility that c-myc 
may co-operate with Tax to induce T-cell lymphomas since c-myc transgenic mice usually 
develop B-cell lymphomas. Alternatively, the enhanced expression of c-myc observed in 
these mice due to Tax transactivation of the LTR n™"1 c-myc promoter may also account 
for the development of these tumours.
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Table 1.4: Phenotypes of various Tax transgenic mice
L T R  HTLV-I- Mesenchymal tumours/ Neurofibromas
Thy-1- to Low frequency, long latency fibroblastic tumours
L T R  HTLV-I ^ Oxidative muscle fibre degeneration
L T R  HTLV-I- Adrenal medullary tumours and iris proliferation
LTR HTLV'[-tax Exocrinopathy resembling Sjogren’s syndrome
LTR-env-pX Inflammatory polyarthritis resembling Rheumatoid arthritis
L T R HILV.I_t o Thymic atrophy
IgHenl“n“r/SV40pr<>n“ter- to Thymic atrophy
LTRMMTV-taX Thymic atrophy
Granzyme Bpwm°‘cr-tax Large granular lymphocytic leukaemia
Table 1.4 summarising the phenotypes and transgene constructs used to generate various 
HTLV-I transgenic mice
1.14 Mechanisms of transformation by Tax
The use of Tax mutants has demonstrated that transformation of immortalised rat 
fibroblasts requires constitutive activation of the CREB/ATF pathway (Smith and Greene
1991). However these results are diametrically opposed to those of Yamaoka et al (1996) 
who demonstrated that the NF-kB pathway is necessary and sufficient for transformation of 
immortalised rat fibroblasts. The importance of this pathway was further underscored by 
the observation that HTLV-I to-transformed tumours transplanted into mice were ablated 
by treatment with antisense NF-kB oligodeoxynucleotides (Kitajima et al, 1992). 
Activation of NF-kB has also been shown to mitigate the effects of tumour necrosis factor 
(TNF), ionising radiation, and anti-cancer drugs by specifically inhibiting apoptosis in cells 
treated with these agents (Beg et al, 1996; Wang et al, 1996; Van Antwerp et al, 1996; and 
Liu et al, 1996). These results argue strongly for the general importance of NF-kB in
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tumourigenesis. In the light of these observations it is difficult to reconcile the discordance 
between CREB/ATF and NF-kB without invoking a hitherto undiscovered interaction 
critical for mediating the transforming potential of tax in rodent fibroblasts.
A third potential mechanism contributing to the transforming ability of tax is the physical 
interaction between Tax and members of the cell cycle apparatus. Low et al, (1997) and 
Suzuki et al, (1996) demonstrated that Tax functionally interacts with the cyclin-dependent 
kinase inhibitor pl6INK4A which releases cells from pl6INK4A induced G1 growth arrest 
(functionally equivalent to retinoblastoma inactivation). Cell lines infected with HTLV-I or 
immortalised by tax also demonstrated low levels of another cdk inhibitor, p is 1^ 40 (Akagi 
et al, 1996).
Tax has also been shown to interfere with p53 function. Cell lines transformed by HTLV-I 
show a diminished p53-mediated response to ionising radiation (Cereseto et al, 1996). This 
could conceivably be due to direct transrepression of the p53 promoter (Uittenbogaard et 
al, 1995) or more directly via enhanced stabilisation of the p53 protein (Reid et al, 1993). 
However since Tax is not known to either transactivate or bind the p53 protein the 
mechanism of this interaction is uncertain. Furthermore the significance of these results in 
vivo are less convincing since only a minority of ATL patients exhibit mutations in the 
evolutionary conserved domain of p53 (Nagai et al, 1991; Yamato al, 1993). [Although 
where this does occur, p53 mutation is usually accompanied by loss of heterozygocity 
(Cesarman et al, 1992)]. Unexpectedly, these cell lines also demonstrated elevated 
expression of the p53 inducible gene, p2lwafl/cipl (another cdk inhibitor) which is mediated 
either by direct transactivation of the p21wafl/cipl promoter (Ceserman et al, 1996) or by p53 
independent mechanisms (Parker et al, 1995).
The central importance of these proteins is well recognised. p53, retinoblastoma, and the 
pi ^ ink4a pjay imp0rt;ant roles in the normal regulation of the cell cycle and the induction of 
growth arrest in senescent cells. They act as critical tumour suppressor proteins whose 
functional inactivation contributes to the genesis of a wide variety of human cancers
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(Nobori et al, 1994; Kamb et al, 1994; Hollstein et al, 1991 and 1994; Hirama and Koeffler, 
1995; Weinberg, 1992a and 1992b). The presence of a biological clock preventing 
indefinite proliferation and their high frequency of inactivation within human neoplasia 
suggests that their functional loss maybe pre-requisite for tumour emergence. Their crucial 
importance to the induction of malignancy is further highlighted by the evolutionary 
convergence of the DNA tumour viruses (Adenovirus, Human Papilloma Virus (HPV), 
SV40) and HTLV-I. Each virus has evolved to inactivate the p53 and retinoblastoma or 
plgiNK4a tumour suppressor genes. In the case of Adenovirus and SV40 the E1B 55 kDa 
protein, and the large T antigen each bind to and stabilise the p53 protein to inactivate its 
transcriptional activity (Linzer and Levine, 1979; Sarnow et al, 1982) whereas HPV-16 and 
HPV-18 E6 proteins bind to p53 (Wemess et al, 1990) and target it for proteolytic 
degradation in vitro (Scheffner et al, 1990). Furthermore Adenovirus El A, SV40 large T 
antigen, and HPV E7 each bind and functionally inactivate the hypophosphorylated (active) 
form of the retinoblastoma protein (DeCaprio et al, 1988; Whyte et al, 1988; and Dyson et 
al, 1989). The retinoblastoma gene acts as another negative regulator of the cell cycle and 
radiation induced apoptosis (Haas-Kogan et al, 1995; Haupt et al, 1995). Inactivation of 
retinoblastoma results in release of the E2F transcription factor (Bagchi et al, 1991; 
Chellappan et al, 1991 and 1992; Nevins et al, 1992; Shirodkar et al, 1992) stimulating 
quiescent cells into G1 cycle progression. This represents a final common pathway for 
these types of viruses necessary for efficient replication and dissemination. Likewise 
HTLV-I tax functionally inactivates the retinoblastoma (pi05, p i07 and p i30) family of 
proteins through inhibition of p i6 ^ ^ .  The pi 6 °*^  cdk inhibitor (plus other family 
members: p i6 ^ ^ ,  pl5INK4b, p is 1^ 40, and plO1^ 40) inhibit the active cyclin D-cdk 4/6 
complex (Hunter and Pines, 1994; Grana and Reddy, 1995; Sherr and Roberts, 1995) which 
are critical negative upstream regulators of retinoblastoma phosphorylation (Akiyama et al, 
1992; Dowdy et al, 1993; Ewen et al, 1993). Retinoblastoma functional activity is tightly 
regulated by phosphorylation at each stage in the cell cycle (DeCaprio et al, 1989; 
Buchkovich et al, 1989; Chen et al, 1989). In this context, hyperphosphorylated 
retinoblastoma is functionally equivalent to inactivation via El A, E7 or large T antigen.
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1.15 Cellular responses to oncogenic stimuli
Cells respond to oncogenic stimuli via two principal mechanisms which appear to represent 
hard-wired default pathways serving to delete initiated cells from the body. Introduction of 
oncogenic ras into immortalised rodent fibroblasts rapidly transforms them whereas 
introduction of the same oncogene into normal primary rat embryo fibroblasts results in 
growth arrest at confluency (Newbold and Overell, 1983). Phenotypically these cells are 
characterised by accumulation of p53 and plb1^ 43 causing G1 growth arrest, which is 
indistinguishable from cellular senescence (Serrano et al, 1997). Complete transformation 
of normal cells (primary REF) requires the co-operation of oncogenic ras with a second 
oncogene, typically loss of a tumour suppressor gene (for example p53 or plb1^ 43) or over­
expression of c-myc, Adenovirus El a, SV40 large T antigen, HPV E7 (reviewed by 
Weinberg, 1997). Similarly HTLV-I tax immortalises primary REF and fully transforms 
them in co-operation with mutant ras (Pozzatti et al, 1990). This property of tax can be 
functionally segregated from activation of either the CREB/ATF or the NF-kB pathways 
(Matsumoto et al, 1994). Thus functional inactivation of pl6INK4A or the retinoblastoma 
protein by HTLV-I and the DNA tumour viruses may circumvent the cellular response to 
proliferative lesions induced by ras or cellular ageing.
Cells respond to other oncogenic stimuli via induction of programmed cell death or 
apoptosis. Apoptosis appears to be an evolutionarily conserved ‘suicide’ programme 
present in all metazoan cells. It is distinguished morphologically by the rapid onset of 
cytoplasmic blebbing, nuclear and cellular fragmentation, and the surface expression of 
novel determinants that trigger phagocytosis (Ucker et al, 1991; Arends and Wyllie, 1991). 
Deregulated expression of c-myc in rodent fibroblasts acts as a powerful mitogen under 
idealised conditions but results in overwhelming apoptosis upon serum withdrawal (Evan et 
al, 1992). Addition of specific cytokines (survival factors) can inhibit this effect (Harington 
et al, 1992). These observations have been extended to the Adenoviral protein El A (White 
et al, 1991; Mymyk et al, 1994; Rao et al, 1992; Debbas et al, 1993), and c-fos (Preston et 
al, 1996) both of which are known to be mitogenic. Unsurprisingly Tax which also acts as a
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potent mitogen very efficiently induces apoptosis in rodent fibroblasts (Yamada et al, 1994) 
and T-cells (Chlichlia et al, 1995) and can be rescued by concomitant expression of bcl-2 
(Yamada et al, 1994) in parallel to that observed for El A (Rao et al, 1992; Chiou et al, 
1994). In contrast Bovine Leukaemia Virus (BLV) induced lymphocytosis in sheep is 
associated with a reduction in spontaneous B-cell apoptosis (SchwartzComil et al, 1997). 
The mechanism by which Tax induces apoptosis is unknown. Induction of apoptosis in tax 
transformed cell lines differs in sensitivity to that observed for Myc and Fos transformed cell 
lines (Fujita and Shiku, 1995) suggesting that transcriptional activation of these proteins is 
not necessary to mediate the apoptotic response. Expression of TNF (Brady et al, 1992) 
and DNA damage in Molt-3 cells (Saggioro et al, 1994) both of which are induced by tax 
could trigger apoptosis directly. However the intimate linkage of tax with the cell cycle 
suggests that induction of apoptosis may be due to enforced inappropriate proliferation in 
the absence of specific survival factors in an analogous manner to that observed for c-myc 
(Evan et al, 1992).
1.16 Development and Progression of ATL
The inactivation of the host response to oncogenic stimuli dictates that tumourigenesis is 
multistep requiring the functional complementation of co-operating oncogenes. C-myc co­
operates with H-ras to transform primary REF, in the same way that crossing MMTV-H-ras 
transgenic mice with MMTV-myc transgenic mice dramatically accelerates tumour 
development (Sinn et al, 1987). Similar co-operation is observed for c-myc transgenic mice 
crossed with bcl-2 transgenic or p53 knock-out mice (McDonnell and Koremeyer, 1991; 
Blyth et al, 1995). The development of acute ATL clearly requires the accumulation of 
several tumourigenic lesions. The Tax protein most likely provides the initiator. 
Inactivation of p53 (Cereseto et al, 1996) and plb1^ 43 function (Low et al, 1997; Suzuki et 
al, 1996), DNA damage induced by tax (Saggioro et al, 1994), as well as trans-repression of 
p-polymerase (Jeang et al, 1989) [a host DNA repair enzyme] and PCNA [a polymerase 6 
cofactor involved in DNA replication and repair] undoubtedly creates genetic instability. 
Loss of p53 function predisposes to gene amplification and aneuploidy (Livingstone et al,
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1992) [although it does not affect the rate of spontaneous point mutation or small deletions 
(Sands et al, 1995)]. Consistent with these notions is the observed rate of proviral deletion 
and chromosomal anomalies within ATL cells. Upto 56% of individuals with ATL have 
defective proviruses monoclonally integrated within their leukaemic cells (Tamiya et al, 
1996) with preferential retention of the transforming pX region. Additionally karyotypic 
instability has been frequently reported in leukaemic cells from ATL patients as well as from 
other forms of leukaemia/lymphoma associated with a Theiper phenotype (reviewed by 
Pandolfi et al, 1992). Sadamori and colleges (1986) showed that six out of eight patients 
with acute ATL had a 14qll anomaly which consisted either of inversions or small 
deletions. A follow up study involving 107 cases of ATL demonstrated that 103 cases 
showed karyotypic anomalies (96%) and that the most frequent structural chromosomal 
anomalies in ATL cells were translocations involving 14q32 (28%) or 14qll (14%) and 6q 
deletions (23%) (Kamada et al, 1992). Moreover, the presence and extent of aneuploidy 
and structural chromosomal abnormalities correlated with clinical ATL subtype and 
therefore the degree of tumour aggressiveness. Interestingly, inversion of chromosome 14 
is also frequently observed in HTLV-I negative chronic lymphocytic leukaemias (Zech et al, 
1984). The significance of these chromosomal breakpoints in ATL progression is still 
unknown although the TCRa chain locus has been located at 14ql 1.2 (Croce et al, 1985) 
and translocations involving this region may juxtapose the TCRa locus and the c-myc locus 
in certain T-cell leukaemias (Mathieu et al, 1985; Mckiethan et al, 1986).
1.17 Concluding Remarks
The full implications of the complexity woven by the interactions between oncoviruses and 
host cells are only now becoming apparent. Cellular metabolism is complex and seemingly 
chaotic -  large biochemical networks co-exist in dynamic equilibrium favouring biochemical 
diversity and functional redundancy. The induction of cancers in multi-cellular organisms is 
therefore correspondingly complex and non-intuitive reflecting the multi-step range of 
genetic aberrations required to subvert the cellular machinery which exists to control normal 
replication and programmed cell death (or apoptosis). Viruses have co-evolved with these
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control mechanisms and selectively disrupted them so as to favour replication and survival 
of infected cells and so enhance the production and dissemination of the virus. In rare 
circumstances these processes go awry and lead to malignancy. The simple retroviruses and 
the DNA tumour forming viruses represent two classes of viruses which have solved this 
problem in seemingly very different ways. However both strategies lead to a final common 
pathway which ultimately impinge upon and deregulate the central control of the cell cycle - 
the simple retroviruses by promoting the unusual contextual expression of cellular proto- 
oncogenes and the DNA tumour forming viruses by functionally inactivating the checkpoint 
control anti-oncogenes. HTLV-I appears to have adopted a hybrid strategy. Convergent 
evolution perhaps has generated a molecule, Tax, that can transcriptionally activate a wide 
repertoire of host oncogenes as well as directly interfering with members of the cell cycle 
machinery. In parallel to this multi-cellular organisms have evolved to carefully couple cell 
replication with programmed cell death or enforced growth arrest which serves to 
functionally delete rogue cells from the body before genetic damage can become stably 
integrated and propagated within the genome.
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Chapter 2 
Materials and Methods
Materials and Methods
2.1 Transgenic Mouse stocks
The tax gene (a gift from Dr G. Franchini, NCI, Bethseda, Maryland) was derived from a 
cDNA of the pX region which was transcribed from an HTLV-I provirus. An EcoRI 
fragment containing the tax gene was subcloned and the SphI site which contained the rex 
initiation site was deleted. The chloramphenicol acetyl transferase (CAT) gene from CD3- 
b p/CAT/1-9 was then replaced by a Bam Hl/Xbal fragment containing tax (Clevers et al, 
1989) thus placing tax under the regulatory control of the CD3-S promoter-enhancer.
The generation of the CD3-tax transgenic mice was carried out by Dr. E. Cameron and Dr. 
K. Blyth. The CD'S-tax transgenic founder mice were made by microinjecting the 
linearised DNA into fertilised mouse ova to generate C57xCBA FI hybrids according to 
previously published protocols (Palmiter et al, 1982). The resultant offspring were then 
bick-crossed onto littermate controls to develop 4 lines of transgenic mice.
The p53'7' knock-out mice were a gift from Donehower (Donehower et al, 1992). The 
p53/tax mice (denoted p/t) were created by crossing p53+/' mice onto the 1300 and 1400 
scries of CD-3 tax mice.
22 Mouse Genotyping by Southern Blot Analysis
22.1 Buffers
Al chemicals were purchased from Sigma Chemical Co. unless otherwise stated.
L/sis buffer. 
llOmM TrisHCL pH 8.5 
5nM EDTA pH 8.0 
02% SDS
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200 mM sodium chloride.
24 x SSC (5 litre")
sodium chloride lkg
500gcitric acid.
Alkali Buffer (5 litre).
sodium chloride 
sodium hydroxide
438.3g
100g
Neutralising Buffer (5 litre). 
Tris base 
sodium chloride 
hydrochloric acid
303.5g 
438.3g 
165 ml
Reaction Mixture 1.
5jil reaction buffer 3 (Gibco BRL)
3(j,l EcoR 1 restriction enzyme (Gibco BRL) 
3pl Bgl 11 restriction enzyme (Gibco BRL) 
ljil Rnase 
1 (j.1 spermidine 
7 pi ultra pure water.
10 x TBE Buffer (2 litre!
Tris base 216g
boric acid llOg
0.5m EDTA pH8.0 80 ml
5x TBE Loading Dye.
50% glycerol 
50% lOxTBE
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bromophenol blue
TE buffer pH8.0 
10 mM Tris-HCL pH8.0 
ImMEDTA pH8.0
2.2.2 Genomic DNA extraction.
High molecular weight DNA was extracted from mouse tails using a Nucleon II Kit 
(Scotlab) according to the manufacturers protocol. A small section of tail (1-2 cm) was 
placed in a 1.5 ml reaction tube with 500pl lysis buffer and 25pi proteinase k (lOmg/ml) 
(Sigma Chemical Co.) and incubated overnight at 55°C on a rocking platform. 125(0.1 of 
5M sodium perchlorate was added and rotary mixed for 15 minutes at room temperature. 
Samples were then incubated in a shaking water bath at 65°C for 25 minutes. DNA was 
extracted by adding 500pl of cold chloroform (BDH Ltd), rotary mixed for 10 minutes at 
room temperature and then microcentrifuged at 3,000 r.p.m. for 1 min. 75pl of Nucleon 
silica suspension was added and the sample was microcentrifuged at 4,000 r.p.m. for 3 
minutes. The DNA phase above the nucleon silica suspension layer was transferred to a 
fresh tube. Two volumes of 4°C 100% ethanol was added and the tube inverted gently to 
precipitate the DNA. The DNA was recovered by lifting the precipitate from the solution 
and dissolved in lOOpl ultra pure water. The DNA was left overnight at room temperature 
to allow complete dissolution. The concentration of DNA was determined by measuring 
the absorbency at 260nm.
2.2.3 Restriction digestion of DNA for detection of the tax transgene
A Bam HI/Eco RI fragment digest was carried out on tail genomic DNA in CD2-tax mice 
to release a tax fragment of l.Okb. Each digestion required 10 pg of DNA made up to 30pl 
of water and 20pl of reaction mixture 1 and was incubated overnight at 37°C. The samples 
were removed from the water bath and 5pl of TBE loading dye was added.
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2.2.4 Separation by gel electrophoresis
The DNA samples were run on an 0.8% agarose gel at 28 volts overnight in lx TBE buffer 
containing a 1/20 dilution of stock ethidium bromide (0.5pg/ml, Sigma Chemical Co.). The 
gel was photographed under UV transillumination.
2.2.5 Southern blot
The gel was washed in alkali buffer for 45 minutes, followed by washing in neutralising 
buffer (45 minutes) and finally in lOx SSC buffer for 15-30 minutes. The DNA was 
transferred overnight onto Hybond membrane (Amersham Ltd) by an upward capillary 
transfer. The DNA on the membrane was immobilised by UV crosslinking for 8s at 1200p 
joules x 100 using a UV stratalinker 1800 (Stratagene).
2.2.6 Radioactive labelled probes
Detection of the CD'S-tax transgene was carried out using a l.Okb Bam Hl/Eco R1 tax 
fragment derived from the original p30 vector. DNA fragments were labelled using a 
multi-prime labelling kit (Amersham Ltd) with a  32 P dCTP (3000 Ci/mMole, Amersham 
Ltd) to specific activities of > 0.5 x 10 8 cpm/pg. 50-100 ng/pl of DNA fragment was 
added to 23 pi water and boiled for 5 minutes, then chilled on ice. 5 pi primer, lOpl 
labelling buffer and 2pl Klenow enzyme were added and mixed gently. To this 8pl of a  
32 P dCTP was added and left overnight at room temperature. The labelled DNA fragment 
was then separated from unincorporated nucleotides by column chromatography and the 
fragment was eluted through a sephedex (G-50, DNA grade, Pharmacia) column using TE 
buffer pH 8.0. The labelled DNA moved down the column quicker than the 
unincorporated nucleotides creating ‘two peaks’ which were detected using a hand held 
minimoniter. The first peak contained the labelled DNA probe which was collected in a 
reaction tube and stored at -20°C until required.
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2.2.7 Hybridisation using dsDNA radioactive probes
DNA blots were prehybridised with 10-15ml Quikhyb (Stratagene) at 68°C for 15 minutes. 
500pl of denatured gene bloc (5mg/ml) (Immunogen Ltd) and lOOpl of denatured tax 
probe was added and incubated at 65°C for three hours. The blots were then washed twice 
in 2x SSC, 0.1% SDS for 15 minutes, followed by 2 x 15 minutes in 0.2% SSC, 0.1%SDS 
and a final wash in 0.1% SSC, 0.1% SDS for 15 minutes. The blot was then dried and 
wrapped in Saran wrap, placed in a hypercassette (Amersham Ltd) with autoradiograph 
hyperfilm-MP (Amersham Ltd) overnight in -70°C freezer prior to development.
2.3 Histopathology Techniques
2.3.1 Preparation of tissues
The mice were examined three times per week and sacrificed according to the home office 
guidelines. Each mouse was autopsied and samples immediately taken for 
histopathological examination and RNA analysis. Tissue samples for histology were fixed 
in 10% neutral buffered formalin, post-fixed in mercuric chloride, and embedded in 
paraffin wax. Sections (2-3pm) for immunocytochemistry were mounted on 3- 
aminopropyltriethoxysilane (Sigma Chemical Co.) coated glass slides and routinely stained 
with haematoxylin and eosin (H+E). Age-matched control samples were taken from 
normal C57/CBA mice and stained in parallel to tumour samples.
2.3.2 Generation of Tax Antibody
Synthetic four branch multiple antigenic peptides (MAPs) were made by Fmoc solid phase 
polyamide synthesis (Jackwood et al, 1995; Tam et al, 1988; Posnett et al, 1988) using 
amino-acid (aa) sequences corresponding to two distinct regions of the Tax molecule (aa 
109-121 NH2-MRKY SPFRNGYME (Tax-14) and aa 338-353 NH2- 
GGLEPPSEKHFRETEV (Tax-16)). New Zealand White rabbits were immunised by a 
subcutaneous injection of lOOpg of the MAPs dissolved in non-ulcerative Freund's
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adjuvent (Guildhay Ltd., UK.) every 6-8wks. The primary immunisation was administered 
complete with BCG vaccine (John Bell + Croyden, UK) - all other immunisations were 
incomplete. Blood from the rabbits was collected aseptically 1-2 weeks after each 
immunisation until a high titre was achieved. After each collection the blood was allowed 
to clot, the serum was harvested and stored at -20°C or at 4°C with the addition of 0.01% 
sodium azide (Sigma Chemical Co.).
2.3.3 Analysis of the anti-peptide Tax serum
Serum from the rabbits, designated Tax-14 arid Tax-16 (denoting antibody generation from 
Tax peptide 14 or 16 respectively) was tested for antibody production by indirect ELISA 
using the Pierce ELISA kit (Pierce & Warriner UK, Ltd.). The system was optimised 
according to the manufacturer’s protocols.
1 jug of MAP was immobilised directly onto 96 well microtitre plates, incubated for 1 hour 
at room temperature, washed, and blocked using manufacturer’s washing and blocking 
solutions. Both primary and secondary antibodies were titrated out by serial 1:2 dilutions 
according to the manufacturer’s standard two-dimensional ELISA protocol. Primary 
antibody was first serially diluted vertically, incubated for 1 hour at room temperature, 
rinsed and washed. Secondary labelled sheep anti-rabbit antibody was serially diluted 
horizontally, incubated for 1 hour at room temperature, rinsed and washed. The alkaline 
phosphatase chromagen was then added, incubated for half an hour at room temperature, 
and the absorption measured at 405nm.
Serial dilutions of serum were then analysed for antibody titre using a fixed dilution of 
secondary antibody (1:1000).
2.3.4 Immunocytochemical Analysis
Fos (SC-052), Myc (N-262) (both from Santa Cruz Biotechnology Inc.), and Jun (PC-07) 
(Calbiochem-Novabiochem, UK) polyclonal antibodies were titrated and optimised on
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known positive samples and used at the appropriate dilution (Fos 1:250; Myc 1:500; Jun 
1:500) together with 0.1% bovine serum albumin/0.01% sodium azide in PBS (Sigma 
Chemical Co.).
Tax-14 and Tax-16 serum was also optimised using the above method by serial dilution on 
control sections which were known to express tax by Northern analysis. Control sections 
were either untreated, pre-incubated with 0.1% trypsin, 0.1% CaCl2  in PBS (120 mM 
NaCl, 11.5 mM NaHhPCU, 31.3 mM KH2PO4, pH 7.6) (Sigma Chemical Co.) or heat 
treated by microwaving in 0.01M sodium citrate (Sigma Chemical Co) for optimum 
antigen retrieval. The optimum dilution of Tax antibody (1:100 on untreated sections) was 
then used for all subsequent immunocytochemical staining.
Immunopositive cells were detected using the ABC method: tissues fixed in formalin were 
deparaffinized, rehydrated, and washed in Lugol's iodine to remove mercuric chloride. 
Incubating in 0.5% hydrogen peroxide in methanol for 30 minutes inactivated endogenous 
peroxidases. Sections, where appropriate, were incubated in saponin (Sigma Chemical 
Co.) according to the recommendations of the suppliers of the primary antibody, washed 
and then pre-blocked in 1.5% normal rabbit serum for 30 min at room temperature (RT). 
(Blocking antibody concentration was varied between 1.5 -  20% to reduce background 
staining. 1.5% was chosen as the optimum concentration of blocking antibody).
Primary antibodies were incubated with the sections overnight at 4°C. The sections were 
then washed and a biotinylated swine anti-rabbit secondary antibody (Dako) was added for 
30 minutes at RT, washed, and an avidin-biotin complex (Dako) containing horseradish 
peroxidase was added for 45 minutes at RT. The sections were washed again, stained 
using 3,3'-diaminobenzidine/hydrogen peroxide tablets (Sigma Chemical Co.) and 
counterstained with Mayer’s/Gill’s haematoxylin.
All washes were performed in triplicate for 5 min at RT in PBS. Incubations were 
performed in humidified chambers.
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The same procedure was used for the p53 antibody (CM5) (Novacastra Laboratories Ltd.). 
However these sections were heat-treated to unmask antigens by pressure cooking for 
either one or two minutes in 0.01M sodium citrate, pH 6.0.
The same procedure was used for the MCA519 (rat anti-mouse macrophage antibody) 
except the sections were not deparaffinised.
2.3.5 DNA Nick End Labelling of Tissue Sections
Sections were deparaffinised and rehydrated as before. Slides were deproteinised with 
20pg/mL proteinase K (Sigma Chemical Co.) for 15 minutes at RT, washed in PBS, and 
endogenous peroxidases were inactivated with 3% hydrogen peroxide in methanol for 5 
min at RT. After washing in PBS, the slides were rinsed in terminal deoxytransferase 
(TDT) buffer (30mM Trizma base pH 7.2 + 140mM Na Cacodylate + ImM C0 CI2 ) for 2 
minutes at RT, and then incubated in a humid chamber for 1 hr at 37°C in TDT 
(Boehringer Mannheim) (0.25 units/pL) and biotinylated-16-dUTP (Boehringer 
Mannheim) made up in TDT buffer. The reaction was terminated by washing in TB buffer 
(300mM NaCl + 30mM sodium citrate) twice for 5 minutes at RT, washed in PBS and then 
incubated for lhr at RT in horseradish peroxidase-streptavidin (Dako) diluted 1:200 in 
house detection diluent (lOOmM Trizma base, 50mM NaCl, 20mM MgCh, with 0.5fiL/mL 
Tween 20, pH 8.5). Staining was performed either with 3-amino-9-ethylcarbazole (AEC) 
(Vector Laboratories, Peterborough, UK) or 3,3'-diaminobenzidine (DAB) (Sigma 
Chemical Co.) and counterstained with Mayer’s/Gill’s haematoxylin. As before all washes 
were performed in triplicate in PBS unless otherwise stated.
2.3.6 Immunofluorescent Co-localisation of Tax expression and Apoptosis
Sections were first nick-end labelled as before and then treated with the Tax antibody 
diluted 1:10. Fluorescent secondary antibodies were then incorporated, incubating with a 
Texas Red-streptavidin (Molecular Probes) (1:1000) and anti-rabbit IgG-FITC (Sigma 
Chemical Co.) (1:25) for 1 hour at RT. The Texas Red-streptavidin was allowed to bind to
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the biotinylated dUTP nucleotides first before the addition of the anti-rabbit IgG-FITC. 
The sections were washed in PBS and directly visualised under UV illumination.
2.3.7 Analysis of apoptotic and mitotic indices
Mitotic and apoptotic indices were measured by counting the average number of cells for 5 
random high power fields (xlOOO) using light microscopy. The numbers of 
metaphase/anaphase mitotic figures or the number of cells staining with PCNA (F051) 
(Santa Cruz Biotechnology Inc.) were counted as an estimate of mitotic index. Similarly 
the number of cells staining with the TUNEL technique were counted as an estimate of the 
apoptotic index.
2.4 Tissue Culture Techniques
All reagents were bought from Gibco BRL unless otherwise stated.
2.4.1 Media 
Complete DMEM
Complete DMEM medium was prepared aseptically by supplementing DMEM (Gibco 
BRL) with 10% heat inactivated foetal calf serum (FCS), lOOU/mL penicillin, lOOpg/mL 
streptomycin, 2mM L-glutamine and lOmM HEPES buffer (all from Gibco BRL). For 
transfections 8% modified bovine serum (Stratagene mammalian MBS transfection kit) 
was substituted for FCS.
Cell Freeze Down Medium
Sterile 10% dimethyl sulphoxide (Sigma Chemical Co.) was added to 90% FCS under 
aseptic conditions.
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Tamoxifen Stock solution
4-hydroxy-tamoxifen was dissolved in ethanol to a final concentration of 5mM and stored 
at -20°C.
2.4.2 Growth of cell lines
Tumour cell lines T1 (derived from a 1300 series mesenchymal tumour), p/t 50 and p/t 54 
(derived from p/t 50 and p/t 54 transgenic mice) were generated by aseptically collecting 
tumour samples into complete DMEM medium and homogenising the tumour using a 
lOOpM wire grill. The homogenate was grown in complete DMEM at 37°C and 5% CO2 . 
Tumour cell lines were serially passaged by splitting 1:4 twice per week into complete 
DMEM solution.
2.4.3 Transplantation of tumour cell lines
Tumour cell lines were washed in warm PBS (37°C), resuspended with 2mL trypsin- 
EDTA (Gibco BRL) and lOmL of warm PBS (37°C), and counted on a calibrated Coulter 
counter. 5xl06 cells were aliquoted into warm PBS (37°C), spun at 1500g for 2 minutes, 
and resuspended in 250pL of complete DMEM. The resuspended cells were then injected 
subcutaneously into nude mice. Each experiment was performed in triplicate.
2.4.4 Analysis of retroviral vector function
Functional integrity and inducibility of each expression construct was determined by 
analysis of the ability of each vector to transiently activate CAT expression from HTLV-I 
LTR-CAT, NF-kB-CAT and SRE-CAT reporter gene expression constructs. Each Tax- 
MER vector was transiently transfected into BHK cells (described later) together with 
HTLV-Iltr cat, fflV-ILTR'CAT and c-fos-CAT reporter gene constructs. The HTLV-Il t r ‘ 
, HIV-Iltr'cat and c-fos-CAT reporter gene constructs each required functional activity 
of the Tax-MER protein CREB/ATF, NF-kB or SRF binding domains, and thereby tested
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the function integrity of this domain. Induction of the Tax-MER protein was assayed by 
the addition of 250nm 4-hydroxy tamoxifen.
2.4.4.1 Transient Transfections
8x104 exponentially growing cells were aliquoted into 35mm dishes 24 hours prior to 
transfection. Transfections were carried out using the mammalian MBS transfection kit 
(Stratagene Ltd., Cambridge). 5pg of DNA was made up to a final vol. of 450|iL with 
sterile water, and 50pL of 2.5M Ca2 Cl added. 500pL of 2xBBS (N,N-bis(2- 
hydroxyethyl)-2-aminoethanesulfonic acid and buffered saline) was added by drop-wise 
addition whilst shaking and allowed to stand at RT for 15-20 min. Cells were washed 
twice in PBS and 4mL of 8% MBS supplemented DMEM medium added. 400pL of 
transfection solution (l/lO111 vol.) was then added and the cells were incubated at 35°C, 3% 
CO2 for three hours. Cells were then washed three times in PBS, 4mL of complete DMEM 
medium added and returned to 37°C, 5% CO2 . Induction of the Tax-MER construct was 
achieved by adding 250nm final concentration of tamoxifen.
2.4.4.2 Optimisation of transfections
Fixing solution (TOOmL)
5.41mL of 37% formaldehyde (2% final concentration)
2.00mL of 10% glutaraldehyde (0.2% final concentration) 
lO.OOmL of lOxPBS (lxfinal concentration)
Sterile water to lOOmL
Histochemical reaction mixture (250mL)
0.41 lg potassium ferricyanide (5mM final concentration)
0.53g of potassium ferrocyanide (5mM final concentration)
5mL of lOOmM MgC12 (2mM final concentration)
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25 mL of lOxPBS (lxfinal concentration)
Add X-gal just before use (40mg/mL in' DMSO stock solution) to give a final 
concentration of lmg/mL and make up to a final volume of 250mL with sterile water. 
Optimisation was carried out according to the mammalian MBS transfection kit 
(Stratagene Ltd., Cambridge). BHK cells were aliquoted at approx. 20% confluency into 
24 well plates 24 hours prior to transfection. A [3-gal expression vector was used as a 
reporter construct. The transfection was carried out as described above except that a two- 
dimensional titration (DNA concentration versus MBS concentration) was performed. 
DNA was serially diluted from 0.5-5.0pg/mL (total amount of DNA per mL of transfection 
solution) in lpg/mL increments. MBS was serially diluted from 2-8% MBS in 1% 
increments.
Cells were stained for expression at 6hr, 24 hours and 48 hours post transfection. This was 
done according to the Stratagene protocol: cells were washed twice in PBS, fixed for 5 
minutes in fixing solution, washed once in PBS, and incubated in histochemical staining 
solution for 14-24 hrs at 37°C. Cells were then washed twice in PBS and viewed under a 
microscope.
Once the optimum concentration of DNA and MBS had been determined the optimum cell 
density (number of cells per dish) was determined. BHK cells were aliquoted at 37k, 
48.1k, 74k, 99k, and 148k per well into 35mm diameter tissue culture dishes and
tlitransfected with 1/10 volume of 5.0pg/mL transfection solution containing the P-gal 
reporter construct and 8% MBS as previously described.
2.4.4.3 Stable Transfections
Stable transfections were performed in the same way using the mammalian MBS 
transfection kit (Stratagene Ltd., Cambridge). However cells were split 1:10 and 1:20 after 
24 hours incubation at 37°C into medium supplemented with G418 (Gibco BRL) at 
800pg/mL. Monoclonal colonies were picked using cloning rings once all control cells 
(untransfected cells) had died, typically at 7-14 days post transfection. Monoclonal
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colonies were allowed to grow to confluence, maintained at 400jig/mL G418, and then 
frozen in freeze down medium and stored in liquid nitrogen.
2.4.4.4 CAT assays
CAT assays were performed using the Flash CAT non-radioactive CAT assay kit 
(Stratagene Ltd., Cambridge). 24hrs after transient transfection cells were washed in PBS, 
harvested using cell scrapers, pelleted, and resuspended in lOOpL of reaction buffer. Cells 
were lysed by freeze thawing twice in a dry-ice/ethanol bath. 15pL of BODIPY 1- 
deoxyCAM substrate reagent and IOjiL of 4mM acetyl Co A (Sigma Chemical Co.) were 
added to 55pL of cell extract and incubated at 37°C for l/2hr -  3hr according to each 
reporter gene expression CAT construct. A positive control (l|iL  of chloramphenicol 
acetyl transferase (0.05IU/fiL) was optionally included (Stratagene Ltd., Cambridge)) to 
validate the CAT reaction conditions as per the manufacturer’s protocol. 5pL of reaction 
products were spotted onto a thin layer chromatography plate together with 5pL of 
acetylated 1-deoxy-CAM reference standard, separated by thin layer chromatography 
(87:13 ratio of chloroform:methanol), and photographed under UV transillumination. 
CAT assays were quantitated by scanning the photographed images into a digital format 
(Microtek Scanmaker) before analysing the image using a commercially available software 
programme (Phoretex Image analysis software). The results of each CAT assay were the 
average of 3 separate experiments performed on at least 2 separate days.
2.4.5 Cell Counting Experiments
Actively growing Rat 1 log phase cells were aliquoted into 24 well plates at lx l04 cells per 
well and grown in complete DMEM medium at 37°C and 5% CO2  for up to 4 days. After 
2 or 4 days incubation the supernatant was removed and the cells washed gently in warm 
PBS (37°C) to remove non-adherent dead cells. The remaining adherent live cells were 
then removed from the wells by incubating with 0.1-0.5 mL of trypsin-EDTA (Gibco 
BRL) solution until retraction of the cells was evident under light microscopy. The cells
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were then removed by agitation with 2mL of warm (37°C) PBS and counted immediately 
using a calibrated Coulter counter.
The concentration of FCS was optimised by serial titration of the FCS from 0.1 to 0.5% 
concentration in 0.1% increments and the total live adherent Rat 1 cells were counted after 
2 and 4 days incubation. Similarly the tamoxifen concentration was optimised by growth 
of Rat 1 cells in lOOnm and 250nm tamoxifen solution and the total live adherent cells 
were counted after 2 and 4 days incubation.
Analysis of apoptosis was performed in the same way. Each of the Rat-1 stably 
transfected cell lines was assayed by growth of each cell line in complete DMEM medium 
at 37°C, 5% CO2  for 2-4 days containing 0.1% FCS with or without the addition of 250nm 
tamoxifen. After 2 or 4 days the number of live adherent cells was counted using a Coulter 
counter. Each experiment was performed 4 times on at least 2 separate days.
2.5 Molecular Biology Techniques
All reagents were purchased from Sigma Chemical Co. unless otherwise stated.
L-broth
1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) sodium chloride in ddH20, 
autoclaved and stored at RT. Ampicillin (final conc. 50pg/mL) or kanamycin (final conc. 
50pg/mL) was added as needed.
STET solution
8% sucrose (w/v), 0.5% Triton X-100, 50mMEDTA, lOmM Tris
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TE solution
lOmM Tris.HCL, ImM EDTA, pH as required.
TBE solution (xlO)
0.9M Tris.HCL, 0.9M Boric Acid, 25mM EDTA pH 8.3.
Xzgai
Stock solution at 40mg/mL dissolved in dimethylformamide.
10 x MOPS buffer 
MOPS
sodium acetate 
EDTA
ultra pure water 
pH was adjusted to 
dark bottle.
RNA loading buffer
formamide 50%
formaldehyde 2.2M
MOPS IX
Stored at -20°C.
DEPC treated water 
DEPC 2 %
ultra pure water
The mixture was shaken vigorously to dissolve the DEPC and left to stand overnight at 
room temperature, then autoclaved.
41.8g
6.8g
3-7g
made up to 1 litre.
7.0 using 10 M sodium hydroxide and stored at room temperature in a
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2.5.1 Preparation of oligonucleotides
Oligonucleotides were synthesised on an Applied Biosystems 3818A Automated DNA 
Synthesiser (operated by Mr McPherson, University of Glasgow, Dept. Veterinary 
Pathology). DNA was eluted from columns using 2.5mL of ammonia and deproteinised by 
incubating overnight (o/n) at 55°C. Ammonia was removed under vacuum and the 
resulting DNA pellet reconstituted in TE (pH 8.0). Yield and purity were estimated by 
measuring the absorbency at 260nm and 280nm on a GeneQuant II spectrophotometer 
(Pharmacia Biotech).
2.5.2 3’ Terminal Tax primers: (amplifies the terminal 5’ portion of tax, removes the 
stop codon and puts it in frame with a 3’ MER fusion molecule).
The following primer pairs were used to facilitate cloning of the tax or modified oestrogen 
receptor cDNAs (a gift from Gerard Evan) into the pBabe retroviral vector to generate 
Tax-MER fusion proteins. PCR, restriction enzyme digestion, ligation, and sequencing 
methods are described later. Initially all per products were cloned into the TA cloning 
vector (pCRII) (Stratagene Ltd., Cambridge).
To generate the Tax-MER fusion protein the 3’ Xmal/BamHI per tax fragment was cloned 
into pCRII (Stratagene Ltd., Cambridge). This fragment was then restriction enzyme 
digested (Xmal/BamHI), purified and ligated to the 5’ BamHI/Smal parental tax fragment 
derived from p30 (original pUC vector containing the tax fragment supplied by Dr 
Campbell). The full length purified BamHI/EcoRI MER fragment was then cloned 
directly into the BamHI/EcoRI retroviral vector multiple cloning site from the parental 
plasmid pBSk+. Finally the modified full-length BamHI tax fragment was cloned into the 
pBabe-MER retroviral vector at the BamHI site which had been previously treated with 
alkaline phosphatase to prevent self-ligation. The tax cDNA was then orientated by 
restriction enzyme digestion.
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27mer |—Sma I—|
Forward primer: 5’-CGG/CCC/GGG/GGC/TTA/GAG/CCG/CCC/AGT/GAA-3’
27mer |—Bam HI—|
Reverse primer: 3’-GC/CGG/AIC/CCA/GAC/TTC/TGT/TTC/GCG/GAA/A-5’
(stop->trp)
2.5.3 MER primers: amplifies the whole of MER, removes the stop codon, and puts it 
in frame with a 3’ tax molecule
The MER-tax fusion molecule was derived in much the same as the Tax-MER molecule. 
In this case the parental tax molecule was cloned directly into the BamHI/EcoRI multiple 
cloning site of the pBabe retroviral vector directly from the parental plasmid p30. The 
whole MER molecule was per amplified and cloned into pCRII (Stratagene Ltd., 
Cambridge) and subsequently sub-cloned into the BamHI site of pBabe-fax. Orientation 
was performed as before by restriction enzyme digestion.
The double MER-Tax-MER molecule was derived by double ligating BamHI tax and 
MER molecules with the pBabe-MER molecule previously generated. Orientation was 
performed by restriction enzyme digestion as before.
All per products were sequenced using either the in house automated sequencer or by “Alta 
Biochem.” (Birmingham).
|—Bam HI—|
Forward primer: 5’-CCC/GGA/ICC/ACG/AAA/TGA/AAT/GGG/TGC/TTC-3’
|-B am H I-|
Reverse primer: 3 * - AAA/ATG/GAT/CCA/GAT/CGT/GTT/GGG/GAA/GCC-5 *
(stop->P)
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2.5.4 Generation of mutant tax expression construct
Three mutant clones of tax based on published data (Smith and Greene, 1990; Semmes and 
Jeang, 1992; Yamaoka et al, 1996) were generated by Dr. M. Campbell. Point mutations 
were introduced into the primary amino acid sequence of Tax by mutating the per primer 
sequences to generate mutations in the parental tax sequence at positions 3 (Ml), 23 
(C23S) and 319 (M47) as previously described (Semmes and Jeang (1992) Ml; Smith and 
Greene (1990); M47 Smith and Greene (1990). These were subcloned into the pBabe-Neo 
retroviral vector to generate C23S, Ml, and M47 -  MER fusion constructs.
2.5.5 Polymerase Chain Reaction (PCR) amplification of DNA molecules
PCR was performed using the thermostable Taq (Thermus aquations) DNA polymerase. 
The PCR reaction mixture was made up of 10pL of template DNA (usually 5ng/pL), 5pL 
of primers ( 1 .2 5 jliM ), 5pL of nucleotides (each nucleotide at 200pM), 5pL of buffer 
(lOmM Tris.HCL pH8.3, 50mM KC1, 1.5mM MgCl2, 0.001% w/v gelatin), 0.4pL of Taq 
enzyme and water to 50p,L. Thermal cycling was carried out in a Perkin-Elmer 9600 
GeneAmp thermocycler. A typical cycle reaction consisted of denaturation at 94°C for 1 
minute, annealing at 50°C for 1 minute, and polymerisation at 72°C for 1 minute.
2.5.6 DNA purification from agarose gels
DNA was purified from agarose gel using the Qiaex I/II Gel Extraction kit (Qiagen Ltd, 
UK). After electrophoresis the DNA was excised from the agar gel under UV 
illumination. The gel was dissolved in buffer, incubated at 50°C for 10 minutes, bound to 
lOpL of Qiaex beads, washed and pulse-centrifuged as per the manufacturer’s 
recommendations. The resulting pellet was air-dried and the DNA eluted with IOjjL  of 
lOmM Tris-Cl, pH 8.5. lpL of the final solution was electrophoresed against a known 
standard (5pL of lkb ladder (Gibco BRL)) to determine fragment size and concentration.
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2.5.7 Ligation of DNA molecules
Ligations of DNA molecules were carried out either using the TA cloning kit (Invitrogen 
BV, UK) for per products, the Rapid DNA Ligation kit (Boehringer Mannheim, UK) or T4 
DNA ligase (Gibco BRL). Where appropriate vector DNA was pre-treated with 1U of calf 
intestinal alkaline phosphatase or 1U of shrimp alkaline phosphatase to prevent self- 
ligation. Approximately 50ng of vector DNA was ligated with a 3-1 Ox excess of insert 
DNA. DNA ligase buffer was added (supplied with enzyme) to a final concentration of lx 
and water to a final volume of 10 or 20pL. Optionally lpL of lOmM ATP was added. 
Ligations were left o/n at 14°C.
2.5.8 Bacterial Transformation
lpL of ligation mixture (approx. 0.5-5ng DNA) together with lpL of 2-mercaptoethanol 
was added to 50pL of DH5a™ competent cells (Gibco BRL) or ‘ 1 shot cells’ (supplied 
with TA cloning kit (Stratagene Ltd., Cambridge)) and incubated on ice for 30 minutes. 
Cells were then heat shocked at 42°C for 45 seconds and returned to ice for 2 minutes. 
450pL of SOC medium or L-broth was then added and incubated in a rotary shaker (220 
rpm) for 1 hour at 37°C. Cells were then plated onto L-agar plates containing either 
ampicillin at 50jj,L/mL or kanamycin at 50jj,g/mL. Optionally agar plates were pre-treated 
with 25fxL of a 40mg/mL stock solution of X-gal if colour selection was required. Plates 
were incubated o/n at 37°C and white recombinant colonies were picked.
2.5.9 Preparation of Plasmid DNA
2.5.9.1 Small scale Preparation
Colonies grown overnight were picked and inoculated into L-broth containing 50pg/mL of 
ampicillin or 50pg/mL of kanamycin. Cultures were grown o/n in a rotary shaker 
(220rpm) at 37°C. Plasmid DNA was purified using the boiling method. lmL of culture
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was pelleted at 6500 rpm for 2 min. The supernatant was discarded and 150|iL of STET 
solution was added plus 10pL of freshly made lysozyme (lOmg/mL) and vortexed. The 
tubes were boiled for 40 sec., cooled on ice for 2 min., and spun at 13000 rpm for 10 min. 
The large glutinous pellet was removed, IOOjiL of isopropanol added and stored at -20°C 
for at least 15 minutes to precipitate plasmid DNA. The DNA was then pelleted at 12000 
rpm for 5 min., and 200|iL of 70% ethanol added. After pelleting all ethanol was removed, 
allowed to dry and the DNA was dissolved in 50jiL of ultra pure water. lpL of RNAse A 
(10|ig/mL) was added to any subsequent enzyme reactions to remove RNA contamination. 
lfiL of the final solution was electrophoresed against a known standard (5fiL of lkb ladder 
(Gibco BRL)) to determine fragment size and concentration.
2.5.9.2 Large Scale Preparation
Bulk scale preparations were prepared using the Wizard Maxi-Prep kit (Promega, UK). 
500mL of colonies are grown overnight in L-broth containing 50pg/mL of ampicillin or 
50(ig/mL of kanamycin in a rotary shaker (220rpm) at 37°C. The DNA was extracted and 
allowed to bind to a ‘Qiagen’ tip as per the manufacturer’s protocol. The DNA was 
washed with TBE, pH 8.0 and then eluted from the column with TE solution, pH 8.0. The 
DNA was then precipitated at room temperature using 70% ethanol, and centrifuged at 
15,000 g for 10 minutes. The resulting pellet was air-dried for 10-15 minutes, and 
redissolved in 500p,L of ultra-pure water. lpL of the final solution was electrophoresed 
against a known standard (5jiL of lkb ladder (Gibco BRL)) to determine fragment size and 
concentration.
2.5.10 Restriction enzyme digestion
Restriction enzyme digestion was performed by adding 2fiL of enzyme (Gibco BRL) with 
2pL of enzyme buffer (Gibco BRL), 6pL of ultra-pure water and generally 0.5-1 fig of 
DNA (4fiL) (total volume 10|iL). The mixture was incubated for 1 hour at 37°C and lfiL
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electrophoresed on an agar gel to determine correct size and concentration of the fragment 
relative to a known DNA reference standard (5|TL of lkb ladder (Gibco BRL)).
2.5.11 Sequencing of PCR reaction products
Reaction products were sequenced either at Alta Biochem. (Birmingham) or on the Licor 
model 4000 DNA automated sequencer. Sequencing reactions were carried out using a 
cycle sequencing protocol based on the chain termination method of Sanger, which 
incorporates an infrared labelled nucleotide. A sequencing reaction mixture was made up 
using a long-read kit (Epicentre Technologies). This contained between 500ng and lpg of 
plasmid DNA, 2pmol of an infrared labelled primer (M l3 forward and reverse primers), 
1.7jj.L of lOxsequencing buffer, lpL of SequiTherm thermostable DNA polymerase, and 
water to 17jiL. The reaction was denatured for 5 minutes at 95°C and then passed through 
30 thermo-cycles (95°C denaturation, 30s. 60°C annealing, 30s., 70°C polymerisation 
lmin.). After cycling 4pL of stop solution was added before automated sequencing.
2.5.12 Extraction of RNA from samples
Total cellular RNA was prepared from mouse tissues and established cell lines using the 
RNazol B method (Biogenesis). Frozen tissue was ground with liquid nitrogen to a fine 
powder using a chilled mortar and pestle (BDH). The powder was resuspended in 2ml 
cold RNazol B liquid/per 100 mg of tissue. Cells were spun at 3,000 r.p.m. for 5 minutes 
to form a pellet and the tissue culture medium was removed. The pellet was washed with 
cold PBS buffer and resuspended in 200pl of cold RNazol B liquid. One tenth volume of 
cold chloroform was added and the homogenate was vortexed for 20 secs and chilled on 
ice for 5 minutes. Samples were then centrifuged at 1300 r.p.m. at 4°C for 15 minutes. 
The aqueous phase was then transferred to 1.5 ml eppendorf tubes and an equal volume of 
cold isopropanol was added. The samples were stored at 4°C for at least 15 minutes before 
centrifuging them at 1300 r.p.m. at 4°C for 15 minutes. A small white pellet is visible, the 
supernatant was moved and the RNA pellet washed with 500jli1 70% ethanol and then
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centrifuged again for 5 minutes at 1300 r.p.m. at 4°C. The ethanol was removed and the 
RNA pellet was dissolved in 40pl DEPC treated water. The RNA concentration was 
determined by measuring the optimal density of the sample at 260 nm. The RNA sample 
was stored in a -70 °C freezer until used.
2.5.13 Separation of RNA by gel electrophoresis.
lOpg of RNA was dissolved in lOpl of DEPC treated water. To this, 17pl of RNA loading 
buffer was added. The samples were heated at 65 °C for 15 minutes and placed on ice for 
5 minutes then 3 pi of loading dye was added. The samples were then separated on a 1% 
agarose / formamide gel in 1 x MOPS overnight at 20 volts. The RNA gel was washed in 
several changes of deionised water for five hours, the gel was subsequently stained with 
1/20 dilution of stock ethidium bromide (0.5pg/ml) for 30 minutes, followed by washing in 
water for a further 30 minutes. The gel was then photographed and washed in 10 x SSC 
for 30 minutes.
2.5.14 RNA Transfer.
The RNA was transferred overnight onto Hybond membrane (Amersham Ltd) by an 
upward capillary transfer in 10 x SSC. The RNA on the membrane was immobilised by 
UV crosslinking for 8 s at 1200 p joules x 100 using a UV stratalinker 1800 (Stratagene). 
Probe labelling and hybridisation was carried out as for DNA probes.
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Chapter 3
Investigation of the pathology of the HTLV-I tax transgenic
mouse tumours
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Investigation of the pathology of the HTLV-I tax transgenic mouse tumours
3.1 Introduction
The generation by several laboratories of HTLV-I tax transgenic mice using a variety of 
different promoters directing expression to the T-cell compartment has not given rise to 
CD4+ T-cell tumours (see Chapter 1, Table 1.4). Moreover expression of tax within the 
lymphoid compartment appears to be associated with thymic atrophy (Furuta et al, 1989; 
Nerenberg et al, 1991) presumably due to the observed toxic effects of deregulated tax 
expression (Nerenberg et al, 1989; Chlichlia et al, 1995) causing apoptosis (Yamada et al, 
1994; Chlichlia et al, 1995; Hall et al, 1998 [in press]). Thus although the advent of 
transgenic mouse technology has not provided a murine model for ATL per se the 
development of several types of tumours within these mice has provided a useful platform 
to investigate the mechanisms by which tax may transform primary cells in vivo.
HTLV-I tax transgenic mice develop a variety of spindle cell tumours, which were 
originally described as mesenchymal tumours (Nerenberg et al, 1987) or neurofibromas 
(Hinrichs et al 1987). Human neurofibromatosis can be divided into two anatomical 
divisions -  the rarer central form (also known as bilateral acoustic neurofibromatosis) and 
the more common peripheral form (McGee et al, 1992). Both forms can occur 
spontaneously, presumably due to de novo somatic mutations, or as an inherited 
predisposition, known as von Recklinghausen’s neurofibromatosis (Riccardi et al; 1981). 
Von Recklinghausen’s disease is complicated by predisposition to other tumour types such 
as gliomas (including optic gliomas and diffuse glial tumours), astrocytomas, 
ependymomas, meningiomas, and phaeochromocytomas, as well as mental retardation, 
epilepsy, and spinal deformities. The central form occurs as an autosomal dominant 
disorder due to inactivation of the neurofibromatosis II (NF-II) gene (Seizinger et al, 1986) 
and is characterised by multiple intracranial and spinal tumours which are mainly 
Schwannomas and meningiomas. The NF-II gene encodes a membrane bound tumour 
suppressor protein called merlin/schwannomin (Rouleau et al, 1993; Trofatter et al, 1993). 
The mechanism of tumour suppression by merlin/schwannomin (Lutchman et al, 1995) is
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unknown although it is thought to form part of a superfamily of proteins - the ezrin- 
moesin-radixin superfamily (Bellivue et al, 1995) -  that associate with the cytoskeleton.
The peripheral form of neurofibromatosis, NF-I, is characterised by cafe-au-lait spots on 
the skin in childhood with neurofibromatosis developing in adults. This form occurs as an 
inherited autosomal dominant disorder due to inactivation of the neurofibromatosis I (NF- 
I) gene (Cawthon et al, 1990; Viskochil et al, 1990; Wallace et al, 1990) - a tumour 
suppressor gene which encodes a GTPase-activating protein named neurofibromin 
(Ballester et al, 1990; Martin et al, 1990; Xu et al, 1990). Significantly the HTLV-I tax 
gene has been shown to repress expression of the NF-I gene (Feigenbaum et al, 1996) and 
may therefore explain the development of neurofibromas in HTLV-I tax transgenic mice.
Neurofibromas are benign, solitary, or in the. inherited form usually multiple proliferations 
of nerve sheath cells consisting of an admixture of Schwann cells, fibroblasts, and 
perineurial cells (Erlandson et al, 1991; Lassmann et al, 1977; Jurecka et al, 1987) together 
with scattered mast cells and phagocytic cells (Erlandson et al, 1982; Harkin et al, 1986). 
The true origin of the tumour cell is still unclear although recent reports favour the 
Schwann cell as the progenitor cell giving rise to all nerve sheath tumours (Sharma et al, 
1990; Kharbanda et al, 1994).
HTLV-I tax transgenic mice express a phenotype, which resembles von Recklinghausen’s 
neurofibromatosis due to the development of “peripheral neurofibromas”, which occur 
principally at sites of wounding. Associated with these neurofibromas are adrenal 
medullary tumours and iris proliferations (Green et al, 1992) whose incidence parallel the 
development of adrenal medullary phaeochromocytomas and iris hamartomas which 
develop in certain forms of human type I neurofibromatosis (NF-I). However the validity 
of these pathological descriptions has recently been brought under close scrutiny. Both the 
adrenal medullary tumours and iris proliferations resemble the fibroblastic spindle cell 
tumours that occur at wound sites. Immunocytochemical analysis of these tumours reveals 
that they stain positively for vimentin, a cytoskeletal growth-regulated gene, expressed 
usually in cells derived from the embryonic mesoderm layer (Lazarides et al, 1980)
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consistent with the notion of a perineurial or fibroblast derivation of neurofibromatosis. 
However the interpretation of this result is complicated by the observation that the HTLV-I 
tax gene trans-activates the vimentin promoter/enhancer (Lilienbaum et al, 1990) by 
relieving negative trans-repression of this gene (Salvetti et al, 1993) which normally serves 
to modulate expression of this protein. Furthermore, expression of the S-100 protein, a 
marker for Schwann cells which form a significant proportion of the neurofibroma cell 
population (Erlandson et al, 1985), could not be detected by most authors (Hinrichs et al, 
1987) and only after trypsin pre-treatment by others (Nerenberg et al, 1991). The intense 
inflammatory infiltrate which accompanies these tumours (presumably due to 
transactivation of GM-CSF and G-CSF promoters [Himes et al, 1993]) does not resemble 
mast cell infiltrates present in human neurofibromas. It was not surprising therefore that 
further evaluation of these tumours led to an alternative pathological description of 
inflammatory malignant fibrous histiocytoma (Nerenberg et al, 1991) based upon the 
histopathological, immunocytochemical and ultrastructural features of these tumours. 
Furthermore, no association was found between the development of human type I 
Neurofibromatosis and HTLV-I infection (Nerenberg et al, 1991). Despite these obvious 
discrepancies within the literature, the spindle cell ear and tail tumours that develop at 
wound sites are still referred to as neurofibromas (Grossman et al, 1996).
HTLV-I tax transgenic mice develop other pathological abnormalities including an 
exocrinopathy, which resembles Sjogren’s syndrome (SS) (Green et al, 1989) an 
inflammatory arthropathy resembling Rheumatoid arthritis (RA) (Iwakura et al, 1991; 
Yamamoto et al, 1993), and large granular lymphocytic leukaemia (LGL) (Grossman et al, 
1995). Mice which develop SS are characterised by initial ductal proliferation followed by 
invasion with lymphocytes and plasma cells (Green et al, 1989). A late feature of the 
disease is extensive epithelial island enlargement with lymphocytic infiltration, leading to 
destruction of acinus architecture. However the aetiological role that HTLV-I plays in the 
development of SS is controversial (Rigby et al, 1996; Mariette et al, 1993 and 1995; 
Eguchi et al, 1995; Nakamura et al, 1997). These reports variously detect the presence or 
absence of HTLV-I antibodies (Mariette et al, 1995) or homologous HTLV pX gene 
sequences (Rigby et al, 1996; Mariette et al, 1993) in a proportion of patients with SS or
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associate the high prevalence of SS in patients infected with HTLV-I (Nakamura et al, 
1997; Eguchi et al, 1995). Other authors implicate the presence of HIV specific antigens 
(gag) (Yamano et al, 1997), novel exogenous retroviruses (Griffiths et al, 1997) or Human 
Endogenous Retroviruses (HERVs) (Urnovitz et al, 1996) as possible agents inducing SS 
and a range of other autoimmune, or inflammatory diseases including RA.
The involvement of retroviruses in destructive arthropathies is well documented (caprine 
arthritis encephalitis [Woodard et al, 1982] and ovine maedi-visna viruses [Dawson et al, 
1983 and 1987]). In addition a substantial body of epidemiological evidence links HTLV 
as a risk factor for an inflammatory arthropathy similar to RA (Motokawa et al, 1996; 
Starkebaum et al, 1996; Eguchi et al, 1996; Pinheiro et al, 1995; Sato et al, 1991, Kitajima 
et al, 1991; Nishioka et al, 1989) - (although direct evidence linking exogenous 
retroviruses as causative agents of RA is still lacking [Nelson et al, 1994]). The first report 
of HTLV-I tax transgenic mice developing joint disease was therefore greeted with 
considerable interest (Iwakura et al, 1991). These mice developed an inflammatory 
arthropathy which resembled RA (Iwakura et al, 1991; Yamamoto et al, 1993; Iwakura et 
al, 1995, Saggioro et al, 1997) which was characterised by synovial and periarticular 
inflammation with articulator erosion caused by invasion with granulation tissue. 
Transgenic joints displayed an elevated profile of pro-inflammatory cytokine expression 
(IL-la, EL-ip, EL-6, TNF-a, TGF-pi, IFN-y, IL-2 [Iwakura et al, 1995]) which was 
thought to induce serum hyperactivity and autoimmunity.
The expression of tax within the lymphoid compartment has been met with only limited 
success (Furuta et al, 1989; Nerenberg et al,.1991). Transgenic mice which develop an 
exocrinopathy similar to SS also develop splenomegaly and lymphadenopathy (Peebles et 
al, 1995) composed primarily of B cells which display abnormal proliferative responses in 
vitro. Targeting of tax to the lymphoid compartment using the granzyme B promoter 
resulted in the development of leukaemia originating at wound sites after a prolonged 
incubation latency (Grossman et al, 1995).
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We therefore decided to generate several lines of HTLV-I tax transgenic mice and 
characterise the various tumour pathologies especially with reference to tumour derivation 
using a variety of antibodies specific for cytoskeletal or neuronal proteins. As an adjunct 
to these studies we also wished to investigate the mechanism by which tax may transform 
primary cells in vivo and the role it plays in tumour development.
3.2 Results
3.2.1 Phenotype exhibited by HTLV-I transgenic mice
Dr Blyth and Dr Cameron generated four lines of HTLV-I tax transgenic mice in which 
expression from the tax transgene was regulated by the T-cell specific CD3 
promoter/enhancer elements (Clevers et al, 1989) [Figure 3.1]. These mice, designated the 
1000 series, 1200 series, 1300 series, and 1400 series, developed a variety of pathologies 
summarised in Table 3.1.
The CD3-/ax transgenic mice developed three major tumour phenotypes, namely 
mesenchymal tumours that developed at sites of wounding (principally ear and tail tips), 
salivary and mammary adenomas, and histiocytic tumours. Expression of tax RNA was 
confirmed by N Blotting within both the mesenchymal tumours and adenomas (carried out 
by Ms J. McMillan). Expression of tax RNA was not detected within the histiocytic 
tumours or within normal tissues derived from tax transgenic mice.
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Table 3.1: Phenotypes exhibited by each line of CD3-tax; transgenic mice
Line
1000
1200
1300
1400
Phenotype
thymic atrophy 
immunosuppression 
parasitic diseases 
mammary adenomas 
salivary adenomas 
mesenchymal tumours 
hind leg ataxia and paresis 
mesenchymal tumours 
histiocytic lymphadenopathy
Average Latency 
(days)
55
457
341
277
229
128
336
Incidence
3/3 (100%)
7/13 (54%) 
3/13 (23%)
2/4 (50%)
5/26 (19%) 
16/27 (59%) 
sporadic (<5%)
Table summarising the phenotypes exhibited by the 1000, 1200, 1300, and 1400 lines of CD3-tax 
transgenic mice. The numbers refer to the line number, average time for the phenotype to emerge 
(in days), and total and percentage incidence.
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Figure 3.1: Schematic representation of the CD3-tax expression construct
1.6kb -* ~ 4-
CD3 Pr. HTLV-I TAX cDNA
2.0kb 
CD3 ENHANCER
REX INITIATION 
SITE DELETED
Pr.=PROMOTER 
kb =KILOBASE
Figure 3.1: the schematic representation of the CD-3 tax promoter/enhancer region.
3.2.2 Mice from the 1300 and 1400 lines exhibit a variety of symptoms
The founders, FI generation and a proportion of the F2 generation from the 1300 and 1400 
lines developed mesenchymal tumours (Figure 3.2) (although this phenotype was not 
observed in subsequent F3 or F4 generations). These tumours developed at sites of 
wounding on the ear and tail tips and occasionally also at other sites prone to local trauma 
such as the face and palmar/plantar aspects of the limbs. Most tumours developed between 
3 and 7 months of age. The tumours were composed of a background population of plump 
spindle cells with ovoid nuclei, and poorly defined eosinophilic cytoplasm set in a fine 
reticulin stroma with, invariably, a heavy accompanying infiltrate of polymorphs and 
macrophages (Figure 3.3). The tumours were locally aggressive and infiltrated along 
tissue planes and nerve fibres. These tumours appeared to be morphologically, and 
phenotypically identical to the neurofibromas reported by other authors (Nerenberg et al, 
1987; Hinrichs et al, 1987). These mice also demonstrated systemic effects of tax 
expression such as ill-thrift and myeloid hyperplasia (within the spleen and red bone 
marrow).
A proportion of mice from the 1300 line exhibited other phenotypes such as wasting 
accompanied by thymic atrophy (although this was not as severe as that observed in the 
1000 line), and hind leg paresis and ataxia. Four mice from the 1400 line also developed 
solitary lymphadenopathy characterised by trabecular thickening due to infiltration by 
large eosinophilic histiocyte like cells.
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Figure 3.2: Photographs of CD3-tax transgenic mice bearing mesenchymal tumours 
at ear and tail tips.
Photographs showing the gross pathology of a CD3-tax mouse bearing a mesenchymal 
tumour. These tumours typically emerged at the ear and tail tips and other frequent sites of 
wounding (in this case ear notching for identification and tail tipping for genotyping).
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Figure 3.2: Photographs of CD3-tax transgenic mice bearing mesenchymal 
tumours at ear and tail tips.
Figure 3.3: H+E photomicrographs of mesenchymal tumours
Photographs of a mesenchymal tumour stained with haematoxylin and eosin. The upper 
photograph (original magnification x4) and lower photograph (original magnification 
xlOOO) demonstrate the histological components of these tumours i.e. a spindle cell 
background population with a superimposed neutrophil and macrophage infiltrate. The 
oedematous nature of these tumours together with the neutrophil infiltrate indicates an 
active acute inflammatory process.
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F ig ur e  3.3: H + E p h o t o m i c r o g r a p h s  o f  m e s e n c h y m a l  t u m o u r s
Top figure (original magnification x4) illustrates an oedematous spindle cell 
tumour developing within the ear of a CD3-to transgenic mouse.
Lower figure (original magnification xlOOO) reveals more detail of the spindle 
cell background population with a superimposed macrophage and neutrophil 
inflammatory cell infiltrate.
1 hyperplastic epithelium; 2 central cartilaginous plate; 3 areas of oedema
3.2.3 Mice from the 1200 line develop salivary and mammary adenomas
Mammary and salivary adenomas were observed in the founder and 77% (54% mammary 
adenomas; 23% salivary adenomas) of the FI generations occurring between 9 and 26 
months of age. These adenomas were histologically identical, circumscribed but non­
encapsulated, composed of closely packed' ductules or tubules lined by a generally 
bilayered epithelium separated by solid trebeculae of epithelial cells (Figure 3.4). The 
luminal layer of the ductule lining comprised of closely packed cells with dark ovoid 
nuclei and scant cytoplasm while the outer layer had larger paler nuclei and moderate 
amounts of pale eosinophilic cytoplasm similar to cells in the more solid trebeculae. 
Mitoses were quite frequent. The bilayered pattern indicates origin from salivary or 
mammary duct and occasional cystic foci were present in larger lesions. The tumours had 
a fine vascular stroma and some had a scant polymorph infiltrate throughout.
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Figure 3.4: H+E photomicrograph of a mammary adenoma.
Photograph of a mammary adenoma stained with haematoxylin and eosin (original 
magnification x4). The low power photograph broadly illustrates the histological nature of 
these lesions which consist of epithelial cells arranged into ductules and broad sheets of 
cells. The tumours are well circumscribed but not encapsulated.
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3.2.4 Mice from the 1000 line develop thymic atrophy and immunosuppression
The 1000 line of mice developed early onset clinical signs of immunosuppression 
(parasitic and bacterial infections) and died generally after 8 weeks resulting in the loss of 
this line. Some mice showed signs of thymic atrophy in which the thymus was 
macroscopically reduced in size. These thymuses had normal cortical architecture but 
reduced size of the medulla. No lymphocytolysis or depletion was evident. Furthermore, 
no increase in the apoptotic index could be detected when these thymuses were stained 
with the TUNEL technique consistent with the observation that other mice from this line 
had histologically normal thymuses but displayed similar immunosuppression and died at 8 
weeks old.
3.2.5 Several lines of mice develop hind leg paresis (HLP) and ataxia
Mice from the 1000 line (F06), the 1300 line (F3, F4 [42%], and F5) and the p53+/'xTax 
(P/T) lines of mice developed hind leg paresis and ataxia after a latency period of 6-12 
months. Clinically mice presented with bilateral hind leg paresis and ataxia together with 
nervous signs such as twitching, trembling, and proprioceptive deficits when challenged. 
In contrast HLP and ataxia was only very rarely seen in other lines of mice (notably one 
case from an HTLV-I rex transgenic mouse). The spinal cord and brain from affected mice 
was fixed by perfusing the circulation with 10% neutral buffered formalin to preserve the 
delicate architecture of the CNS. Histological examination revealed extensive vacuolation 
extending from the brain stem to the caudal lumbar spinal cord. Vacuolation was restricted 
predominantly to the ventral fasiculi extending laterally and dorsally, and into the central 
grey. There was no evidence of lymphocytic meningomyelitis, lymphocytic infiltrate, or 
reactive astrogliosis within the substance of the spinal cord.
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3.2.6 HTLV-I tax transgenic mouse tumours display an atypical immunostaining 
pattern
A thorough analysis of the pattern of cytoskeletal filament staining was not possible due to 
the limited availability of specific antibodies suitable for use in mouse tissues. However 
analysis of the mesenchymal and adenoma tumours with antibodies specific for proteins of 
neuronal lineage revealed that these tumours did not display an expression pattern 
normally associated with neurofibromas. Furthermore, immunocytochemical staining of 
the inflammatory infiltrate did not reveal a diffuse mast cell infiltrate typical of human 
neurofibromas, but a mixed inflammatory infiltrate normally associated with a wound 
response.
S-100 specifically stains cells displaying the S-100 A or S-100 B proteins. In the CNS it 
stains glial and ependymal cells as well as Schwann cells within the PNS. In the skin it 
stains melanocytes and Langerhans cells whereas in lymph nodes it stains interdigitating 
reticulum cells. The antibody also stains benign and malignant melanocytic tumours. S- 
100 staining of tumour samples revealed an unusual pattern. Mesenchymal and adenoma 
tumours were generally negative for this protein except distinct, variably sized foci of 
weakly staining immunopositive cells (within both tumour types) randomly distributed 
throughout the substance of the tumour (Figure 3.5). Trypsin pre-treatment had no effect 
upon the staining pattern or distribution of this protein.
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Figure 3.5: H+E photomicrographs of S-100 staining of a mesenchymal tumour.
Photographs of a mesenchymal tumour stained immunocytochemically for S-100 protein 
and counterstained with haematoxylin (original magnification xlOOO). The upper 
photograph is a mesenchymal tumour demonstrating weak expression of S-100 occurring 
in isolated foci. The lower photograph is the epidermis from the same tumour illustrating 
weak expression of the s-100 protein in the upper epithelial layers (stratum granulosum).
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Figure 3.5: H+E photomicrographs of S-100 staining of a mesenchymal tumour
3
High power photomicrographs (original magnification xlOOO) demonstrating 
weak S-100 staining in the parenchyma (upper photo) and hyperplastic 
epithelium (lower photo) of a mesenchymal tumour.
1 inflammatory cell infiltrate with immunopositive staining cytoplasm; 2 
occasional tumour cells expressing S-100 protein; 3 epithelial cells expressing S- 
100 protein
Glial Fibrillary Acidic Protein (GFAP) is a protein which specifically stains astrocytes 
and some groups of ependymal cells within the central nervous system (CNS) and 
Schwann cells, enteric glial cell and satellite cells within the peripheral nervous system 
(PNS). Weak staining of axons also occurs due to cross-reaction with a neurofilament 
protein (Dako specification sheet). Staining of mesenchymal and adenoma tumour 
samples demonstrated that mesenchymal tumours and salivary adenomas were uniformly 
negative. Mammary adenomas were generally negative although they exhibited very weak 
staining of isolated cells which were distributed as small foci within the expanded 
trabecular regions which were distinct from the ductular proliferations. This may indicate 
the presence of proliferating epithelial or myoepithelial cells (Viale et al, 1991).
MCA519 is a rat anti-mouse monoclonal antibody that specifically stains macrophages in 
cryostat sections. Staining of ear and tail lesions demonstrated that a not insubstantial 
proportion of the tumour mass (approx. <10% cells) consisted of infiltrating macrophages 
(Figure 3.6). Conversely very few macrophages were found within adenoma samples.
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Figure 3.6 Photomicrographs illustrating macrophage staining within a mesenchymal
tumour
Photographs of cryostat cut sections from a mesenchymal tumour stained with MCA519 
(macrophage specific antibody) and counterstained with haematoxylin. The upper 
photograph (original magnification xlOO) and the lower photograph (original 
magnification xlOOO) demonstrate the strong cytoplasmic staining within the substance of 
the mesenchymal tumours.
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Figure 3.6 Photomicrographs illustrating macrophage staining within a
mesenchymal tumour
Low (original magnification xlOO) and high (original magnification xlOOO) power 
photomicrographs of a cryostat stained section demonstrating strong 
immunoreactivity with MCA519 (macrophage specific antibody) in a 
mesenchymal tumour.
3.3 Discussion
The CD3-tax transgenic mice exhibit a variety of pathologies ranging from proliferations 
of either epithelial or mesenchymal cells (resulting in tumour formation) to degenerative 
conditions (resulting in thymic atrophy, immunosuppression, or hind leg paresis). 
Expression of the tax transgene was demonstrated by N. blotting within both the 
mesenchymal tumours and adenomas. Weak expression was detected within the thymuses 
of those mice with thymic atrophy and immunosuppression whereas no tax mRNA was 
detected within normal tissues of tax transgenic mice or within the histiocytic tumours. 
Presumably under normal conditions the specificity of the CD3 promoter/enhancer 
prevented detectable expression within non-tumour tissue. “Switch-on” of the transgene 
(either stochastic or upregulation from a background low level expression) and tumour 
evolution most likely accounted for enhanced expression and detection of tax mRNA 
within tumours. Lack of tax expression associated with the histiocytic tumour phenotype 
may be due to either low level expression of the tax transgene which is sufficient to initiate 
tumours but below the level of sensitivity of detection by conventional N. blotting.
Loss of the tax phenotype in subsequent generations is unexplained but may be due to drift 
in the genetic background of the mice leading to an alteration in the susceptibility or 
permissiveness to transgene “switch on” through the CD3 promoter/enhancer in non­
lymphoid tissues. Reports using p53 knock out mice have demonstrated that genetic 
background can influence tumour spectrum and latency (Purdie et al, 1994; Harvey et al, 
1993; Donehower et al, 1992). Alternatively, methylation and genetic silencing of the 
transgene could reduce tax expression from the transgene (Turker et al, 1997). 
Methylation of the viral LTR in fresh ATL cells (Saggioro et al, 1990) inhibits tax directed 
transactivation from the viral promoter/enhancer regions of the LTR (Cassens et al, 1994; 
Saggioro et al, 1991) contributing to low level viral mRNA expression and viral latency.
Several lines of evidence indicate that the ear and tail lesion observed in several of the 
lines of mice are not neurofibromas. The intense inflammatory infiltrate consisting of 
polymorphs and macrophages does not resemble the scattered mast cell infiltrate noted in
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human neurofibromas. Furthermore tumours are not consistently associated with nerve 
sheaths. Finally tumours fail to stain consistently with markers of neuronal lineage such as 
GFAP and S-100. An unusual pattern of expression of S-100 occurs in mesenchymal 
tumours, and adenomas, as well as being occasionally observed within the epithelium 
surrounding the ear and tail tumours. This turned out to be remarkably similar to the 
pattern of tax expression within these tumours raising the possibility that S-100 expression 
may be upregulated within tax expressing cells as a result of transactivation of the S-100 
promoter by tax or a reflection of the profile of gene expression within apoptosing cells 
(discussed further in Chapter 4).
The adenoma tumours are most likely a proliferation of ductular epithelial cells as 
indicated by the bilayered ductular pattern observed within most of these tumours. A 
myoepithelial component may also be present giving rise to the weak GFAP staining 
occasionally encountered within some tumours. Light infiltrates of polymorphs or 
lymphocytes (the latter centred on ducts) were occasionally observed. However the 
secondary changes which occurred in the mice of Green et al, (1989) were not observed 
making this pathology distinct and unique to the CD'S-tax mice.
The solitary histiocytic tumours that arose in four tax transgenic mice were unusual in that 
tax expression could not be detected by N. blotting. The reason for this is unknown but 
could be due to very low level expression of tax RNA beyond the sensitivity limit of 
conventional N blotting. Indeed, as little as 25pm exogenous Tax can stimulate 
proliferation of human lymphocytes (Marriott et al, 1991 and 1992) in vitro. However 
since this phenotype was only observed within one line of tax mouse it is also possible that 
the integration site of the transgene influenced tumourigenesis.
The clinical symptoms of hind leg paresis and ataxia accompanied by nervous disturbances 
(twitching and proprioceptive deficits) were interesting due to their similarity to patients 
with TSP/HAM. However the presence of vacuoles rather than a chronic demyelinating 
disease with lymphocytic infiltration (Iwasaki et al, 1990; Izumo et al, 1997) and the 
inability to associate tax expression with pathology did not favour an interpretation of
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murine TSP/HAM. However this pathology did bear striking resemblance to a well- 
documented retroviral induced neurodegeneration (Saida et al, 1997; Stoica et al, 1993; 
Hoffman et al, 1992).
Finally, restricted expression of tax within the CD3 specific compartment was not 
consistently achieved. Similar to other groups (Furuta et al, 1989; Nerenberg et al, 1991) 
expression appears to be associated with deleterious effects which may be dependent upon 
the level of expression of the transgene (Saggioro et al, 1997). Low level expression may 
be tolerated within certain compartments (such as the solitary histiocytic tumours) but high 
level expression may induce apoptosis or degeneration (Nerenberg et al, 1989). These 
dichotomous effects of tax -  proliferation versus apoptosis or degeneration - may therefore 
be dependent upon a number of complex and subtle interactions in vivo. Evidence for this 
is just emerging - whilst the association of tax expression with apoptosis is well established 
(Yamada et al, 1994; Chlichlia et al, 1995) recent reports suggest that under certain 
conditions tax may mitigate or even inhibit apoptotic induction (Brauweiler et al, 1997; 
Kishi et al, 1997; Schwartz-Comil et al, 1997).
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Chapter 4
Tumours derived from HTLV-I tax transgenic mice are 
characterised by enhanced levels of apoptosis and oncogene
expression
96
Tumours derived from HTLV-I tax transgenic mice are characterised by enhanced 
levels of apoptosis and oncogene expression.
4.1 Introduction
Although the transforming potential of the HTLV-I tax oncogene is well established 
(Tanaka et al, 1990; Grassmann et al, 1989 and 1992; Ozden et al, 1996) the precise 
mechanism by which tax transforms cells is unknown. A consensus of opinion now 
purports that the transforming properties of tax reside, at least in part, in its ability to 
transactivate a wide number of cellular genes (Gazzolo et al, 1987) - especially those 
involved in T-cell activation and proliferation. However the significance and the 
contribution that each gene makes to the transformed phenotype in vivo is uncertain. 
Pertinent examples include the immediate early oncogenes c-myc (Duyao et al, 1992a and 
1992b), c-fos{Fujii et al, 1988; Nagata et al, 1989; Alexandre et al, 1991; Iwakura et al, 
1995), and c-jun (Iwakura et al, 1995; Hooper et al, 1991Fujii et al, 1991) as well as the T- 
cell growth factor IL2 (Inoue et al, 1986), and the IL2 a  chain receptor (Leung et al, 1988).
Hand-in-hand with transformation and immortalisation is the third facet of tumour biology 
-  apoptosis. Tax conforms to this basic framework of ideas since expression of tax in 
serum starved Rat 1 fibroblasts (Yamada et al, 1994) and human T-cells (Chlichia et al, 
1995) causes apoptosis. This effect has also been observed with other oncogenes such as 
c-fos (Preston et al, 1996), c-myc (Evan et al, 1992) and the Adenoviral protein El a (Rao et 
al, 1992). Although these effects are most clearly defined in vitro, it appears likely that in 
vivo, tax expression would be coupled to apoptosis. In order to test this hypothesis, we 
examined the pattern of Tax expression and apoptosis within the CD3-fax transgenic 
mouse tumours by generating specific anti-tax antibodies using the multiple antigenic 
peptide (MAP) system (Tam et al, 1988; Posnett et al, 1988).
The MAP system (Tam et al, 1988; Posnett et al, 1988) provides a direct method to 
generate high molecular weight synthetic peptides in which a core matrix made up of a 
tetravalent or octavalent poly-lysine nucleus provides the scaffolding to chemically link 4-
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8 short immunogenic peptides. The high molecular weight (typically >10,000) of these 
MAPs precludes the need to chemically conjugate them to carrier proteins and therefore 
avoids the potential problem of an immune response to the carrier protein. The resultant 
peptides are highly immunogenic (Tam et al, 1988; Posnett et al, 1988; Wang et al, 1991), 
recognise both continuous and conformational determinants (Posnett et al, 1988) as well as 
frequently recognising the native protein (Tam et al, 1988; Posnett et al, 1988). This 
technology has now been advanced such that multivalent peptides can be developed 
allowing the simultaneous presentation of both B- and T-cell epitopes (Tam and Lu, 1989) 
without the need for a protein carrier (which normally provides the T-cell epitope help 
(Mitchinson et al, 1971; Benacerraf and McDevitt, 1972).
4.2 Results
4.2.1 Prediction of HTLV-I Tax Immunogenicity
A profile of the hydrophilicity (Hopp and Woods, 1981), surface probability (Emini et al, 
1985), flexibility (Karplus and Shultz, 1985) and Jameson-Wolf (Jameson and Wolf, 1988; 
Wolf et al, 1988) antigenic index was generated based upon the HTLV-I Tax primary 
amino acid sequence using the Genetic Computer Group Sequence Analysis software 
package. This data was used in conjunction with a Chou-Fasman prediction (Chou and 
Fasman, 1978a and 1978b) of hydrophilicity/hydrophobicity and antigenic index to select 
two regions of the Tax molecule which combined regions of high hydrophilicity, high 
surface probability, and high flexibility (i.e. a high antigenic index). Based upon these 
criteria two likely immunogenic epitopes were selected corresponding to amino acids 109- 
121 and 338-353 (Table 4.1 and Figures 4.1-4:3).
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Table 4.1: Primary amino acid sequence of peptide epitopes chosen for MAP
production
Peptide identity Single letter amino acid code Epitope and MAP length
Tax Peptide (16) MRKYSPFRNGYME (aa 109-121 [13aa] MAP)
Tax Peptide (13) GGLEPPSEKHFRRETEV (aa 338-353 [17aa] MAP)
Table summarising the peptide epitopes (using the single amino acid code) used for the 
production of the multiple antigenic peptides. The figures 16 and 13 refer are arbitrary 
numbers used to identify each peptide epitope and subsequent antibodies produced from 
immunisation with that epitope. The figures 109-121 and 338-353 refer to the amino acid 
position in the primary Tax amino acid sequence used for MAP production. The figures in 
square brackets refer to the number of amino acids comprising each epitope.
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Figure 4.1: HTLV-I Tax Plot structure: The curves are one-dimensional representations 
of the secondary structure of HTLV-I p40 Tax protein obtained using the programs 
“PeptideStructure” and “PlotStructure”. Amino acid residues are numbered on the x-axis. 
Attributes to the sequences are shown as continuous curves. The top four panels indicate 
hydrophilicity (Hopp and Woods, 1981 [KD]), surface probability Emini et al, 1985), 
flexibility Karplus and Schulz, 1985), and antigenic index (Jameson and Wolf, 1988). The 
next three panels show the locations of turns, alpha helices and beta sheets as predicted by 
the algorithm of Chou and Fasman (1978a; 1978b) (CF). The bottom three panels show 
the predicted sites of tuns, alpha helices arid beta sheets according to the algorithm of 
Gamier et al (1978) (GOR). The numbers 16 and 13 refer to the approximate amino acid 
regions chosen to generate MAPs 16 and 13 respectively.
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Figure 4.2: Chou-Fasman antigenic index: The predicted secondary structure and 
antigenic index of HTLV-I p40 Tax obtained using the programs “PeptideStructure” and 
“PlotStructure”. The structure shown was derived from the algorithm of Chou and Fasman 
(1978 a/b). Alpha helices are shown with a sine wave, beta sheets with a sharp saw-tooth 
wave, coils with a dull saw-tooth wave and turns with 180° changes in line direction. 
Superimposed on the curve are octagonals indicating sites where the antigenic index 
exceeds a value of 1.2. The size of each octagonal is proportional to the value of the 
antigenic index. The amino-terminal (NH2) and carboxy-terminal (COOH) ends of the 
protein are indicated. The numbers 16 and 13 refer to the approximate amino acid regions 
chosen to generate MAPs 16 and 13 respectively.
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Figure 4.3: Chou-Fasman Hydrophilicity/hydrophobicity index: The predicted 
secondary structure and hydrophilicity/hydrophobicity o f HTLV-I p40 Tax obtained using 
the programs “PeptideStructure” and Plot Structure” . The structure shown was derived 
from the algorithm o f Chou and Fasman (1978 a/b). Alpha helices are shown with a sine 
wave, beta sheets with a sharp saw-tooth wave, coils with a dull saw-tooth wave and turns 
with 180° changes in line direction. Superimposed on the curve are octagonals and 
diamonds at sites where the hydrophilicity or hydrophobicity exceeds 1.3. The size o f 
each octagonal or diamond is proportional to the hydrophilicity or hydrophobicity 
respectively. The amino-terminal (NH2) and carboxy-terminal (COOH) ends o f  the 
protein are indicated. The numbers 16 and 13 refer to the approximate amino acid regions 
chosen to generate MAPs 16 and 13 respectively.
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4.2.2 Monitoring of Antibody Production
New Zealand White Rabbits were immunised with 4 branch M APs based on the above 
amino-acid sequences as previously described and the production o f antibodies was 
monitored by ELISA (Table 4.2). The following graphs (Graphs 4.1 and 4.2) illustrate the 
specific binding o f immune sera to MAP peptides before and after purification by 
precipitation with caprylic acid (McLaren et al, 1994) and subsequent dialysis.
Table 4.2: Results of Tax peptide immunisations
Rabbit Antibody Production Titre
Tax Peptide 13 (H) No ... N/A
Tax Peptide 13 (L) Yes 2048
Tax Peptide 16 (H) Yes 2048
Tax Peptide 16 (L) Yes 1280
Legend: H high (lOOfig peptide per) immunisation; L low (25|j.g peptide per) immunisation; N/A not 
applicable.
Table summarising the production o f antibodies from each o f the MAP immunisations. 
The figures refer to the antibody titre produced from each MAP.
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4.2.3 Determination of Antibody Specificity
Since we had no available source of Tax protein to directly determine specific recognition 
of the native protein by the anti-peptide antibodies we decided to test antibody specificity 
immunocytochemically. A paraffin embedded formalin fixed tumour (92/5259-3) derived 
from a founder HTLV-I tax transgenic mouse (Fol63) [which was known to express tax 
mRNA] was stained immunocytochemically for Tax protein expression using anti-Tax 
antibodies from rabbits 13L and 16H. Samples were pre-treated using three methods to 
unmask antigenic sites: microwave oven treatment, trypsin treatment, and untreated. In 
each case the pattern of staining was identical. Microwave oven and trypsin pre-treated 
slides stained slightly more intensely compared to untreated slides but also showed 
concomitant gains in background staining. Antibody 13L was judged to give the optimum 
staining diluted at 1:100 (Figure 4.4). Negative control tissues and non-tumour tissues 
showed no staining with Tax anti-serum.
4.2.4 Immunocytochemical analysis of Tax expression within the CDZ-tax transgenic 
mouse tumours
Immunocytochemical analysis of tumours arising in CD3-faoc mice demonstrated that Tax 
expression was detected in 9 of 9 mesenchymal tumours, 5 of 5 mammary adenomas, and 
3 of 4 salivary adenomas (summarised in Table 4.3). No expression was detected in 
normal control samples. Northern blotting confirmed these results.
The pattern of Tax expression was characteristically diffuse occurring as individual as well 
as discrete clusters of immunopositive cells (Figure 4.4 and 4.5) distributed randomly 
throughout the substance of the tumours. Staining was predominantly nuclear although 
weaker cytoplasmic staining was also noted. Phagocytosis of apoptotic debris by the 
accompanying inflammatory infiltrate was frequently noted, indicated by weak 
cytoplasmic staining of those inflammatory cells closely juxtaposed to the immunopositive 
foci (Figure 4.4 inset). Interestingly, the overlying epithelium was hyperplastic and
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frequently contained clusters of immunopositive cells predominantly localised to the 
terminally differentiating stratum spinosum/granulosum (Figure 4.4 photo (3)).
Mammary and salivary adenomas showed an identical pattern of Tax expression, which 
was broadly similar to that noted for the mesenchymal tumours. Immunopositive cells 
were distributed as individual or more often discrete clusters of expressing cells distributed 
diffusely throughout the substance of the tumour (Figure 4.5).
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Table 4.3: Summary of Myc, Fos, Jun, and p53 protein expression in tumour samples
Table summarising the immunostaining of the mesenchymal tumours, mammary adenomas 
and salivary adenomas (plus appropriate control salivary gland, mammary gland, and pinna 
tissues) with Tax, Myc, Fos, Jun and p53 protein specific antibodies. The figures in the 
first column refer to the identity allocated to each tissue during histological processing. 
The scoring system is qualitative and scored either as positively stained, weakly staining or 
no staining. Where strong staining is present but is seen only in a few isolated foci the 
term occasional is used to denote this. The figures in the ‘tumours’ section of the table 
refers to the incidence of staining of each antibody for each type of tumour.
Key: + positive; - negative; occ occasional; n/t not tested
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Table 4.3: Summary of Myc, Fos, Jun, and p53 protein expression in tumour samples
Tumour Type Protein Immunostaining
Mesenchymal Tax Mvc Fos Jun d53
93/63-4 occ + occ. + occ. + occ. +
93/1239-2 + + + + +
93/1241-2 + + occ. + + +
93/1245-1 + occ + occ + OCC + +
93/3627-1 occ + occ + + OCC + occ +
93/3628-1 + + + + occ. +
92/4907-4 OCC + occ + + occ + occ +
92/5259-3 + + + n/t n/t
92/5259-4 + weak + + + +
Mammary Tax Mvc Fos Jun n53
93/7599-1 + weak + + + +
93/7660-2 OCC + occ + occ + occ + occ +
93/7662-4 + occ + + occ + +
93/7665-2 + + + + +
93/8068-1 + + + + +
Salivary Tax Mvc Fos Jun d53
93/1861-1 - - - - -
93/2412-3 occ + + + + weak +
93/3086-1 occ + OCC + + occ + occ +
93/7600-4 + + + + +
Tumours Tax Mvc Fos Jun d53
Mesenchymal 9/9 8/9 9/9 8/8 8/8
Mammary 5/5 5/5 5/5 5/5 5/5
Salivary 3/4 3/4 3/4 3/4 3/4
All tumours 17/18 16/18 17/18 16/17 16/17
(94%) (89%) (94%) (94%) (94%)
Controls Tax Mvc Fos Jun d53
96/1166-1 . . salivary gland
96/1166-2 - - - - - salivary gland
96/1166-3 - - - - - mammary gland
96/1166-4 - - - - - mammary gland
96/1166-5 - - - - - mammary gland
97/764-2 - - - - - pinna
97/763-2 - - - - - pinna
97/765-2 - - - - - pinna
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Figure 4.4: Photomicrographs demonstrating Tax protein expression in a
mesenchymal tumour
Photographs of a mesenchymal tumour immunostained with a Tax specific antibody. 
Photograph 1 demonstrates Tax immunostaining throughout the substance of a 
mesenchymal tumour (original magnification xlOO). Photograph 2 is a higher power view 
of the same tumour (original magnification xlOOO). The inset reveals details of the 
predominantly cytoplasmic rather than nuclear immunostaining. Photograph 3 
demonstrates Tax expression within the terminally differentiating epithelium (S 
spinosum/granulosum) surrounding the tumour (original magnification xlOOO). All slides 
counterstained with haematoxylin.
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Figure 4.4: Photomicrographs demonstrating Tax protein expression in a
mesenchymal tumour
High power photomicrographs il lustrating immunocytochemical detection of Tax expression using antibody 
13L in a mesenchymal tum our (photo (I): original magnification xlOO; photo (2) oringinal magnification 
xlOOO nickel enhanced) and the hyperplastic epithelium surrounding a mesenchymal tum our  (photo (3): 
original magnification xlOOO).
Figure 4.5: Photomicrograph demonstrating Tax protein expression in a mammary
adenoma
Photograph of a mammary adenoma immunostained with a Tax specific antibody (original 
magnification xlOOO). Immunopositive cells demonstrate strong, predominantly nuclear 
staining for the Tax protein. Slide counterstained with haematoxylin.
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Figure 4.5: Photomicrograph demonstrating Tax protein expression in a
mammary adenoma
Expression of Tax protein within the mammary and salivary adenomas occurs as 
isolated foci of expressing cells randomly distributed throughout the substance of 
the tumour. This pattern was remarkably similar to that observed for Myc, Fos, 
Jun and p53 protein expression as well as the pattern of apoptosis.
4.2.5 Analysis of apoptosis in tumours
All the tumours in the cohort were assessed for apoptosis by DNA fragment labelling (Tdt- 
mediated dUTP Nick End labelling (TUNEL) technique) after the method of Gavrieli et al 
(1992). All tumours showed enhanced levels of apoptosis compared to normal control 
samples. The level and pattern of apoptosis within each tumour appeared to be highly 
correlated with the corresponding extent and distribution of Tax expression.
Mesenchymal tumours demonstrated apoptosis as individual cells and discrete clusters in a 
similar pattern to that observed for Tax expression (Figure 4.6 photo (1)). In addition they 
frequently exhibited apoptosis associated with phagocytic engulfment - a feature not 
unexpected given the high proportion of macrophages within these tumours. This served 
to restrict the pattern of apoptosis compared to the adenoma samples. We also noted 
apoptosis in the terminally differentiating layers (S. spinosum/granulosum) of the 
superficial epidermis (Figure 4.6 photo (3)) - again in a similar pattern to that observed for 
Tax expression.
Salivary adenomas and mammary adenomas demonstrated similar patterns of apoptosis. 
In these tumours apoptosis occurred as discrete clusters of cells and occasional individual 
cells which conformed very closely to the pattern seen for Tax expression (Figure 4.6 
photo (2)).
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Figure 4.6: Photomicrographs demonstrating apoptosis within mesenchymal tumours
and mammary adenomas
Photographs of a mesenchymal tumour and mammary stained using the TUNEL technique. 
Photograph 1 demonstrates strong predominantly nuclear staining of a mesenchymal 
tumour (original magnification x400). Photograph 2 demonstrates strong nuclear staining 
of a mammary adenoma (original magnification xlOOO). Photograph 3 demonstrates 
strong nuclear staining of the terminally differentiating epithelium (stratum 
spinosum/granulosum surrounding a mesenchymal tumour(original magnification xlOOO). 
All slides counterstained with haematoxylin.
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Figure 4.6: Photomicrographs demonstrating apoptosis within mesenchymal
tumours and mammary adenomas
*  * L  0 m  *  *
W  •*itfR L r * <5v. ~
Photomicrographs of DNA fragment labelling using the TUNEL technique in 
mammary and mesenchymal tumours (DAB chromagen [brown] or AEC 
chromagen [red]). Photo (1) (original magnification x400) and photo (2) 
(original magnification xlOOO) demonstrate apoptosis occurs as discrete clusters 
of cells (as for Tax expression). Photo (3) (original magnification xlOOO) 
demonstrates apoptosis within the skin of the terminally differentiating 
epithelium of a mesenchymal tumour.
4.2.6 Immunofluorescent Co-localisation of Tax Expression and Apoptosis
The remarkable degree of overlap between Tax expression and apoptosis prompted us to 
investigate the spatial pattern and coincidence between these two processes. A mammary 
adenoma was chosen for double expression since this would be subject to the least 
distortion due to phagocytic clearance of apoptotic debris. Immunofluorescent co­
localisation demonstrated that Tax expression was very highly associated with apoptotic 
induction (Figure 4.7 and 4.8). Indeed, only very rare cells exhibited spontaneous 
apoptosis without Tax expression (Figure 4.8 arrows). Control samples stained only for 
Tax expression or apoptosis showed no cross-reactivity.
4.2.7 Analysis of oncogene expression and p53 protein expression within tumours
Each tumour sample was also immunocytochemically analysed for Myc, Fos, Jun, and p53 
protein expression (Figure 4.9). Myc expression was detected in 16/18 of tumours, Fos 
expression in 17/18 of tumours, Jun expression in 16/17 of tumours and p53 in 16/17 of 
samples (Summarised in Table 4.2). Normal control samples demonstrated no appreciable 
staining. Again, the pattern and extent of expression was very similar to that observed for 
Tax. Furthermore, positive staining was confined morphologically to the same cell types 
as seen for Tax expression. P53 expression although present in the majority of samples 
was generally weak, possibly indicative of low levels of protein expression. Expression 
was predominantly nuclear, with weak cytoplasmic staining. Control tissue taken from 
non-transgenic age-matched animals (pinna, mammary gland and salivary gland) 
demonstrated no staining for p53, Myc, Fos, or Jun protein expression.
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Figure 4.7: Immunofluorescent photomicrographs demonstrating coincidence of Tax
expression and apoptosis.
Photographs of a mammary adenoma fluorescently stained for Tax expression and 
apoptosis. The upper photograph demonstrates Tax immunofluoresence (original 
magnification xlOO) whereas the lower photograph demonstrates TUNEL staining 
(original magnification xlOO). Both photographs are taken from identical fields of view.
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Figure 4.7: Immunofluorescent photomicrographs demonstrating coincidence of
Tax expression and apoptosis.
Upper photomicrograph (original magnification xlO) illustrates Tax expression 
(FITC secondary conjugate) whereas lower photomicrograph (original 
magnification xlO) illustrates apoptosis (Texas red secondary conjugate).
Figure 4.8: Immunofluorescent photomicrographs demonstrating coincidence of Tax
expression and apoptosis.
Photographs of a mammary adenoma fluorescently stained for Tax expression and 
apoptosis. The upper photograph demonstrates Tax immunofluoresence (original 
magnification xlOOO) whereas the lower photograph demonstrates TUNEL staining 
(original magnification xlOOO). Both photographs are taken from identical fields of view. 
The arrows demonstrate TUNEL staining without Tax expression.
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Figure 4.8: Immunofluorescent photomicrographs demonstrating coincidence of
Tax expression and apoptosis.
Upper photomicrograph (original magnification xlOOO) illustrates Tax 
expression (FITC secondary conjugate) whereas lower photomicrograph 
(original magnification xlOOO) illustrates apoptosis (Texas red secondary 
conjugate). Although the coincidence of these two processes is almost complete 
the arrows indicate that background apoptosis occurs without Tax expression.
Figure 4.9: Photomicrographs illustrating Myc, Fos, Jun and p53 protein expression
in mammary adenomas
Photographs of a mammary adenoma immunostained with Myc, Fos, Jun and p53 specific 
antibodies. Photographs 1, 2, 3 and 4 demonstrate strong predominantly nuclear 
immunostaining with Fos, Myc, Jun and p53 specific antibodies respectively (original 
magnification xlOOO).
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4.3 Discussion
This report demonstrates that Tax induces a variety of phenotypes in CD3-tax transgenic 
mice that are characterised by enhanced levels of apoptosis. Tax expression and apoptosis 
show a remarkable degree of coincidence as evidenced by the pattern and distribution of 
expression and double immunofluorescence. These tumours also demonstrate enhanced 
levels of Myc, Fos, and Jun oncoprotein expression, as well as elevated levels of the p53 
tumour suppressor gene product. An unexpected feature of these tumours was their 
common profile of gene expression. This occurred regardless of the derived lineage of 
tumour cell and raises the intriguing possibility that at least in the CD3-tax: transgenic 
mouse system, tax induces a common phenotype which in susceptible cell types leads to 
transformation.
The Tax protein represents an immunodominant epitope (Kannagi et al, 1992; Pique et al,
1996) being subject to a vigorous immune response (Niewiesk et al, 1994; Parker et al, 
1994) during the natural course of infection by HTLV-I. It was therefore not surprising 
that the MAP system generated high titre antibodies specific to the native protein allowing 
the immunocytochemical detection of the protein within the tax transgenic mouse tumours. 
Specific recognition of the Tax protein was concluded from several sources of data. The 
pattern of staining produced by both antibodies was identical despite the specificity of each 
antibody, which was directed towards different regions of the Tax protein. No staining was 
observed when parallel experiments were performed using no primary antibody or when 
non-transgenic tissues were stained with the Tax antibody. Furthermore the pattern of 
expression conformed to the expected pattern of Tax expression based on the known sub- 
cellular localisation of Tax i.e. intense nuclear staining with weaker cytoplasmic staining 
(Goh et al, 1985; Lee et al, 1989). Additionally, the pattern of staining generated by both 
anti-Tax sera was consistent with a previously published report demonstrating Tax 
expression immunocytochemically (within HTLV-ILTR-tax transgenic mouse 
neurofibromas) (Green et al, 1992). Finally, immunostaining was specific to the tumour 
(ovoid-spindle) cell population. Infiltrating inflammatory cells adjacent to positive foci 
demonstrated weak cytoplasmic staining but never any nuclear staining which we
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concluded was due to phagocytosis of immunopositive debris rather than evidence of gene 
expression per se.
In situ immunocytochemical detection of Tax expression not only confirmed the presence 
of Tax protein within tumour material (and conversely its absence from non-tumourous 
material) but also further defined the pattern and distribution of expression. Expression of 
Tax is confined to the background spindle cell population and is absent from the 
superimposed inflammatory cell influx. The peculiar heterogeneous pattern of Tax 
expression is consistent with other transgenic mouse tumour models in which transgene 
expression has been examined immunocytochemically (Schuch et al, 1990; Green et al, 
1992).
Our results show that a very high proportion of tax induced tumours displayed increased 
Myc, Fos, and Jun oncoprotein expression, as well as elevated levels of the p53 tumour 
suppressor gene product. Accompanying this profile of gene expression were enhanced 
levels of apoptosis, which were coincident with Tax expression. It therefore appeared that 
a functional consequence of inappropriate Tax expression in vivo might be the enforced 
induction of apoptosis. Apoptosis has been described as a general feature of many 
spontaneously occurring tumours and more recently apoptotic induction has been 
attributed to a limited repertoire of oncogenes such as c-myc (Evan et al, 1992), c-fos 
(Preston et al, 1996), and Adenovirus E l a (Rao et al, 1992). Likewise tax has been linked 
with induction of apoptosis in immortalised rodent fibroblasts (Tanaka et al, 1990) and 
human T-cell lines (Grassman et al, 1989 and 1992). Our results demonstrate that Tax 
expression in vivo is associated with elevated levels of apoptosis. The high degree of 
coincidence between Tax expression and apoptosis suggests that these two processes are 
intimately linked and that like c-myc (Alarcon et al, 1996), tax is a potent inducer of 
apoptosis in vivo. However these observations also lead to an enigma concerning the role 
of tax in tumourigenesis. One possible explanation is that high levels of Tax may lead to 
cell death. Low levels of expression, which may occur within the background population, 
and which is undetectable by immunocytochemical analysis, may have a proliferative role
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(Marriott et al, 1992) or even an anti-apoptotic role (Kishi et al, 1997; Brauweiler et al,
1997).
However, the mechanism by which Tax induces apoptosis is uncertain. Tax is known to 
upregulate a number of genes including c-myc (Duyao et al, 1992a and 1992b), c-jun 
(Iwakura et al, 1995; Hooper et al, 1991, Fujii et al, 1991) and c-fos (Fujii et al, 1988; 
Nagata et al, 1989; Alexandre et al, 1991; Iwakura et al, 1995) which have been shown to 
induce apoptosis. Our results demonstrate that a very high proportion of Tax induced 
tumours express elevated levels of these proteins which lends support to the notion that tax 
upregulates these genes in vivo. The similar deregulated expression of these oncogenes in 
pre-neoplastic lymphoproliferative conditions (Stone et al, 1996; Iwahashi et al, 1994; 
Kanaitsuka et al, 1989) and HTLV-I infected cell lines (Hooper et al, 1991) suggests that 
these oncogenes may be of wider significance than the tax transgenic system and may 
contribute to the induction of the neoplastic process. Conceivably these oncogenes could 
also act as transcriptional intermediates mediating the apoptotic response to tax expression. 
However it is unlikely that these genes alone are responsible for this effect since the 
sensitivity of rat 1 fibroblasts transformed by tax to the induction of apoptosis differed 
from cells transformed by either c-myc or c-fos (Fujita et al, 1995). An alternative 
hypothesis is that tax directly induces apoptosis in a manner analogous to that previously 
observed for c-myc (Evan et al, 1995) and c-fos (Preston et al, 1996) in which the activation 
of other genes is not required. In this system the induction of apoptosis by c-myc, and E la  
has been intimately linked with the inappropriate entry into the cell cycle (Mymryk et al, 
1994; Evan et al, 1992) which can be inhibited by the addition of specific cytokines 
(Harrington et al, 1994).
An additional feature noted within these tumours were enhanced levels of the p53 tumour 
suppressor gene product. Wild-type p53 protein is usually only detected at very low levels 
due to rapid turnover of newly synthesised protein (Rogel et al, 1985). Stabilisation of the 
p53 tumour suppressor gene (Reid et al, 1993) and impairment of its function (Ceresto et 
al, 1996) has been noted in cell lines transformed by HTLV-I infection as well as 
uncultured ATL cells. Since tax is not known either to transactivate (Reid et al, 1993;
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Uittenbogaard et al, 1995) or bind the p53 protein (Reid et al, 1993) the mechanism by 
which this effect is achieved is unknown. The frequency with which these tumours 
express elevated levels of this protein indicates that this may be a direct consequence 
resulting from tax expression.
The observation of proliferation and concomitant apoptosis together with the characteristic 
latencies for each tumour phenotype in the CD3-tax transgenic mouse system provides a 
framework for tumourigenesis. The high degree of coincidence between Tax expression 
and apoptosis suggests that deregulated Tax expression induces apoptosis. The induction 
of tumours in CD3-tax transgenic mice favours a model whereby deregulated expression of 
tax results in apoptosis. In other cell types such as thymocytes and oxidative muscle cells, 
tax expression is non-permissive and results in thymic involution (our unpublished results 
and Furuta et al, 1989) or oxidative muscle fibre degeneration (Nerenberg et al, 1989). In 
the context of this model tumours emerge only if this pathway can be abrogated. 
Mesenchymal tumours only develop at sites of wounding, typically ear and tail tips. One 
possible mechanism is that a cocktail of growth promoting cytokines derived from 
inflammatory mediators released at wound sites provides a survival signal promoting 
tumour induction. To this point, the induction of fibrosarcomas in v-jun transgenic mice 
also requires wounding (Schuh et al, 1990) suggesting the need for epigenetic events to 
influence tumour genesis. The importance of this model in tumourigenesis and the role of 
survival factors in mitigating the effects of apoptosis is well established in cell culture 
(Harrington et al, 1994). In other systems of carcinogenesis, tumour promoters such as 
phorbol myristate acetate (PMA) and a-hexachlorocyclohexane (Thompson et al, 1995) 
have been shown to achieve their tumour promoting effects by acting as specific survival 
factors. The development of mammary and salivary adenomas in CD3-tax transgenic mice 
occurs after a latency of many months. This prolonged latency is compatible with the 
acquisition of a second complimenting genetic lesion, which allows the survival of Tax 
expressing cells. Clearly expression of Tax in vivo imposes a balance between life and 
death. In the absence of complimenting genetic lesions environmental factors such as 
survival cytokines may determine the fate of these cells and ultimately the emergence of 
the neoplastic phenotype.
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Chapter 5
Investigation of the role of p53 in tax mediated tumourigenesis
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Investigation of the role of p53 in tax mediated tumourigenesis
5.1 Introduction
The importance of the p53 tumour suppressor gene as the most frequently mutated gene in 
human cancer is firmly established (Nigro et al, 1989; Bartek et al, 1991; Hollstein et al, 
1991). About half of all cancers have inactivating p53 mutations (Hollstein et al 1991) 
which appear to represent a critical late step (Vogelstein and Kinzler, 1993; Wynford- 
Thomas 1993; Kemp et al, 1993) in the evolution of malignant disease.
The generation of p53 knockout mice has allowed the assessment of p53 function in vivo. 
These mice develop normally but are prone to a variety of tumours at an early age (mainly 
lymphomas and sarcomas) (Donehower et al, 1992; Purdie et al, 1994). The importance of 
p53 loss of function is highlighted by its complementation with c-myc (Blyth et al, 1995; 
Hsu et al, 1995) in which there is dramatic acceleration of tumour development. This 
synergy mirrors that seen between over-expression of bcl-2 and c-myc (Mcdonnell and 
Korsmeyer, 1991), and underlines the importance of this group of tumour suppressor genes 
in multi-stage tumourigenesis.
The role however that p53 plays in the development of ATL is still unclear since few 
naturally occurring p53 mutations have been found in ATL samples (Nagai et al, 1991). 
Tax has been shown to trans-repress the p53 promoter (Uittenbogaard et al, 1995) and 
inhibit its function (Akagi et al, 1997; Ceresto et al, 1996) as well as upregulating p21 
wafl/cipl (Ceresto et al, 1996). Furthermore tax may inhibit apoptosis (Kishi et al, 1997; 
Schwartz-Cornil et al, 1997) possibly through tax mediated trans-repression of box 
(Brauweiler et al, 1997). The resulting phenotype of ATL cells is a marked resistance to 
chemotherapeutic intervention. Despite an intact p53 genotype, most patients with ATL 
die within 6-12 months of diagnosis (Taguchi et al, 1996; Uozomi et al, 1995). In contrast, 
tumours which have a functional p53 status, such as testicular carcinomas or childhood 
acute lymphoblastic leukaemias often respond favourably to chemotherapy (Lutzker and 
Levine, 1996; Lowe et al, 1993).
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5.2 Aims of the experiments
We therefore decided to assess the role p53 plays in the development of mesenchymal 
tumours in CD3-tax transgenic mice. CD'S-tax transgenic mice were crossed onto a p53 
null background (Donehower et al, 1992) to generate an FI p53+/7tax breeding cohort of 
mice (breeding experiments set up by Dr Blyth). The FI generation was then backcrossed 
to generate an F2 experimental cohort containing tax transgenic mice on either a p53 wild 
type (p53+/+), hemizygous (p53+/‘) or null (p53'/_) background. The contribution that the 
p53 protein played in tumourigenesis could then be assessed by measuring tumour 
incidence, phenotype and latency as well as gene expression and apoptosis.
5.3 Results
5.3.1 p53 cross tax breeding experiments
The FI breeding cohort produced 84 experimental F2 mice (Table 5.1). Mice not showing 
any pathology after 12-18 months were culled.
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Table 5.1: Result of p53+/' x tax breeding experiment
Table summarising the results of the p53+/' cross tax transgenic mouse breeding 
experiments which generated the p53/tax (denoted as p/t) line of mice. The top pane
summarises the phenotypes of the mice which carry either a p53_/* (null), p53+/‘
(heterozygous) or p53+/+ (wild type) allele together with a tax allele. The middle panel 
summarises the phenotypes of the mice which carry either a p53‘7' (null), p53+/*
(heterozygous) of p53+/+ (wild type) allele only. The bottom panel summarises the overall
tumour incidence for each transgenic mouse cross. The p/t nomenclature refers to the 
identification number allocated to the offspring of the p53+/' cross tax mice.
Top panel: Summary of the phenotype of the p53'/7tax, p53+/7tax, p53+/+/tax mice. The 
individual cause of death for each mouse is indicated by the symbols: * ear and/or tail 
(mesenchymal) tumours; • thymic lymphoma; *  sarcoma; * hind leg paresis. Animals 
that do not have a symbol were culled after 12-18 months. The figures refer to the total 
number of animals in each group (grand total in brackets).
Middle panel: Summary of the phenotype of the p53*A, p53+A, p53+/+ mice. The individual 
cause of death for each mouse is indicated by the symbols: * ear and/or tail (mesenchymal) 
tumours; • thymic lymphoma; *  sarcoma; A hind leg paresis. Animals that do not have a 
symbol were culled after 12-18 months. The figures refer to the total number of animals in 
each group (grand total in brackets).
Lower panel: Summary of the overall tumour incidence and average latency (in days) for 
each of the p53/tax mice. Figures in brackets in the ‘pathology’ column refer to the total 
number of tumour for each mouse cross.
Key: * ear and/or tail (mesenchymal) tumours; • thymic lymphoma; *  sarcoma; A hind leg paresis
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Table 5.1: Result of p53+/' x tax breeding experiment
p5 y'ltax p53+/7tax p53 +,+/tax
•p/t 42; «p/t 77; p/t 121 *p/t 43; pt 66; p/t 97 p/t 58; *p/t 123
Ap/t 49; *Ap/t 78; Ap/t 124 *p/t 48; p/t 67; p/t 111 p/t 85;
Ap/t 52; Ap/t 90; p/t 126 *p/t 50; p/t 68; p/t 117 p/t 92
p/t 56; *p/t 96; 
Ap/t 62; p/t 100; 
•p/t 63; »p/t 108 
•p/t 69; *p/t 114 
Ap/t 71; »Ap/t 116
*p/t 54; p/t 70; A p/t 120 
*p/t 57; p/t 72; *p/t 125 
p/t 60; p/t 74; p/t 140 
p/t 61; p/t 79 
p/t 64; p/t 80
p/t 93 
♦•p/t 99 
p/t 101 
p/t 115 
p/t 122
19 22 9 Total (50)
p53' p53+/‘ p53+/+
•p/t 53; p/t 143 
Ap/t 55 
•p/t 65 
Ap/t 75 
•p/t 88 
Ap/t 98 
p/t 107 
Ap/t 113
p/t 44; p/t 84; p/t 105 
p/t 45; p/t 86; Ap/t 106 
A p/t 51; p/t 87; p/t 112 
p/t 73; p/t 91; p/t 119 
p/t 76; A p/t 94; p/t 141 
p/t 81; p/t 95; «Ap/t 142 
p/t 82; p/t 103 
p/t 83; p/t 104
p/t 59 
p/t 89 
p/t 118
9 22 3 Total (34)
Genotype Pathology Average Latency 
(days)
Tumour Incidence
p53+/7tax 
p53 +l+/tax
p53+/'
p5y'ltax
p537'
mesenchymal tumours (6) 233 
mesenchymal tumours (2) 156 
thymic lymphoma (1) 
thymic lymphoma (1) 249 
sarcomas (4)
thymic lymphoma (9) 163 
sarcomas (8)
thymic lymphoma (3) 157 
sarcomas (4)
6/22 (27%) 
2/9 (22%)
4/22 (18%)
15/19 (79%)
7/9 (78%)
135
5.3.2 Analysis of tumour incidence and latency
The p/t series of mice produced mesenchymal tumours at a reduced incidence rate 
compared to the original cohort of CD3-tax tumours but with no reduction in the tumour 
latency (Table 5.2). This indicates that a hemizygous or null p53 background did not 
accelerate tumour induction. p53 related pathology (chiefly thymic lymphoma and/or 
sarcomas) arose with high incidence, predominantly in the p53 null mice (approximately 
four fold more frequently compared to p53 hemizygous mice). Since these tumours 
emerged after only a short latency period and proved invariably fatal, this type of 
pathology may have pre-empted the emergence of the tax phenotype forestalling the 
development of tax related tumours in these mice.
Table 5.2: Comparison of tumour phenotypes emerging on a p53 homo- or 
hemizygous background compared to a p53 wild type background
Genotype Average Latency Tumour Incidence
p53+/Vtax 233d (7.8 months) 6/22(27%)
p53 +,+/tax 156d (5.2 months) 2/9 (22%)
1300 series 2116. (9.2months) 2/4 (50%)
1400 series 128d (4.3 months) 16/27 (59%)
Table summarising the average latency in days (and months) and tumour incidence for the 
p53+/'/tax, p53+/+/tax, and 1300/1400 series tax mice.
5.3.3 Histological analysis of tumours
Analysis of the p/t series of mesenchymal tumours indicated that they were phenotypically 
and histologically similar to the original cohort of mesenchymal tumours. Tumours 
typically developed at wounding sites (ear and tail tips) in an identical fashion to the 
original cohort of 1300/1400 series of tax transgenic tumours. Histopathological 
examination revealed a spindle cell population together with a superimposed intense 
inflammatory cell infiltrate (polymorphs and macrophages) (Figure 5.1 and 5.2 - compare
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to Figure 3.3). Again these tumours were locally aggressive infiltrating along tissue planes 
although no evidence of metastasis was noted. Frequently a large necrotic area within the 
centre of these tumours was observed (Figure 5.1) indicating rapid tumour growth - a 
feature not present within the original tumour cohort.
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Figure 5.1: H+E photomicrographs of a mesenchymal tumour emerging in a p53
hemizygous background.
Photographs of a mesenchymal tumour which developed in a p53+/'/tac mouse. Upper 
photograph (original magnification xlO) and lower photograph (original magnification 
x400) showing the similarities and differences between the original 1300/1400 tax series of 
mesenchymal tumours and p53+/'/tax tumours.
1 area of central necrosis; 2 cartilage plate; 3 spindle cell population
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Figure 5.1: H+E photomicrographs of a mesenchymal tumour emerging in a p53
hemizygous background.
j  * T*s
L o w  p o w e r  (u p p e r  p hoto:  o r ig in a l  m a g n i f ic a t io n  x lO ) a n d  high  p o w e r  
p h o t o m ic r o g r a p h  ( lo w e r  p h oto :  o r ig in a l  m a g n if ic a t io n  xlOO) o f  a m e s e n c h y m a l  
t u m o u r  a r is in g  in th e  p53x/0x: c o h o r t  o f  m ic e  r e v e a l in g  a sp in d le  cell  
b a c k g r o u n d  p o p u la t io n  o f  T a x  e x p r e s s in g  tu m o u r  ce l ls  a c c o m p a n ie d  by an  
in te n se  in f la m m a to r y  cell in f i ltra te .
1 a r e a  o f  c e n tr a l  n ecros is ;  2 c a r t i la g e  p late;  3 s p in d le  ce l l  p o p u la t io n
5.3.4 Analysis of gene expression and apoptosis
TUNEL analysis of four tumours derived from the p53+/7tax cohort revealed that apoptosis 
occurred at a reduced rate and with an alternative pattern compared to the original cohort 
of mesenchymal tumours. Apoptotic cells were distributed as rare discrete cells scattered 
throughout the substance of the tumour (Figure 5.2). No foci of apoptotic cells were ever 
visible. Furthermore, Tax protein, oncoprotein (Myc, Fos, and Jun) as well as p53 protein 
expression could not be detected immunocytochemically indicating that localised high 
level expression of these proteins did not occur. However tax RNA expression could be 
detected by in situ hybridisation [Ms J. McMillan personal communication] and by 
Northern analysis from cell lines derived from these tumours.
5.3.5 Analysis of cell lines derived from p53+l'/tax mesenchymal tumours
Two cell lines were derived from these tumours p53+/7tax 50 [p/t 50] and p53+/7tax 54 [p/t 
54]. Morphological analysis of these cell lines together with a tax expressing cell line Tax 
1 [T 1] derived from the original cohort of mesenchymal tumours revealed different 
patterns of growth. T 1 and p/t 54 grew as a contact inhibited monolayer being made up of 
an orderly array of ovoid or hexagonal cells. In contrast, p/t 50 grew as a disorderly array 
of smaller spindle shaped cells, which showed considerable cellular pleiomorphism, 
frequently piling up into foci of contact uninhibited independent cells (Figure 5.3). In cell 
culture, p/t 50 grew considerably more quickly and to a higher cellular density than either 
T 1 or p/t 54 (Graph 5.1).
PCR genotype analysis after 4 months in continuous culture revealed no loss of the wild- 
type allele (Figure 5.4). These results were confirmed using an alternative pair of primers 
directed to the same exon. Southern blot analysis (performed by Dr Campbell) confirmed 
the presence of an intact wild type p53 allele within the p/t series of tumours but loss of the 
wild type allele from the p/t 50 cell line and the nude tumours derived from that cell line 
(Figure 5.5).
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Figure 5.2: Photomicrograph demonstrating apoptosis within a mesenchymal tumour
emerging in a p53 hemizygous background .
Photograph of a mesenchymal tumour which developed in a p53+/7tax; mouse 
demonstrating apoptosis staining using the TUNEL technique (original magnification 
xlOOO). Counter stained with haematoxylin.
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Figure 5.2: Photomicrograph demonstrating apoptosis within a mesenchymal
tumour emerging in a p53 hemizygous background
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High power photomicrograph (original magnification xlOOO) of a TUNEL 
stained section demonstrating apoptosis in a mesenchymal tumour derived 
from the p53x/0.v cohort of mice. No foci of apoptotic cells were visible -  
apoptosis occurred only as occasional single cells.
Figure 5.3: Photomicrographs of p/t 50 and p/t 54 cell lines after 4 months of
continuous cell culture
Photograph of the p/t 50 and p/t 54 cell lines after 4 months in continuous culture. The 
upper photograph (original magnification xlOO) of the p/t 50 cell line illustrates malignant 
behaviour whereas the lower photograph (original magnification xlOO) illustrates non- 
malignant behaviour.
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Figure 5.3: Photomicrographs of p/t 50 and p/t 54 cell lines after 4 months of
continuous cell culture
Comparison of p/t 50 cell line (upper photo: original magnification xlOO) and p/t 
54 cell line (lower photo: original magnification xlOO) after 4 months of 
continuous cell culture. Cell line p/t 50 shows considerable variation in size and 
shape, and foci of contact uninhibited cells whereas p/t 54 maintains a uniform 
monolayer of hexagonal cells.
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Figure 5.4: Photograph demonstrating p53 PCR genotyping of cell lines derived from 
p53+/7tax; mesenchymal tumours (p/t 50 and p/t 54) and a p53+/+/tax (Tl) 
mesenchymal tumour after 4 months in culture.
Photograph of an ethidium bromide stained acrylamide gel demonstrating p53 allele 
genotyping of the tax and p53/tax derived cell lines. Lanes 1, 3, and 5 refer to cell lines 
Tl, p/t 50, and p/t 54 respectively using PCR primers to detect the p53 knockout (p53‘) 
allele. Lanes 2, 4, and 6 refer to cell lines Tl, p/t 50, and p/t 54 respectively using PCR 
primers to detect the p53 wild type (p53+) allele. Lanes 7, 9, and 11 refer to p53+/+, p53+/' 
and p53'/_ control DNA respectively using PCR primers to detect the p53 knockout allele 
(p53‘). Lanes 8, 10, and 12 refer to p53+/+, p53+/‘ and p53*7' control DNA respectively 
using PCR primers to detect the p53 wild type allele (p53+) respectively. Lane 13 and 14 
refer to negative control water using PCR primers to detect the p53 knockout (p53“) and 
p53 wild type (p53+) allele respectively. Lane 0 (not marked) refers to 5uL of Phi X 
molecular weight DNA ladder.
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Figure 5.5: p53 Southern blot of mesenchymal tumours (p/t 125, p/t 54, p/t 50) and p/t 
50 cell line
Photograph of a Southern blot demonstrating p53 allele genotyping of the p53/tax 
mesenchymal tumours or p53/tax derived cell lines. Lane 1 refers to the PhiX molecular 
weight DNA ladder. Lanes 2, 3, and 4 refer to the p/t 125, p/t 54, and p/t 50 mesenchymal 
tumours respectively. Lanes 5 and 6 refer to the p/t 50 and p/t 50-2 cell lines respectively. 
The p53 pseudogene, p53 knock out allele and p53 wild type allele are marked.
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Figure 5.5: p53 Southern blot of mesenchymal tumours (p/t 125, p/t 54, p/t 50)
and p/t 50 cell line
<4----- P53 pseudogene
<4----- p53 knockout
allele
<----- p53 wild type
allele
1 PhiX Molecular Weight Marker
2 p/t 125 tumour
3 p/t 54 tumour
4 p/t 50 tumour
5 p/t 50 cell line
6 nude p/t 50-2 cell line
Southern blot demonstrating the presence of both wild type and knockout p53 
alleles retained within the p/t series of mesenchymal tumours (Lanes 2, 3, and 4). 
Cell line p/t 50 (Lane 5) has lost the wild type p53 allele but retains the knockout 
allele. Cell line nude p/t 50-2 (Lane 6) derived from cell line p/t 50 after 
transplantation into nude mice shows a weak p53 knockout allele and 
rearrangement to yield a weak band of similar size to the p53 wild type allele.
9
m
Transplantation of 5x106 cells from each cell line (p/t 50, p/t 54 and Tl) into nude mice 
resulted in the generation of tumours in only those mice which were injected with the p/t 
50 cells (Table 5.3). These tumours grew rapidly to a diameter of l-2cm (Figure 5.6) 
within 2-3 weeks of transplantation confirming that the p/t 50 cell line was fully 
transformed (whereas the failure of the other cell lines to establish in nude mice indicated 
that these cell lines are merely immortalised).
Table 5.3: Growth of transplanted cell lines in nude mice
Cell Line Tumour Development Latency
P/t 50 3/3 2-3 weeks
P/t 54 0/3 sacrificed after 3 months
T 1 0/3 sacrificed after 3 months
Table summarising the malignant potential (judged by the transplantability of tumour cell 
lines into nude mice) and latency of tumour production for cell lines P/t 50, P/t 54, and Tl. 
The cell line reference P/t is taken from the parental P/t transgenic mouse from which the 
tumour cell line was derived.
5.3.6 Analysis of gene expression within the transplanted tumours
Histologically these tumours were unlike the original p/t 50 tumours being composed of a 
bland sheet of spindle cells unaccompanied by any inflammatory infiltrate (Figure 5.7). 
Mitoses and apoptotic bodies were frequently observed (Figure 5.7 and 5.8) scattered 
randomly as individual cells throughout the substance of the tumour (in a similar pattern to 
the original p/t 50 tumour). As for p/t 50, oncoprotein (Tax, Myc, Fos, and Jun) and p53 
tumour suppressor protein expression could not be detected immunocytochemically 
(although again tax RNA was detected by Northern analysis from these tumours and cell 
lines derived from these tumours).
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Figure 5.6: Photograph illustrating the growth of p/t 50 cells transplanted into a nude 
mouse.
Photograph of a nude mouse bearing a malignant tumour induced by transplantation of the 
p/t 50 cell line.
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Figure 5.7: H+E photomicrographs of a transplanted tumour derived from the p/t 50
cell line.
Photograph of a tumour derived from transplantation of the p/t 50 cell line into nude mice. 
The upper photograph (original magnification xlO) and lower photograph (original 
magnification x 400) illustrate the malignant nature of these tumours. Staining 
haematoxylin and eosin.
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Figure 5.7: H+E photomicrographs of a transplanted tumour derived from the
p/t 50 cell line
. - ' f ' Si**
*w i„v
91  ™ iW i
H E k  <%'
k  h1" - >#4 *  #><_; V >' ., 1 2 )j l
' f a * *  * *.fc J  »f  A ; « M f *<■ *
• , f l M l r  *  * . v  •
U  «*. * I f .
Si
Low (upper photo: original magnification xlO) and high (lower photo: original 
magnification xlOO) power photomicrographs of p/t 50 transplantable tumours 
growing in a nude mouse. The upper photo illustrates a large area of central 
necrosis whereas the lower photo illustrates the bland spindle cell population with 
numerous mitotic figures.
1  area of central necrosis; 2  area of apoptotic bodies * mitotic figures
Figure 5.8: Photomicrograph of apoptotic bodies stained with the TUNEL technique 
in the transplanted p/t 50 tumour.
Photograph of a tumour derived from transplantation of the p/t 50 cell line into nude mice. 
High power (original magnification xlOOO) demonstrating the high apoptotic rate. Stained 
by the TUNEL technique; counter stained with haematoxylin.
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5.3.7 Analysis of apoptotic and mitotic indices
In order to estimate the contribution to tumour growth imparted by the relative rates of 
apoptosis and mitosis we decided to estimate the numbers of mitotic figures and apoptotic 
bodies within TUNEL stained sections. Five random fields for each tumour were counted 
and averaged in order to derive the mitotic or apoptotic index. Analysis of apoptotic 
indices (AI) and mitotic indices (MI) revealed that although the rates of mitosis were 
similar between the original cohort of mesenchymal tumours/adenomas and the p53+/7tax: 
tumours the rates of apoptosis were different (Table 5.4). The original cohort of 
mesenchymal tumours and adenomas had on average less than 1  mitotic figure per random 
high power view (indicative of a benign tumour). The p/t series of tumours also had on 
average less than 1 mitotic figure per random high power field view. In contrast the 
original group of mesenchymal tumours and adenomas had much higher levels of 
apoptosis compared to the p/t series of tumours. These figures indicate slower net tumour 
growth for the original 1300/1400 tumour series compared to the p/t series of tumours by 
virtue of their higher apoptotic indices consistent with the presence of large necrotic foci 
within the latter tumours. Finally, the transplantable tumours derived from the fully 
transformed p/t 50 cell line had very high mitotic and apoptotic indices indicating very 
rapid tumour growth with a correspondingly large area of central necrosis.
When this experiment was repeated for the original cohort of 1300/1400 series of tumours 
using PCNA immunocytochemical staining (performed by Ms J. McMillan) as a more 
accurate estimate of mitosis, the mitotic index was always greater than the apoptotic index 
(Table 5.5) indicating progressive tumour growth.
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Table 5.4: Analysis of mitotic and apoptotic indices within each tumour type
Table summarising the mitotic index (MI) and apoptotic index (AI) for tax transgenic 
mouse tumours. The first column refers to the identification number assigned to the 
tumour at histological processing. P/T refers to tumours derived from the p53/tax 
transgenic mouse cross and Nu refers to tumours derived from p/t50. The mitotic index 
refers to the average number of mitotic cells (judged by light microscopy) at high power 
(xlOOO). The apoptotic index refers to the average number of apoptotic cells (judged by 
TUNEL technique) at high power (xlOOO).
Key: • original cohort of 1300/1400 series of mesenchymal or adenoma tumours with wild-type p53 status; 
*  p53 +l'/tax tumours; *  tumours derived from p/t 50 cell line transplanted into nude mice
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Table 5.4: Analysis of mitotic and apoptotic indices within each tumour type
Tumour Mitotic Index* (MI) Apoptotic Index* (AI)
•93/8086-1 0.625 12.81
•93/7665-2 1.875 6.87
•93/7599-2 0 26.56
•93/1245-1 0 5.62
•93/1239-2 0.31 4.68
Average 0.940 11.308
*P/T96/1441-4 0.31 1.875
*P/T96/1440-5 0.31 2.18
*P/T96/1440-4 0.31 4.68
Average 0.31 2.91
*Nu96/4390-4 26.2 25.2
ANu96/4389-4 18.4 11.6
aNu96/4368-4 26 14.4
Average 23.53 17.06
Table 5.5: Analysis of mitotic and apoptotic index from the original cohort of 1300 
and 1400 series of tumours
Tissue Proliferation Standard Apoptotic Standard
Index Deviation' Index Deviation
Healthy salivary and
mammary tissue (4) 0 0 0.2 0.2
Mammary
Adenocarcinoma (3) 118.3 21.4 8.8 0.6
Tax mammary and
Salivary adenomas (8) 9.4 8.7 3.2 3.1
Tax ear and tail
Tumours (5) 12.6 7.1 2.8 0.5
Table summarising the proliferation (mitotic) index (MI) and apoptotic index (AI) for tax 
transgenic mouse tumours. The numbers in brackets in the ‘tissue’ column refers to the 
total number of tumours examined. The figures in the proliferation and apoptotic index 
refer to the average number of cells stained with PCNA and the TUNEL technique 
respectively. The mammary adenocarcinomas were derived from spontaneously occurring 
tumours in outbred strains of mice.
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5.4 Discussion
Analysis of the p531 tax breeding experiments revealed that the p/t series of mesenchymal 
tumours occurred at a reduced frequency but equivalent latency period compared to the 
original 1300/1400 series tumours. Macroscopically and microscopically the p/t tumours 
were identical to the original cohort of mesenchymal tumours. However further analysis 
revealed a reduced apoptotic index, which correlated with the presence of a variably sized 
centres within these tumours, indicating rapid tumour growth. Two cell lines (T 1 and p/t 
54) derived from these tumours and propagated for 4 months in cell culture remained 
untransformed (non-malignant). One cell line (p/t 50) however was highly malignant and 
grew rapidly in tissue culture. Malignancy in the p/t 50 cell line correlated with loss of the 
remaining wild type allele by Southern blot analysis (although PCR analysis indicated the 
presence of a wild-type p53 allele in all three cell lines). The reason for the discrepancy 
between these results is unknown but may reflect the greater sensitivity of the PCR based 
assay detecting rare cells retaining the wild type allele or retention of part of the PCR exon 
with loss of other critical parts of the p53 gene.
The results of the p53 cross tax breeding experiment revealed that p53 null genotype did 
not co-operate with the tax transgene to accelerate mesenchymal or lymphoma tumour 
development. This is in contrast to the collaboration observed between the c-myc 
oncogene on a p53 null background (Blyth et al, 1995; Hsu et al, 1995) or bcl-2 
background (McDonnell et al, 1991) which dramatically accelerated tumour development 
with rapid progression to high grade malignancy. Presumably the complete absence of 
mesenchymal tumours in this cohort resulted from the rapid development of p53 related 
pathology. In this scenario the latency period of tax related pathology is outside the life 
span of the p53 null mice.
Analysis of the p53+l'/tax mice similarly indicated no synergy between p53 hemizygous 
genotype status and tax transgene status since the resultant mesenchymal tumours were 
phenotypically identical to the original cohort of tumours indicating no malignant 
progression. This agrees closely to that observed when CD2-myc mice are crossed onto a
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p53+/' background (Dr Blyth PhD thesis) but is contrary to that observed when E|x-myc or 
MMTV-/nyc mice are crossed onto a p53+/' background (Hsu et al, 1995). This may imply 
that for efficient co-operation, constitutive expression of the transgene is necessary since 
CD2-myc mice, like CD'i-tax mice, only express the transgene in transformed cells. 
However failure of two of the three (T 1 and p/t 54) tumour derived cell lines to progress 
to a malignant phenotype in extended cell culture indicates that loss of the p53 wild type 
allele is not strongly selected for in vitro. In contrast, p53+/7CD2-/wyc cell lines rapidly 
lose their remaining wild type allele in cell culture (Dr Blyth PhD thesis).
Lack of p53 synergy and failure to lose the remaining wild type p53 allele in extended cell 
culture suggests that the loss of the p53 protein is not an important co-operating event in 
tax induced malignancy. Loss of the remaining wild type p53 allele is a common late 
event in human malignancy (Nigro et al, 1.989; Baker et al, 1989) and tumours which 
develop in p53+/' mice (Harvey et al, 1993; Purdie et al, 1994) as well as p53+/7myc 
tumours (Hsu et al, 1995; Elson et al, 1995). However, retention of the wild type p53 
allele in 2 of 3 p53+/7tax cell lines is consistent with other authors who failure to detect p53 
mutations in naturally occurring cases of ATL (Nagai et al, 1991). Stabilisation (Reid et 
al, 1993) and functional inactivation of p53 (Ceresto et al, 1996; Gartenhaus et al, 1995) 
presumably substitute for p53 loss in vivo. Furthermore, inactivation of the cdki, pi 6 °®^, 
probably serves to induce cell cycling (and inhibit senescence) - a function also served by 
p53 inactivation (Hsu et al, 1995).
The low frequency of tumours observed in the p/t series of mice (16% overall) most 
probably reflects increasing DNA methylation of the transgene over successive generations 
of mice (Allen et al, 1990) -  an effect which is most apparent when multiple copies of the 
transgene are present within the genome (Garrick et al, 1998). This is consistent with the 
observed loss of the tax phenotype in later generations of 1200, 1300, and 1400 mice as 
well as the tax cross p53 mice..
Analysis of the p/t series of mesenchymal tumours clearly showed an alternative form of 
apoptosis compared to the original 1300/1400 tumours, as evidenced by the pattern (no
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foci) and frequency of apoptosis, and the absence of concomitant oncogene expression. 
This alternative pattern was not associated with high level Tax expression per se since Tax 
could not be detected immunocytochemically within any of these tumours. It is more 
likely that this pattern represents background or spontaneous apoptosis associated with 
cycling cells, occurring in the absence of p53. pr oncoprotein expression. This is consistent 
with in vitro models of tumourigenesis (Evan et al, 1992) in which conflicting 
environmental cues (typically growth factor deprivation for cultured cells; anoxia in c-myc 
induced transgenic mouse tumours [Alarcon et al, 1996]) readily induce apoptosis in 
cycling cells. Indeed the higher levels of apoptosis within the transplanted tumours, may 
be a direct consequence of the elevated mitotic rate seen in theses tumours [although the 
contribution of other apoptotic inducers activated by secondary mutations acquired during 
in vitro passage and in vivo selection cannot be determined].
Loss of a major (Tax associated) apoptotic pathway within the p53 +l'/tax tumours resulted 
in lower apoptotic indices compared to the original cohort of tumours. Consistent with this 
observation were the frequently noted areas of necrosis occurring within the centre of these 
tumours indicative of a rapidly growing neoplasm outstripping its blood supply. The 1200, 
1300 and 1400 tumours never exhibited central necrosis consistent with a slower growth 
rate due to retention of both apoptotic pathways (i.e. background apoptosis upon which is 
superimposed the major Tax associated pattern of apoptosis). Background apoptosis 
within the original tumours was evident as rare cells undergoing apoptosis without 
concomitant Tax expression (Figure 4.8 arrows) in dual stained sections.
The reason for the absence of Tax associated apoptosis within the p/t tumours is unknown 
although progressive epigenetic down-regulation (methylation) of transgene expression 
may alter the tumour phenotype. In this model of tumourigenesis low level tax expression 
is sufficient to induce proliferation but not apoptosis i.e. the p/t cohort of tumours display 
the spontaneous background pattern of tax expression noted for the original 1300/1400 
series of tumours. Clearly low-level expression of Tax must promote tumourigenesis as 
well as dissemination of virally infected lymphocytes in HTLV-I infected patients. 
Furthermore, evidence supporting the dual role of tax is just emerging. Low
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concentrations of Tax (lOpM [Marriott et al, 1991]) effectively induces proliferation in 
human lymphocytes whereas expression of tax under certain circumstances may repress 
apoptosis (Brauweiler et al, 1997; Kishi et al, 1997; Schwartz-Cornil et al, 1997). Thus the 
pharmacological effects of tax demonstrated and established in vitro may not necessarily 
reflect the consequences of normal tax expression from the HTLV-I viral promoter in vivo.
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Chapter 6
Generation of a modified Tax expression system
Generation of an inducible tax expression system
6 . 1  Introduction
The HTLV-I tax oncogene transforms both rodent fibroblasts (Tanaka et al, 1990) and 
human T-cells (Grassman et al, 1989 and 1992) in culture as well as inducing tumours in 
HTLV-I tax transgenic mice (Ozden et al, 1996). The mechanism through which tax 
achieves this effect is still unclear although key functional domains have been implicated as 
likely oncogenic determinants. The most important of these domains are those which allow 
protein-protein interactions with the transcription factors NF-kB, CREB/ATF, and the SRF, 
as well as the cyclic dependent kinase inhibitor (cdki), p ^ 1^ 4*.
The NF-kB transcription factor has recently been implicated in the suppression of apoptosis 
in T-cells (Beg et al, 1996; Wang et al, 1996; Van Antwerp et al, 1996; and Liu et al, 1996) 
and appears essential to mediate the tumourigenic effects of tax (Kitajima et al, 1992; 
Yamaoka et al, 1996). However other authors have found that the CREB/ATF 
transcription factors, necessary for transcriptional transactivation of the HTLV-I LTR 
(Beimling et al, 1992; Zhao et al, 1992, Franklin et al, 1993), are also essential for 
transformation (Smith and Greene, 1991). This discrepancy highlights the equivocal role 
that each of these factors independently contribute towards the transformed phenotype. 
The generation of tax mutants, which segregate the CREB/ATF and NF-kB pathways, 
(Smith and Greene, 1991; Semmes and Jeang, 1992; Yamaoka et al, 1996) has 
demonstrated that the events leading to transformation are highly complex. In rodent 
fibroblasts, both the CREB/ATF and NF-kB domains have been shown to be independently 
necessary and sufficient for transformation (Smith and Greene, 1991; Yamaoka et al, 1996). 
Complementation by the alternative phenotype does not appear to be necessary since both 
tax mutants (CREB/ATF+/NF-kB' [Smith and Greene, 1991] and NF-kB+/CREB/ATF' 
[Yamaoka et al, 1996]) transform rodent fibroblasts. Furthermore, the recent 
demonstration that a variant of tax, incapable of activating NF-kB can immortalise primary 
human T cells (Rosin et al, 1998) has further obscured the resolution to this paradox.
166
Additionally the SRF (Suzuki et al, 1993b; Fujii et al, 1995) and the cdki, pld 1^ 4 3  (and 
other family members) (Low et al, 1997; Suzuki et al, 1996) have also been suggested to 
contribute to the oncogenic effects of tax. The role that plb1^ 43, and other family members 
play in the development of ATL is well-established (Hatta et al, 1995; Suzuki et al, 1997) 
suggesting that the importance of the Tax .NF-kB binding domain may relate to the 
requirement of Tax to bind both IkB and plb 0 ^ 4 3  through their common repeated ankrin 
motifs (Yoshida et al, 1997).
The generation of inducible vectors has provided a valuable tool to dissect gene function. 
Historically, a number of inducible systems have been developed in an attempt to generate 
high level expression with little background induction. Many of these relied upon induction 
by hormones (oestrogens), antibiotics (tetracycline) or heavy metal ions (metallothionin) 
and suffered from a number of drawbacks -  most notably poorly regulated expression. The 
second generation of inducible vectors offered high level expression (Littlewood et al, 1995; 
Yoshida et al, 1997; Biebinger et al, 1997; Massie et al, 1998). The modified oestrogen 
receptor system offered an advantage in that the oestrogen analogue, 4-hydroxy tamoxifen, 
tightly regulated background induction, since the MER was unresponsive to natural 
oestrogens present in vivo and in tissue culture media (Littlewood et al, 1995). Fusion of 
the MER in frame with any gene, particularly transcription factors such as c-myc, c-fos, tax 
and p53 provided a simple switch (Littlewood et al, 1995; Preston et al, 1996; Vater et al, 
1996; Chlichlia et al, 1995). The resulting fusion protein was constitutively expressed, but 
sequestered with heat shock proteins as an inactive complex within the cytoplasm. The 
addition of lOOnm tamoxifen induced a conformational change in the fusion product 
allowing translocation of the active protein to the nucleus (Littlewood et al, 1995).
6.2 Aims of the experiment
In order to investigate the role that the various domains of Tax contributed towards the 
transformed phenotype in vitro, we decided to generate an inducible tax vector and mutants 
thereof (based on published data) which efficiently segregated the CREB/ATF and NF-kB
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domains. The use of an inducible tax vector would not only provide a more refined way to 
investigate the importance of each functional domain, but would also allow more flexibility 
with other downstream experiments.
6.3 Results
6.3.1 Generation of the inducible tax retroviral vector
Three inducible tax constructs were generated by fusing tax in frame with either a 5’ MER, 
a 3’ MER or a 573’ double MER (as described in chapter 2: Materials and methods and 
Figure 6.1). Restriction enzyme digests were performed to validate the orientation and 
fidelity of the sub-cloning steps (Figure 6 .2 ). Additionally, each construct was sequenced to 
ensure accuracy of the PCR-cloning step using the ‘in house’ licor automated gene 
sequencer.
168
Figure 6.1: Schematic diagram summarising the cloning steps involved in the
generation of the Tax-MER fusion construct.
Step 1: The 5’ portion of tax was per amplified with primers which maintained the Bam 
Hl/Sma I restriction site. The per product was then ligated into the TA cloning vector, ‘per 
II’.
Step 2 : The 3’ portion of tax was per amplified with primers which removed the stop codon 
(tga->tgg), shifted the open reading frame to that of the MER, and introduced appropriate 
restriction sites (Sma V Bam HI). The per product was then ligated into the TA cloning 
vector for subsequent fusion with the MER.
Step 3: The 5’ and 3’ portions were ligated to generate the full-length tax molecule and 
subcloned into the pBabe retroviral vector.
Step 4: the MER molecule was then ligated in frame with the tax molecule.
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Figure 6.1: Schematic diagram summarising the cloning steps involved in the
generation of the Tax-MER fusion construct
tax
3’ tax
Hind Sma 1Bam HI
Sma I Bam HI
Hind III Bam HI Sma
tax
Sma I
Sma I Bam HIHind III Bam HI
multiple cloning site 
of pBabe-neo (5.2 kb)
Figure 6.2: Diagnostic digests of Tax-MER fusion construct
The top figure represents the predicted restriction fragments based on the DNA sequence of 
the pBabe-Tax-MER construct.
The bottom figure is a photograph of the restriction fragments produced by digestion of the 
pBabe-Tax-MER plasmid with Sma I (lane 1), Bam HI (lane 2), Bsp El (lane3). Lane 4 is 
the parental undigested pBabe-Tax-MER plasmid. The fragment sizes were calculated 
relative to the reference lkb DNA molecular weight ladder as indicated on the photograph. 
Correct sized fragments at 424bp (Lane 1) and 1145bp and 967bp (Lane 2) were generated 
indicating fidelity of the subcloning steps. The wild type tax molecule does not contain a 
Bsp El restriction site (Lane 3).
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Figure 6.2: Diagnostic digests of Tax-MER fusion construct
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6.3.2 Demonstration of expression and inducibility of the Tax-MER/tamoxifen system
6.3.2.1 Optimisation of transient CAT assays
A transient CAT assay was chosen as the method of choice to measure functional protein 
expression from each of the inducible tax constructs. This was achieved using reporter gene 
plasmids which were upregulated through each of the functional domains of Tax (i.e. 
CREB/ATF responsive (HTLV-I LTR), NF-kB responsive (HIV-I LTR), and SRE 
responsive (c-fos upstream element) CAT constructs). Initially a transient transfection 
assay system using BHK cells and a P-gal/fax reporter assay system was optimised. Our 
results indicated that 5pg of tax DNA with 2.5pg of carrier DNA (ratio 2:1), 8 % modified 
bovine foetal serum, and 80,000 cells per 35mm dish (lane 4 Figure 6.3) provided optimal 
transfection conditions. The use of a fluorescent substrate (1-deoxy-CAM) with only one 
acetylation site was chosen as this produced only one reaction product with greater reaction 
linearity.
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Figure 6.3: Photographs illustrating optimisation of transient transfections
Optimisation of the transient transfection system. Lanes 1 and 2 represent 10|ig of tax 
DNA with 5pg of LTRlm'v'l'CAT DNA and 55,000 or 80,000 cells per petri dish 
respectively. Lanes 3 and 4 represent 5pg of tax DNA with 2.5pg of LTRHrLV'I‘CAT DNA 
and 55,000 or 80,000 cells per petri dish respectively. Lanes 5 and 6  represent 2.5p,g of tax 
DNA with 1.25pg of LTRlm'v'1'CAT DNA and 55,000 or 80,000 cells per petri dish 
respectively. Lane 7 represents acetylation of 1-deoxy-CAM with 0.5pL of CAT enzyme 
control. Lane 8  represents 5p,L of acetylated reference standard.
Optimal transfection efficiency with BHK cells occurred using 5jim of tax DNA, 2.5pg of 
reporter plasmid (2:1 ratio) DNA. Signal detection was maximised using 80,000 BHK cells 
per culture dish (30}j.g of protein). The use of a non-radioactive substrate (1-deoxy-CAM) 
with only a single acetylation site produced only one reaction product with greater reaction 
linearity.
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Figure 6.3: Photographs illustrating optimisation of transient transfections
Transient transfection o f  a beta-gal reporter construct into BHK cells followed by 
histochemical staining 24 hours after transfection.
1 2 3 4 5 6 7 8
Lane Transfection
1 lOug tax; 5ug LTR-cat; 55,000 cells per dish
2 1 Oug tax; 5ug LTR-cat; 80,000 cells per dish
3 5ug tax; 2.5ug LTR-cat; 55,000 cells per dish
4 5ug tax; 2.5ug LTR-cat; 80,000 cells per dish
5 2.5ug tax; 1.25ug LTR-cat; 55,000 cells per dish
6 2.5ug tax; 1.25ug LTR-cat; 80,000 cells per dish
7 0.5uL cat enzyme positive control
8 5uL acetylated reference standard
6.3.2.2 Functional transactivation of reporter plasmids
Functional activity of the inducible fusion constructs was investigated using this system by 
measuring transactivation of the LTRhtlv'i-CAT (CREB/ATF responsive) and LTR1^ '1- 
CAT (NF-kB responsive) reporter plasmids relative to wild type tax (TaxGlaWT). Our results 
(Table 6 .1 ) indicated that transactivation of the LTR ^^-C A T  (CREB/ATF) reporter 
plasmid by tax is efficient. However transactivation of the LTR^^-CAT (NF-kB) using 
this system was inefficient. Background induction matched that induced by tax. These 
results were similarly repeated using the adenovirus major late promoter-CAT reporter 
construct which contains three repeated NF-kB responsive motifs. These results were also 
confirmed later using the inducible mutants of tax (M47, Ml and C23S) and also an 
external wild type tax (IEX-Tax) [a gift from Dr KT Jeang, NIAID Bethseda, USA] 
[described later].
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Table 6.1: Transactivation of the LTRmLV I-CAT (CREB/ATF) and LTRrav l-CAT 
(NF-kB) reporter plasmids by wild type tax (Tax GlaWT)
TaxG1,WT
LTRHTLV'i/pBabe
TaxG laW T
LTR /pBabe
CREB/ATF 
% acetylation
37.4
15.31
NF-kB
% acetylation
12.59
13.51
ST Dev
11.1
6.3
ST Dev
6.9
7.66
Fold Induction
2.4
* 1
Fold Induction
0.93
*1
The % acetylation and all subsequent results were the average of at least 3 separate experiments performed 
on different days.
♦Results normalised to 1
Table summarising percentage acetylation of CREB/ATF or NF-kB CAT reporter 
constructs with TaxGlaWT and LTR-pBabe plasmids. The figures refer to percentage 
acetylation of 1-deoxy-CAM, standard deviation, and fold induction relative to the LTR- 
pBabe construct.
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6.3.2.3 Transactivation of the SRE
In order to assess transcriptional upregulation of the SRE through the third critical domain 
of tax we decided to measure CAT activity from a number of c-fos promoter mutants (a gift 
from Dr G. Birrie, Beatson Institute, Glasgow, UK) which segregated the important 
upstream regulatory elements governing c-fos transcription (Figure 6.4). The results 
indicated (Table 6.2 and Figure 6.5) that tax transactivated c-fos-1, c-fos-2 and c-fos-5- 
CAT reporter constructs most efficiently (-1.6-1.7 fold). These constructs each contained 
the minimal promoter elements (DRE and CRE the latter containing a CREB responsive 
element). Presence of the SRE and or the ATF element did not further upregulate CAT 
activity. Tax transactivated the c-fos-3 and c-fos-7 construct least efficiently (-1.2-1.3 
fold). Since these constructs contain both the minimal promoter element plus the SRE 
element, reduced CAT activity indicated inhibition through the SRE. The presence of 
additional elements such as the SIE and ATF served only to increase transactivation by tax 
with a concomitant proportional increase in background transactivation.
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Figure 6.4: Schematic diagram illustrating the various c-fos promoter mutant
constructs.
The c-fos upstream promoter region contains at least 5 regulatory promoter elements 
(Alexandre and Verrier, 1991): v-sis conditioned medium inducible element (SIE), the 
serum response element (SRE), the activating transcription factor/activating protein element 
(ATF/AP1), the octanucleotide direct repeat element (DRE), and the cyclic AMP response 
element (CRE). Tax is able to transactivate the c-fos promoter through each of these 
elements (Alexandre and Verrier, 1991). Five promoter mutant reporter constructs were 
used to dissect the c-fos promoter: c-fos-2 (the minimal promoter region), c-fos-7 (the full 
upstream region), and c-fos-3 and c-fos-5 which segregate the SRE and ATF1/AP1 sites.
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Figure 6.4: Schematic diagram illustrating the various c-fos promoter
mutant constructs.
SIE SRE ATF/AP1 DRE CRE
-400 -350 -31y  -80 -60 +42
i  i  i f  1 1  ta tm __________
:—D -a-------s s  c m — +  c*‘
SIE v-sis conditioned medium inducible element
SRE serum response element
DRE direct repeat element
ATF/AP1 activating transcription factor/activating protein
CRE cyclic AMP response element
-fos-1 DRE+CRE+SRE+ATF/AP1 [1— D O
-fos-2 DRE+CRE — D O
-fos-3 DRE+CRE+SRE D —D O
-fos-5 DRE+CRE+ATF/AP1 l— O O
-fos-7 DRE+CRE+SRE+ATF/AP1+SIE — O i l ------------------D O
Table 6.2: Transactivation of the c-fos-CAT reporter plasmids by wild type tax
(TaxG,aWT)
TaxGla WT Background Fold
%  acetylation ST Dev % acetylation ST Dev Induction
Fos-1 18.2 6.8 10.6 2.4 1.7
Fos-2 30.0 9.1 19.3 9.4 1.6
Fos-3 20.3 2.4 16.7 7.4 1.2
Fos-5 25.5 6.7 15.9 5.5 1.6
Fos-7 30.2 10.5 22.7 9.7 1.3
Table summarising the percentage acetylation.of the various c-fos-CAT reporter plasmids 
by wild type tax (TaxGlaWT) with and without tamoxifen induction. The figures refer to 
percentage acetylation of 1-deoxy-Cam, standard deviation, and fold induction relative to 
background induction normalised to 1 .
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Figure 6.5: Transactivation of the various c-fos promoter mutant reporter plasmids
by the pBabe-tax construct.
Photograph of transactivation of the various c-fos promoter regions by wild type Tax. 
Lanes 1, 3, 5, 7, and 9 represent induction of c-fos 1, 2 , 3, 5 and 7 plasmids by wild type 
Tax respectively with the addition of tamoxifen. Lanes 2, 4, 6 , 8 , and 10 represent 
induction of c-fos 1, 2, 3, 5 and 7 plasmids by wild type Tax respectively without the 
addition of tamoxifen. Lane 11 represents 5pL of acetylated 1-deoxy-CAM reference 
standard.
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Figure 6.5: Transactivation of the various c-fos promoter mutant reporter
plasmids by the pBabe-fajc construct.
1 2 3 4 5 6 7 8 9  10 11
Lane Construct Lane Construct
1 pBabe-Tax c-fos-1 2 pBabe-ER c-fos-1
3 pBabe-Tax c-fos-2 4 pBabe-ER c-fos-2
5 pBabe-Tax c-fos-3 6 pBabe-ER c-fos-3
7 pBabe-Tax c-fos-5 8 pBabe-ER c-fos-5
9 pBabe-Tax c-fos-7 10 pBabe-ER c-fos-7
Transient transactivation o f  the c-fos promoter mutant reporter plasmids 
by Tax. Maximal expression occurs with c-fos-7 (full upstream 
regulatory region) although background induction is also high. 
Constructs c-fos-2, -3, and 5 give greatest induction relative to 
background. The principal elements upregulated by tax are the CRE and 
ATF/AP1 sites (c-fos-5). However tax can also upregulate expression 
through the SRE and the minimal DRE/CRE elements.
6.3.2.4 Tamoxifen induction of Tax activity
Functional inducibility of the Tax-MER construct was then assayed using LTRhtlv_i-CAT 
reporter plasmid in a transient transfection assay together with (and without) induction by 
4-hydroxy-tamoxifen (Figure 6 .6 ). These results indicated that Tax-MER upregulated 
transcription from the LTRhtlv*i-CAT construct demonstrating the synthesis of a functional 
fusion protein, which was actively sequestered in the cytoplasm. Induction by tamoxifen 
over a range of concentrations (lOO-lOOOnm) [optimal 4-hydoxy-tamoxifen concentration 
of 500nm] demonstrated functional activation of the Tax protein and translocation to the 
nucleus.
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Figure 6.6: Tamoxifen induction of the LTR^^^-CAT (CREB/ATF) and
LTRmvI-CAT (NF-kB) reporter constructs by the tax-MER fusion construct.
Photograph of transactivation of the LTRhtlv'i-CAT and LTR^^-CAT reporter 
plasmids by the wild type tax-ER fusion construct. Lanes 1-6 represent 
transactivation of LTRHTLV'I-cat by the wild type tax-MER fusion construct with 0, 
100, 500, 1000, 2500, and lOOOOnm tamoxifen. Lanes 7 and 8  represent 
transactivation of LTR^^-CAT by the wild type tax-MER fusion construct with 0 
and 500nm tamoxifen. Lanes 9 and 10 represent transactivation of the LTRhtlv i- 
CAT and LTR^^-CAT reporter plasmids by PIC (negative control) with no 
tamoxifen. Lane 12 represents 5uL acetylated reference standard.
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Figure 6.6: Tamoxifen induction of the LTRh tlv i-CAT (CREB/ATF) and
LTRI,IVI-CAT (NF-kB) reporter constructs by the tax-ER fusion construct.
1 2 3 4  5 6  7 8 9  10 11
14.37 48.57 59.65 49.70 15.48 8.92 11.72 17.36 0 0 (% Acetylation)
Lane Transfection
1 pBabe-Tax-MER LTRHTLV'1-cat no tamoxifen
2 pBabe-Tax-MER LTRHTLV-‘-cat lOOnm tamoxifen
3 pBabe-Tax-MER L I R ^ -C c a t 500nm tamoxifen
4 pBabe-Tax-MER LTRHTLV-*-cat, lOOOnm tamoxifen
5 pBabe-Tax-MER LTRHTLV'*-cat 2500nm tamoxifen
6 pBabe-Tax-MER LTRHTLV-'-cat 10,000nm tamoxifen
7 pBabe-Tax-MER LTRHIV1-Cat no tamoxifen
8 pBabe-Tax-MER LTRHlv-'-Cat 500nm tamoxifen
9 PIC LTRHTLV->-cat no tamoxifen
10 PIC LTRHIV-[-cat no tamoxifen
11 5uL acetylated reference standard
Tamoxifen induction of the Tax-MER fusion construct: lane 1 and 7 
illustrate background induction without tamoxifen; lanes 2-4 demonstrate 
strong induction of the using the LTRHTLV ,-cat (CREB/ATF) reporter 
construct; lane 8  demonstrates weak induction of the LTR -cat 
construct; lanes 9 and 10 demonstrate low cat activity in the absence of tax.
6.3.2.5 Analysis of each of the inducible pBabe-Tax-MER fusion constructs
Comparative analysis of each of the Tax-MER fusion constructs [Tax-MER, MER-Tax and 
MER-Tax-MER] with the LTRhtlvi-CAT reporter plasmid demonstrated that maximal 
expression occurred from the 3’ Tax-MER construct [2.6 fold induction] (Figure 6.7 and 
Table 6.3). This figure compared favourably to that obtained from experiments using a 
constitutively expressed pBabe-Tax construct [2.4 fold]. Both the 5’ MER-tax and the 5’3’ 
double MER-Tax-MER constructs showed reduced activity compared to the 3’ Tax-MER 
construct (1.3 and 1.4 fold induction respectively).
Background induction of the fusion constructs was tightly controlled. Those constructs 
with a 5’ MER demonstrated no appreciable CAT activity (relative to background) without 
tamoxifen induction (1 fold [MER-Tax] and 0.8 fold [MER-tax-MER] induction). The 
Tax-MER construct demonstrated some unregulated activity (relative to [pBabe-MER] 
background) without tamoxifen induction (1.5 fold induction).
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Figure 6.7: Tamoxifen induction of the LTR^^^-CAT reporter construct using the
Tax-MER, MER-Tax, and MER-Tax-MER fusion constructs.
Tamoxifen induction of the LTR ^^-C A T reporter plasmid with the various inducible 
pBabe-Tax fusion constructs. Lanes 1, 2, 3, "5 and 7 represent induction of the LTRhtlv i- 
CAT reporter construct with the addition of 500nm tamoxifen by pBabe-MER, pBabe-Tax, 
pBabe-MER-Tax, pBabe-Tax-MER, and pBabe-MER-Tax-MER respectively. Lanes 4, 6 , 
and 8  represent induction of the LTR ^^-C A T reporter construct without tamoxifen 
addition by pBabe-MER-Tax, pBabe-Tax-MER and pBabe-MER-Tax-MER respectively. 
Lane 9 represents 5|liL of acetylated reference standard.
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Figure 6.7: Tamoxifen induction of the LTRm LVI-CAT reporter construct 
using the Tax-MER, MER-Tax, and MER-Tax-MER fusion constructs.
1 2 3 4 5 6 7 8 9
Lane Transfection
1 pBabe-MER LTRHTLV'1-cat 500uM tamoxifen
2 pBabe-Tax LTRMTLV_,-cat 500uM tamoxifen
3 pBabe-MER-Tax LTRHTLV-‘-cat 500uM tamoxifen
4 pBabe-MER-Tax L I R ^ ^ - c a t No tamoxifen
5 pBabe-Tax-MER LTRHTLV-I-cat 500uM tamoxifen
6 pBabe-Tax-MER LTRHTLV I-Cat No tamoxifen
7 pBabe-MER-Tax-MER LTRHTLV I-cat 500uM tamoxifen
8 pBabe-MER-Tax-MER LTRHTLV I-cat No tamoxifen
9 5uL acetylated reference standard
Tamoxifen induction of the various inducible pBabe-Tax fusion constructs 
demonstrates that most efficient induction occurs with the 3’ Tax-MER 
construct. Reduced levels of expression from the other constructs is likely 
due to steric hindrance of the active tax domain by the fusion MER molecule. 
Note inhibition is strongest in the double MER construct. Little inhibition is 
noted for the 5’ Tax-MER construct (which approaches wild type activity) 
presumably due to the redundancy of the terminal 5’ 20-30 amino-acids.
Table 6.3: Tamoxifen induction of each of the Tax/MER fusion constructs with the 
LTRhtlv i CAT constructs
TaxG,aWT-MER
Tax-MER
MER-Tax
MER-Tax-MER
.HTLV-I
tTamoxifen 
% acetylation
37.4
39.05
20.4
22.0
LTR“ ^ V VpBabe-MER 15.31
ST Dev 
11.1
4.1
8.2 
6.6 
6.3
Fold Induction
2.4
2.6
1.3
1.4 
*1
Tax-MER
MER-Tax
MER-Tax-MER
No Tamoxifen 
%  acetylation
22.6
16
12.7
ST Dev
4.1
3.7
4.3
Fold Induction
1.5
1.0
0.8
fTamoxifen used at optimal concentration (500nm) in this and all subsequent experiments; * normalised to 
1
Table demonstrating the percentage acetylation of the various tax/MER fusion constructs 
with and without tamoxifen induction. The figures refer to the percentage acetylation of 1- 
deoxy-Cam, standard deviation, and fold induction relative to background induction 
normalised to 1 .
The results of these experiments indicated that the fusion constructs synthesised functional 
proteins whose activity could be regulated by the modified oestrogen receptor analogue, 4- 
hydroxy-tamoxifen, and that the fusion construct efficiently upregulated CREB/ATF 
responsive promoters with little background induction but poorly upregulated the NF-kB or 
SRE promoter constructs.
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6.3.3 Analysis of the functional domains of Tax
6.3.3.1 Segregation of trans-activating domains of Tax
Having demonstrated that the MER fusion constructs produced functional proteins, we 
decided to make mutants of tax based upon previously published data. This data had 
demonstrated that single or double amino acid mutations in the primary amino acid 
sequence of Tax generated discrete functional mutations in the domains of the Tax protein 
(Smith and Greene, 1991; Semmes and Jeang, 1992) [Figure 6 .8 ] effectively segregating the 
key functional NF-kB and CREB/ATF activating domains (Table 6.4).
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Table 6.4: Phenotypes of M l, M47 and C23S relative to wild type tax
LTRhtlvi l t r h i v -i Reference
M l <5% 55% Smith and Greene (1990)
M47 <5% > 1 2 0 % Smith and Greene (1990)
C23S 1 0 0 % < 1 0 % Semmes and Jeang (1992)
Table summarising the relative induction of LTRh t l v ' 1 and LTR1^ ' 1 CAT reporter gene 
constructs by mutants Ml, M47 and C23S.
Our laboratory reproduced these mutations using the wild type Tax protein (Figure 6 .8 ) as 
the parent backbone (itself a gift from Dr Franchini, NIH, Bethseda, USA). These mutants 
were cloned into the pBabe retroviral vector as previously described to generate three 
inducible mutants of tax, designated Ml-MER, M47-MER, and C23S-MER.
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Figure 6.8: Schematic diagram illustrating the position in the primary amino acid 
sequence of Tax in which mutations have been introduced to generate the HTLV-I 
tax mutants M l, C23S and M47.
Schematic diagram illustrating the primary amino acid sequence position of the engineered 
mutations (Ml, M47 and C23S) of wild type Tax together with the key functional domains.
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6.3.3.2 M l, M47 and C23S transactivation of the LTRlrrLVI-CAT (CREB/ATF)
reporter plasmid
As before, each mutant was analysed for functional transactivation of the CREB/ATF, and 
NF-kB reporter plasmids. These results indicated (Figure 6.9 and Table 6.5) that mutant 
C23S and wild type Tax most efficiently upregulated the CREB/ATF reporter construct 
(4.8 fold and 4.2 fold induction respectively) relative to the other mutants. Mutant Ml and 
wild type inducible Tax demonstrated intermediary amounts of CAT activity (2.7 fold 
induction each) whereas mutant M47 demonstrated minimal CREB/ATF activity (0.72 fold 
induction). CAT activity was also assessed without tamoxifen induction and as before was 
tightly regulated. Background activity ranked in the same order as before, with C23S 
showing most activity (1.6 fold activity) and M47 showing least activity (0.56 fold 
induction).
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Table 6.5: Transactivation of the LTR^^^-CAT (CREB/ATF) reporter plasmid by
mutants C23S, M47, and M l
Tamoxifen Fold
% acetylation ST Dev Induction
TaxG,aWT-MER 19.2 1 . 6 2.7
Ml-MER 19.31 1 . 2 2.7
M47-MER 5.11 3.94 0.72
C23S-MER 33.99 2.5 4.81
TaxG,aWT 33.0 1 . 6 4.22
l t r h t l v -i  pBabe_MER 7.06 2.95 1 . 0
No Tamoxifen Fold
% acetylation ST Dev Induction
TaxG,aWT-MER 5.98 4.5 0.85
Ml-MER 8.16 3.98 1 . 2
M47-MER 3.94 1.32 0.56
C23S-MER 1 1 . 1 2 2.06 1 . 6
Table summarising the percentage acetylation of the LTRhtlv i-CAT (CREB/ATF) reporter 
gene plasmid with and without tamoxifen induction by TaxGla ^-MER, Ml-MER, M47- 
MER, C23S-MER, TaxGla WT, and lTR h t l v ' 1 pBabe-MER. The figures refer to the 
percentage acetylation of 1-deoxy-Cam, standard deviation, and fold induction relative to 
background induction normalised to 1 .
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Figure 6.9: Tamoxifen induction of the LTR HTLV-I-CAT (CREB/ATF) reporter 
construct by wild type tax-MER, Ml-MER, M47-MER, and C23S-MER fusion 
constructs.
Photograph summarising transient transfection of the LTR HTLV-I-CAT (CREB/ATF) 
reporter gene construct by the various inducible Tax mutants. Lanes 1, 3, 5, and 7 refer to 
pBabe-Tax-MER, pBabe-Ml-MER, pBabe-M47-MER, and pBabe-C23S-MER with 
500pM tamoxifen induction respectively. Lanes 2, 4, 6 , 8  refer to pBabe-Tax-MER, 
pBabe-Ml-MER, pBabe-M47-MER, and pBabe-C23S-MER without tamoxifen induction 
respectively. Lanes 9 and 10 refer to wild type Tax (pBabe-Tax) and pBabe-MER 
respectively. Lane 10 represents 5pL of acetylated reference standard.
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Figure 6.9: Tamoxifen induction of the LTR HTLV-I-CAT (CREB/ATF)
reporter construct by wild type tax-MER, Ml-MER, M47-MER, and C23S-
MER fusion constructs.
1 2 3 4 5 6 7 8 9  10 11
Lane
1
Construct
pBabe-Tax-MER L T RHTLV-I_c a t 500uM Tamoxifen
2 pBabe-Tax-MER L T RHTLV-l_c a t No Tamoxifen
3 pBabe-Ml-MER L T R HTLV-I_c a t 500uM Tamoxifen
4 pBabe-M 1-MER L T R HrLV-i-c a t No Tamoxifen
5 pBabe-M47-MER L X RHTLV-I_c a t 500uM Tamoxifen
6 pBabe-M47-MER L T RHTLV-Lc a t No Tamoxifen
7 pBabe-C23S-MER L T R H T L V -i.c a t 500uM Tamoxifen
8 pBabe-C23S-MER L T R H T L V -L cat No Tamoxifen
9 pBabe-Tax L T RHTLV-I.c a t 500uL Tamoxifen
10 pBabe-MER LTRHTLV-I_c a t 500uM Tamoxifen
11 5uL acetylated reference standard
Transient transfection of the various inducible tax mutants demonstrates 
that M47 is unable to transactivate the CREB/ATF pathway whereas mutant 
C23S hyper-transactivates the CREB/ATF (compared to wild type fusion 
Tax-MER) and is comparable to the activity of wild type Tax without the 
fusion MER molecule. Ml shows intermediate levels of CREB/ATF 
transactivation similar to wild type Tax-MER.
6.3.3.3 Transactivation of the LTRfflVI-CAT (NF-kB) reporter plasmid
Analysis with the NF-kB reporter construct (Figure 6.10 and Table 6 .6 ) with tamoxifen 
induction indicated that Ml and C23S demonstrated most CAT activity (1.4 fold induction 
each) compared to M47 which displayed intermediary levels of CAT activity (1.0 fold 
induction respectively). Both versions of the wild type Tax (constitutively expressed and 
inducible) displayed least activity (0.93 and 0.61 fold induction respectively). CAT activity 
without tamoxifen induction demonstrated the same relative order of activity. Mutant C23S 
and Ml displayed most activity (1.1 and 1.4 fold induction respectively) whereas wild type 
Tax displayed least activity (0.59 fold induction). M47 displayed intermediary levels of 
activity (0.85 fold induction).
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Table 6.6: Transactivation of the LTRfflVI-CAT (NF-kB) reporter plasmid by
mutants C23S, M47, and M l
Tamoxifen Fold
TaxGlaWT-MER
% acetylation ST Dev Induction
8.33 3.03 0.61
Ml-M ER 18.8 4.21 1.4
M47-MER 13.7 3.8 1 . 0
C23S-MER 19.2 4.2 1.4
TaxGlaWT 12.59 6.87 0.93
LTRhtlV'V 13.51 7:66 1 . 0
pBabe-MER
No Tamoxifen Fold
TaxGlaWT-MER
% acetylation ST Dev Induction
7.95 3.03 0.59
Ml-MER 18.8 3.14 1.4
M47-MER 1 1 . 6 4.44 0.85
C23S-MER 15.07 2.16 1 . 1 1
TaxGlaWT n/d n/d n/d
Table summarising the percentage acetylation of the LTR^^-CAT (NF-kB) reporter gene 
plasmid with and without tamoxifen induction by TaxGla ^-MER, Ml-MER, M47-MER, 
C23S-MER, TaxGIa WT, and LTR1^ 1 pBabe-MER. The figures refer to the percentage 
acetylation of 1-deoxy-Cam, standard deviation, and fold induction relative to background 
induction normalised to 1 .
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Figure 6.10: Tamoxifen induction of the LTR HTV-I-CAT (NF-kB) reporter construct 
by wild type tax-MER, Ml-MER, M47-MER, and C23S-MER fusion constructs
Photograph of transient transfection of the LTR HtV-I-CAT (NF-kB) reporter gene 
construct by the various inducible Tax mutants. Lanes 1, 3, 5, and 7 refer to pBabe-Tax- 
MER, pBabe-Ml-MER, pBabe-M47-MER, and pBabe-C23S-MER with 500pM tamoxifen 
induction respectively. Lanes 2, 4, 6 , 8  refer to pBabe-Tax-MER, pBabe-Ml-MER, pBabe- 
M47-MER, and pBabe-C23S-MER without tamoxifen induction respectively. Lanes 9 and 
10 refer to wild type Tax (pBabe-Tax) and pBabe-MER respectively. Lane 10 represents 
5pL of acetylated reference standard.
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Figure 6.10: Tamoxifen induction of the LTR HIV-I-CAT (NF-kB) reporter
construct by wild type tax-MER, Ml-MER, M47-MER, and C23S-MER
fusion constructs
1 2 3 4 5 6 7 8 9  10 11
Lane Construct
1 pBabe-Tax-MER L T R H iv - L c a t  500uM Tamoxifen
2 pBabe-Tax-MER LTRHiv-i-Cat No Tamoxifen
3 pBabe-Ml-MER L T R H iv - L c a t 500uM Tamoxifen
4 pBabe-Ml-MER L T R H iv - L c a t  No Tamoxifen
5 pBabe-M47-MER L T R Hiv - i - c a t  500uM Tamoxifen
6 pBabe-M47-MER LTRH]V-Lcat No Tamoxifen
7 pBabe-C23S-MER ETRHiv-Lcat 500uM Tamoxifen
8 pBabe-C23S-MER L T R Hi v - i - c a t No Tamoxifen
9 pBabe-Tax LTRmv*i-cat 500uM Tamoxifen
10 pBabe-MER L T R H * v - i- c a t 500uM Tamoxifen
11 5uL acetylated reference standard
Tamoxifen induction of the LTRmv l-cat (NF-kB) reporter construct. Again 
weak induction of the NF-kB pathway with high background levels. As 
before mutant C23S shows hyper-transactivation of the NF-kB pathway 
relative to wild type Tax. M47 shows good induction whereas Ml is inactive 
in this pathway.
Table 6.7: Summary of CAT activity with tamoxifen induction of mutants Ml-MER, 
M47-MER, and C23S-MER relative to wild type Tax-MER
LTR HTLVI LTR fflV
C23S-MER 178% 229%
Ml-MER 1 0 0 % 229%
M47-MER 26% 164%
TaxG,aWT-MER *1 0 0 % *1 0 0 %
♦Wild type Tax normalised to 100%
Table summarising the relative percentage acetylation of the LTRhtlv i-CAT (CREB/ATF) 
and the LTR^^-CAT (NF-kB) reporter gene plasmid with and without tamoxifen induction 
by C23S-MER, Ml-MER, M47-MER, and TaxGla ^-MER. The figures refer to the 
percentage acetylation of 1-deoxy-Cam relative to induction by wild type Tax (TaxGIa WT- 
MER) normalised to 100%.
These results indicated that C23S demonstrated the most relative activity with both reporter 
plasmids whereas M47 showed the least activity. These results suggest that within this 
system, the engineered mutations do not have the same discrete effects as predicted from 
published data (Table 6.4).
6.3.3.4 Comparison of different clones of tax
The results generated with the NF-kB reporter plasmid were unexpected. We therefore 
decided to test the validity of the BHK transient transfection system by comparing the 
activity of our wild type tax clone relative to a clone of tax (TaxTum0UI) derived from a 
transgenic mouse mesenchymal tumour and a second external clone of wild type tax (IEX- 
Tax). These experiments would also help us to assess the importance of each of the 
functional domains of Tax with regard to tumour induction in the transgenic mouse 
experiments.
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Repeating the same analysis as before, our results indicated (Table 6 .8 ) that the parental 
wild type tax clone (Tax w  Gla) strongly upregulated the CREB/ATF pathway (5.2 fold 
induction). The clone of tax derived from the mesenchymal tumour (TaxXumour) displayed 
intermediate levels of CREB/ATF CAT activity (3.8 fold induction) compared to external 
wild type tax clone (IEX-Tax) (2.6 fold induction).
Induction of NF-kB CAT activity with wild type tax (Taxw  Gla), the tumour derived tax 
clone (TaxTumour) and the external tax clone (IEX-Tax) produced similar levels of CAT 
activity.
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Table 6.8: Transactivation of the LTRhtlv‘i (CREB/ATF) and LTRrav l-CAT (NF-kB) 
reporter plasmid by Tax"™', TaxTum<’“r, and IEX-Tax
CREB/ATF ST Dev Fold
% acetylation % acetylation Induction
T ax'™ 3 27.82 4.91 5.2
TaxTumour 2 0 . 6 6 6.95 3.8
IEX-Tax 14.02 6.58 2 . 6
LTRHtlv-V 7.63 5.38 1 . 0
pBabe-MER
NF-kB ST Dev Fold 
% acetylation % acetylation Induction
T a x '™ 1 1 . 2 0 4.49 1 . 0
TaxTumour 12.42 6.40 0.81
IEX-Tax 13.96 6.24 0.90
LTRmv‘V 13.76 8.70 1 . 0
pBabe-MER
Table summarising the percentage acetylation of the LTRhtlv‘i-CAT (CREB/ATF) and the 
LTRHivI-CAT (NF-kB) reporter gene plasmid with tamoxifen induction by TaxGla WT, 
Taxtumour, IEX-Tax, and LTRh t l v ' 1 pBabe-MER. The figures refer to the percentage 
acetylation of 1-deoxy-Cam, standard deviation, and fold induction relative to background 
induction normalised to 1 .
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6.4 Discussion
The tamoxifen-modified oestrogen receptor system was created as an improved switch to 
regulate inducible gene activity (Littlewood et al, 1995). This system had significant 
advantages over other oestrogen receptor based systems since it did not suffer from 
endogenous activation from naturally circulating oestrogens found in serum and did not 
require phenol-red free tissue culture medium (Littlewood et al, 1995). Furthermore, the 
modified oestrogen binding domain was not thought to be transcriptionally active 
(Littlewood et al, 1995) -  a confounding factor to the interpretation of experiments using 
unmodified oestrogen receptor binding domains.
Analysis of the Tax-MER fusion proteins using the various reporter plasmids indicated the 
potential of this system. Good induction of the CREB/ATF reporter plasmid with relatively 
little background was achieved. Fusion of the MER at either the 3’ or 5’ terminus of tax 
did not significantly reduce activity apart from that expected from steric hindrance. The 
redundancy of the terminal 22 amino acids of Tax (Smith and Greene, 1990) may account 
for the slighter greater activity of the 3’ terminal Tax-MER fusion protein. The flexibility of 
this system was further underscored by the use of a retroviral-based strategy, which allowed 
the downstream option to infect primary cells via an amphotropic or ecotrophic packaging 
cell. However this system had significant drawbacks, not least the inefficiency of NF-kB 
and SRF induction using BHK cells. A second potential drawback was the small but 
significant amount of background CAT activity observed in the absence of tamoxifen 
induction. CREB/ATF activity appeared to be tightly regulated whereas NF-kB activity, 
although more difficult to assess, appeared to be less well regulated (discussed further in 
Chapter 7). This may be due to the ability of this system to more tightly regulate nuclear 
transcription factors (Littlewood et al, 1995; Preston et al, 1996; Vater et al, 1996; 
Chlichlia et al, 1995) [i.e. CREB/ATF versus NF-kB] as the modified oestrogen receptor 
sequesters the fusion complex within the cytoplasm. Therefore, since Tax binds the ankrin 
repeat motifs of the cytoplasmic NF-kB inhibitor protein, IkB, residual activity may be
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expected resulting in the sequestered complex exhibiting more cytoplasmic NF-kB activity 
than nuclear CREB/ATF activity.
The low activity of tax with the LTR^'-CA T reporter construct suggested that in our 
hands tax did not efficiently upregulate the HIV LTR. Although this could formally be due 
to mutation of the tax molecule or one of the two consensus NF-kB binding sites found in 
the HIV-I viral LTR (or flanking sequences thereof) we favoured a more simple explanation 
based on low endogenous levels of NF-kB activity in BHK cells. Other authors have 
commented upon this phenomenon in certain cell types (Semmes and Jeang, 1992) which 
further serves to underline the importance of developing relevant models to study human 
disease and the possibility of idiosyncratic effects between different species. Similarly, 
cooperation of Tax with the SRF may require HeLa cells for optimal induction (Fujii et al, 
1988).
The three mutants of Tax - Ml, C23S, and M47 - were developed in our laboratory 
according to published data which introduced specific functional deficits into the protein 
binding domains of Tax (Table 6.4) designed to segregate the NF-kB and CREB/ATF 
binding domains. Analysis of our mutants revealed a departure from the predicted 
phenotypes suggesting that mutations within the primary amino acid structure of Tax 
imparted subtle and unpredictable effects on the overall conformation of the protein. 
Reproductions of these mutations in other laboratories have also highlighted similar effects. 
In two similar systems, M22 developed by Smith and Greene (1990) was able to induce NF- 
kB activity whereas the same mutant (named M l37) developed by Semmes and Jeang 
(1992) was unable to induce NF-kB activity. Presumably introduction of identical 
mutations into clones of wild type Tax which differ slightly in primary amino acid structure 
imparts unique overall patterns of folding of the native protein and therefore different 
functional effects.
Comparison of different clones of wild type Tax revealed differences in the overall activity 
of these proteins. All three clones were able to activate the CREB/ATF transcription
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factors, although Taxw  Gla was two fold more efficient than IEX-Tax. Induction of the NF- 
kB  transcription factor was uniformly weak with little difference between the clone of Tax 
derived from our laboratory and IEX-Tax donated by Dr Jeang. These differences may 
reflect point mutations in the Tax open reading frame occurring during the course of natural 
infection in humans which presumably similarly impart functional differences in the native 
protein responsible for variance in the immune response to the protein. These effects may 
be important not only in the persistence of Tax expression and TSP induction (previously 
discussed in Chapter 1) but may also be important for the selection of more pathogenic 
clones of Tax in ATL patients. This therefore raises the intriguing possibility that the search 
for functional phenotypes associated with pathogenicity may not be straightforward since 
introduction of specific point mutations into Tax imparts functional properties dependent 
upon the overall amino acid sequence of the parental clone.
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Chapter 7
Functional effects of the inducible Tax mutants in vitro
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Functional effects of the inducible Tax mutants in vitro
7.1 Introduction
The precise mechanism by which HTLV-I transforms naturally infected human lymphocytes 
in vivo is unknown. The requirement of taxi or taxu in the transformation process, although 
absolutely necessary for immortalisation (Tanaka et al, 1990; Ross et al, 1996), is still 
largely unknown. Full transformation of human lymphocytes requires infection by the 
complete virus (HTLV-I or -II) (Popovic et al, 1983; Chen et al, 1983) and presumably 
secondary events in addition to tax, expression. To this effect the role of pl2 and other 
minor pX gene products is still largely unknown (Mulloy et al, 1996; Franchini et al, 1993; 
Koralnik et al, 1993). Secondary events such as transrepression of the P polymerase gene 
(Jeang et al, 1990) and inactivation of the p53 tumour suppressor gene by tax (Cereseto et 
al, 1996; Akagi et al, 1997) although important, are more likely to play late events in the 
progression of ATL by promoting karyotypic instability (Kamada et al, 1992).
HTLV-I tax however can induce tumours in transgenic mice (Nerenberg et al, 1987), and 
acts as a dominantly acting oncogene in vitro. Indeed, tax transforms rodent fibroblasts 
(Tanaka et al, 1990), and co-operates with the ras oncogene to transform primary rat 
embryo fibroblasts (Pozzati et al, 1990) [which ordinarily it immortalises (Pozzati et al, 
1990)]. Depending upon the context of expression, tax like c-myc (Evan et al, 1992) and c- 
fo s  (Preston et al, 1996) can also serve to induce apoptosis (Yamada et al, 1994) or 
possibly inhibit it (Brauweiler et al, 1997; Kishi et al, 1997; Schwartz-Comil et al, 1997).
Previous analysis of the Tax-tamoxifen system (Chapter 6 ) had already demonstrated the 
functional induction of Tax expression in vitro by tamoxifen. However this system was not 
without certain restrictions since it was known that tamoxifen clinically induced apoptosis in 
certain forms of human cancer (Burroughs et al, 1997; Cameron et al, 1997; Ellis et al, 
1997). Induction of apoptosis was not restricted to hormone dependent tumours since 
tamoxifen reliably induced liver tumours in rats due to promotion through reactive
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hyperplasia secondary to chronic cell loss by apoptosis (Carthew et al, 1996). Furthermore, 
these effects were attributed, at least in part, to the induction of c-myc, bcl-2 and p53 genes 
(Kellen et al, 1996) which are known to modify the apoptotic response.
7.2 Aims of the experiment
In light of the plethora of functional attributes imbued upon tax we decided to test which of 
the functional domains of tax, were necessary for transformation and apoptosis using the 
inducible Tax-MER system. Due to the low level of NF-kB activity in the BHK cells we 
switched to a well characterised Rat 1 model system which had been previously 
characterised in other apoptosis assays (Evan et al, 1992).
7.3 Results
7.3.1 Generation of stable cell lines
Rat 1 cells were transfected with each vector (Tax-MER, Ml-MER, M47-MER and C23S- 
MER) and selected in G418 to generate stable cell lines (Chapter 2: Materials and 
methods). This procedure produced in excess of 20 to 30 colonies per transfection 
experiment indicating that tax expression per se was not associated with a toxic phenotype 
in Rat 1 cells.
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7.3.2 Analysis of cell lines
In order to determine the effects of tax expression in vitro, we decided to initially assess the 
growth rate of the tax expressing cell lines in 1 0 % bovine foetal calf serum together with 
and without tamoxifen induction. The results of these experiments (Graph 7.1) indicated 
that although growth rates were similar between each cell line, by day six, each cell line 
grew to a higher cell density with tamoxifen induction compared to its counterpart grown 
without tamoxifen addition. These experiments indicated that tamoxifen induction had not 
markedly altered mitotic rate but may have reduced contact inhibition - a classical feature 
usually associated with transformation of immortalised cell lines by dominantly acting 
oncogenes.
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Graph 7.1: Growth of stable cell lines in 10% bovine foetal calf serum expressing Tax-
MER, C23S-MER, M l-M ER, and M47-MER
- Rat 1 + tmfn 
-TE + tmfn 
TE - tmfn 
-C23S+tmfn 
-C23S - tmfn 
-M1+tmfn 
-M1 - tmfn 
-M47+tmfn 
M47 - tmfn
Growth of Rat 1 cells expressing Tax-Mer, C23S-Mer, M1-Mer, and M47- 
Mer grown in 10% bovine foetal calf serum and 100nm tamoxifen
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Each data point (and all subsequent experiments) represents the average o f four separate 
cell counts performed on at least two separate occasions.
Graph illustrating the growth o f Rat 1 cells, Tax-MER, C23S-MER, M l-M ER, and M47- 
MER expressing cell lines in 10% bovine foetal calf serum with the addition o f lOOnm 
tamoxifen. Cell lines grown in tamoxifen reach a higher cell density by day 6 compared to 
the same cell lines grown without tamoxifen.
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7.3.3 Analysis of apoptosis
7.3.3.1 Optimisation of apoptosis assay
In order to assess the effect of tax expression upon apoptosis we decided to measure viable 
cell numbers (live adherent cells) in each of the cell lines after 2 days and 4 days growth in 
0.1% FCS. Cells grown in 0.1% (or less) FCS normally undergo growth arrest -  however 
cells expressing oncogenes which induce inappropriate entry into the cell cycle die by 
apoptosis (Evan et al, 1992 and 1995). We therefore decided to characterise this system 
using control Rat 1 cells grown in either lOOnm or 250nm tamoxifen. Our results (Graph 
7.2) indicated that Rat 1 cells grown in lOOnm tamoxifen were unable to proliferate in 0.2-
0.5% bovine foetal calf serum. However, Rat 1 cells grown in 250nm tamoxifen were able 
to proliferate (conforming to the pattern of Rat 1 cell growth when no tamoxifen is added). 
The presence of dead cells within the supernatant indicated that a proportion of cells were 
detaching and dying both at 100 and 250nm tamoxifen. These results indicated that 250nm 
tamoxifen was the optimum concentration to assay apoptosis using Rat 1 cells in 0.1% FCS.
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Graph 7.2: Growth of Rat 1 cells in lOOnm and 250nm tamoxifen.
Growth of Rat 1 cells in 100nm tamoxifen versus 
bovine foetal calf serum concentration
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Graph illustrating the growth o f Rat 1 cells in lOOnm or 250nm concentration o f tamoxifen 
at 0.1 -  0.5% bovine foetal calf serum over a 4 day time period. At lOOnm concentration 
o f tamoxifen Rat 1 cell numbers remain stable from day 0 to day 4 whereas at 250nm 
concentration o f tamoxifen Rat 1 cell numbers increase.
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7.3.3.2 Analysis of apoptosis in cell lines
In order to assay the effect that tax expression (and the various engineered mutants thereof) 
contributed to apoptosis we repeated the previous apoptosis assay using the stable tax 
expressing Rat 1 cell lines. The results of these experiments (Graph 7.3) indicated that each 
of the stable cell lines exhibited enhanced apoptosis and consequently reduced viable cell 
numbers compared to the parental Rat 1 control cells. Most cell death occurred in cell lines 
expressing wild type Tax, mutant C23S and Ml, whereas M47 exhibited least cell death. 
Treatment with 250nm tamoxifen appeared to reduce the amount of apoptosis. Indeed, 
background induction of Tax activity without tamoxifen addition appeared sufficient to 
efficiently induce apoptosis. Although the contribution through transactivation of the NF- 
kB  pathway was difficult to determine in the BHK cell lines, these results indicate that 
induction of apoptosis was weakest in the M47 cell line. This cell line least efficiently 
transactivated the CREB/ATF pathway, and may indicate the general importance of this 
pathway for apoptotic induction in vitro.
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Graph 7.3: Growth of stable cell lines expressing Tax-MER, C23S-MER, Ml-MER
and M47-MER in 0.1% FCS and 250nm tamoxifen.
Growth of Rat 1 cells expressing Tax-Mer, C23S- 
Mer, M1-Mer, and M47-Mer grown in 0.1% bovine 
foetal calf serum and 250nm tamoxifen
w 12000 
10000 
|  8000 
i  6000
5  4000
« 2000 
°  0
□  day 0
□  day 4
<?-
A  ^ A  ^ A> A> A  ^ A  ^ A  ^ A  ^ A^
> <an &  &  &  ^
ol- A  &
Graph illustrating growth o f Rat 1 cells and Tax-MER, C23S-MER, M l-M ER, and M47- 
MER cell lines in 0.1% bovine foetal calf serum, with and without 250nm concentration of 
tamoxifen over a 4 day time period. Cell lines expressing the inducible tax vector show 
reduced cell numbers compared to the parental Rat 1 cell line. The addition o f tamoxifen 
increased the number o f viable cells for each tax expressing cell line compared to the same 
cell line grown without tamoxifen.
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7.4 Discussion
The results of these experiments indicate that expression of tax is associated with a 
stochastic risk of apoptosis. Expression of tax in vivo resulted in apoptosis in a sub­
population of ‘high expressing cells’ in CD3-tax transgenic mice. Expression of tax in vitro 
also resulted in apoptosis. Since environmental effects in vitro should be similar if not 
identical, and since all cells were clonally derived, apoptosis in vitro must also be stochastic. 
Presumably a complex biochemical network in which the balance between inducers and 
repressors determines the overall outcome governing apoptosis. In this scenario, the level 
of tax expression would be one factor contributing to the apoptotic decision. Low level 
expression presumably would be consistent with cell survival. To this effect, low level 
expression of tax from the pBabe promoter may have contributed to the apparent ease of 
generating a large number of tax expressing stable cell lines -  in apparent contrast to other 
authors using more efficient promoters (Chlichlia et al, 1995; Furuta et al, 1989). This is 
also consistent with the expression of tax in the naturally infected host in which evolution 
has likely resulted in the selection of those viral clones, which express tax at sufficiently low 
levels to escape immune surveillance and apoptotic induction.
Growth of Rat 1 cells in low FCS conditions resulted in reduced viable cell numbers when 
grown at lOOnm tamoxifen compared to 250nm tamoxifen. Tamoxifen therefore appears to 
have opposing effects at different concentrations. The results of the apoptosis experiments 
in the tax expressing cell lines suggests that 250nm tamoxifen may inhibit or rescue from 
apoptosis since viable cell numbers are increased in those cells which receive tamoxifen. 
[Similar results have been observed in c-myc-MEK transgenic mice (Dr Cameron personal 
communication)]. This is consistent with the observation that control Rat 1 cells (already 
committed to mitosis from prior culture in 10% FCS) proliferate at 0.2-0.5% FCS 
compared to the same cells grown in lOOnm tamoxifen which detach, presumably due to 
apoptosis. The differential effects of tamoxifen may be related to a concentration dependent 
induction of gene activity that serves to modify the apoptotic response.
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Background activity of the Tax-MER system, although apparently negligible, is sufficient to 
exert potent biological effects. In vitro this resulted in efficient apoptotic induction, 
whereas in vivo this resulted in tumour formation in c-myc-MEK transgenic mice (Dr 
Cameron personal communication). This serves to illustrate that a mild biochemical 
perturbation can markedly shift the overall biological response of the cell suggesting that the 
outcome between life and death is finely balanced.
Our results indicated that induction of apoptosis was least efficient in the M47 cell line. 
Although the contribution of the NF-kB pathway could not be established for the BHK cell 
lines, the M47 cell line least efficiently transactivated the CREB/ATF pathway. These 
results may therefore indicate the general importance of the CREB/ATF pathway for 
apoptotic induction in vitro (Smith and Greene, 1991; Rosin et al, 1998). These results are 
also consistent with the notion that the decision to engage apoptosis is dependent upon the 
level of tax expression. Results from the transgenic mouse experiments in which only those 
cells expressing high levels of Tax protein enter into apoptosis support this notion, whereas 
the background population expressing lower amounts of Tax protein proliferate (Hall et al, 
1998).
Recent work has now shed light on other biochemical interactions between tax and cell 
cycle control proteins -  most notably plb 1^ 4 2  (Suzuki et al, 1996) and the mitotic 
checkpoint protein, MAD1 (Jin et al, 1998). The importance of these interactions and the 
contribution that they make towards the transformed phenotype and induction of apoptosis 
remain to be seen, but most likely will reveal yet more functional attributes to the already 
considerable repertoire of this most enigmatic of proteins.
219
Future Work
The results presented here concur with the observations made by other authors that tax 
expression results in the induction of a variety of tumours as well as certain degenerative 
conditions. Expression using the CD3-e enhancer-promoter regulatory elements resulted in 
mesenchymal tumours at ear and tail tips, salivary and mammary adenomas, and histiocytic 
tumours. We also observed thymic atrophy, immunosuppression, and hindleg paralysis. 
Analysis of the mesenchymal tumours and salivary and mammary adenomas using an in situ 
technique demonstrated that although all tumours were presumalby clonally derived, their 
patterns of gene expression were not uniform. Expression of large amounts of Tax protein 
as well as Myc, Fos, Jun and p53 proteins occurred as isolated foci of cells distributed 
randomly throughout the substance of the tumours. Coincident with Tax expression we 
also observed similar patterns of apoptosis indicating that the processes of apoptosis and 
Tax protein expression were intimately linked in vivo. In addition to these studies we also 
demonstrated that induction of apoptosis by tax was dependent upon the CREB/ATF 
activating domain.
Expression of tax within the lymphoid compartment has not resulted in T-cell lymphoma, 
but rather in severe immunosuppresion due to thymic atrophy. This phenotype may result 
form the expression of the Tax protein using very efficient promoter-enhancer elements 
inducing apoptosis rather than neoplasia. Expression from less efficient regulatory elements 
may prove more permissive. Regulation of tax expression using inducible promoters or 
activation of sequestered proteins may therefore allow targeted expression within the 
lymphoid compartment. To this effect the tamoxifen-modified oestrogen receptor may 
prove useful although our experience indicates that background induction probably would 
be sufficient to allow penetrance of the transgene phenotype.
The generation of mutants that segregate the various activating domains of Tax has already 
generated discordant results. The introduction of Tax into a complex biochemical network 
of proteins clearly has subtle effects dependent upon the assay system employed. The
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importance of individual protein-protein interactions may therefore vary depending upon the 
context of expression - hence the relevance of Tax expression in rodent fibroblasts in vitro 
may be questionable since species and cell specific effects cannot be easily assessed. It 
therefore appears pertinent to generate an improved transgenic model, possibly using 
species other than rats and mice (due to their propensity to develop tumours). The 
development of this model system would then allow the elucidation of oncogenic 
collaborators and mechanisms of apoptosis in tax transformed T-cells.
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